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The aim of this body of work was to evaluate the association between exposure to different 
nutrients and dietary patterns and the risk of mortality (all-cause and cause-specific) and hospital 
admissions (any, and cause-specific) in adults with chronic kidney disease (CKD) and specifically 
those with or end stage kidney disease (ESKD) receiving  hemodialysis for renal replacement 
therapy. 
Adults receiving hemodialysis still experience high mortality rates. Several interventions that 
address the typical cardiovascular risk factors which are almost universally present in people with 
ESKD have been introduced. These interventions unfortunately do not significantly improve health 
outcomes in such populations. They are effective on a series of surrogate biomarkers, but survival 
remains poor in these populations. The search continues to be on for novel and testable 
determinants of health in hemodialysis in order to identify additional interventions. Nutrition and 
dietary patterns are potential factors influencing health in other health settings but poorly 
explored in the setting of ESKD. Such research area warrants investigation in multinational studies 
in men and women treated with hemodialysis, given the potential impact at population level. 
My PhD, in the area of clinical epidemiology research in ESKD, focused on understanding the 
impact of diet and nutrient intake, on CKD and ESKD through a comprehensive and systematic 
series of literature reviews and the design and conduct of the first large scale multinational 
primary cohort study to explore the association between nutrition (dietary intake) and clinical 
adverse events in the setting of hemodialysis (the Dietary Intake in Hemodialysis, DIET-HD study). 
The results of my work are presented in the following chapters, which represent the results of 
studies published with my strong contribution: 
Chapter 1. Meta-analysis of cohort studies evaluating the association between dietary patterns 
and mortality or end-stage kidney disease among adults with chronic kidney disease. Published, 
Clin J Am Soc Nephrol. 2016 Dec 8.  
Chapter 2. Rationale and protocol of the DIET-HD study, a prospective, multinational, cohort study 
evaluation the prevalence of nutrition patterns and the association of dietary intake/patterns and 
the risk of mortality and hospitalisation in adults receiving hemodialysis. Published, BMJOpen. 
2015 Mar 20;5(3): e006897. 
6 
 
Chapter 3: A prospective cohort study (arising from DIET-HD) of the association between the 
dietary intake of n-3 and cardiovascular and all-cause mortality in adults treated with 
hemodialysis. Published, Clin Nutr. 2017 Dec 6. 
Chapter 4-5: Analysis of the benefits and harms of large categories of interventions related to 
nutritional aspects in CKD/hemodialysis (two network meta-analyses of randomized controlled 
trials comparing and ranking the efficacy of phosphate binding agents in CKD and the relative 
efficacy and safety of glucose-lowering drugs including insulin in people with type 2 diabetes, a 
major risk factor for CKD and ESKD). Published, Am J Kidney Dis. 2016 Nov;68(5):691-702; JAMA. 
2016 Jul 19;316(3):313-24. 
Chapter 6: Analysis of the benefits and harms of dietary intervention in people with CKD (specific 
nutritional interventions for CKD/ESKD) in the form of a Cochrane systematic review of 
randomized controlled trials. Published, Cochrane Database Syst Rev. 2017 Apr 23;4:CD011998.   
Chapter 7: Analysis of patients perspectives on dietary and fluid restrictions in CKD (thematic 
synthesis of patient views from qualitative studies).  Published, Am J Kidney Dis. 2015 
Apr;65(4):559-73. 
This large series of studies has been designed and conducted with coordination of my supervisors 
(and will continue to generate substantial research output in my post-doctoral work) with the 
intention of acquiring competence in several areas of clinical research methodology including 
systematic reviews of both randomized and prognostic studies, the design and conduct of a 
primary cohort study, and qualitative research methods. 
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Publications arising from the thesis and produced during the years of my PhD in collaboration 
with other members of the extended research team 
As indicated in the introduction, all chapters presented in this thesis have been published in peer 
reviewed medical journals. Over these years, besides the specific studies which form the core of 
this PhD, my research has been focused on strategies to prevent adverse vascular outcomes in 
CKD/ESKD, and will continue in this direction. I have also gained some relevant expertise in specific 
methods of research which have been useful to help other members of the extended team with 
their studies. Below I report the full list of publications during these years, and in brackets the 
relevant chapters of this thesis: 
1: Saglimbene VM, Wong G, Ruospo M, Palmer SC, Campbell K, Larsen VG, Natale P, Teixeira-Pinto 
A, Carrero JJ, Stenvinkel P, Gargano L, Murgo AM, Johnson DW, Tonelli M, Gelfman R, Celia E, 
Ecder T, Bernat AG, Del Castillo D, Timofte D, Török M, Bednarek-Skublewska A, Duława J, 
Stroumza P, Hoischen S, Hansis M, Fabricius E, Wollheim C, Hegbrant J, Craig JC, Strippoli GFM. 
Dietary n-3 polyunsaturated fatty acid intake and all-cause and cardiovascular mortality in adults 
on hemodialysis: The DIET-HD multinational cohort study. Clin Nutr. 2017 Dec 6. pii: S0261-
5614(17)31418-8. doi: 10.1016/j.clnu.2017.11.020. [Epub ahead of print] PubMed PMID: 
29248251. (Chapter 3) 
2: van Zwieten A, Wong G, Ruospo M, Palmer SC, Barulli MR, Iurillo A, Saglimbene  V, Natale P, 
Gargano L, Murgo M, Loy CT, Tortelli R, Craig JC, Johnson DW, Tonelli M, Hegbrant J, Wollheim C, 
Logroscino G, Strippoli GFM; COGNITIVE-HD study investigators. Prevalence and patterns of 
cognitive impairment in adult hemodialysis patients: the COGNITIVE-HD study. Nephrol Dial 
Transplant. 2017 Nov 22. doi: 10.1093/ndt/gfx314. [Epub ahead of print] PubMed PMID: 
29186522. 
3: Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous 
erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane 
Database Syst Rev. 2017 Aug 7;8:CD009904. doi: 10.1002/14651858.CD009904.pub2. Review. 
PubMed PMID: 28782299. 
4: Billy CA, Lim RT, Ruospo M, Palmer SC, Strippoli GFM. Corticosteroid or Nonsteroidal 
Antiinflammatory Drugs for the Treatment of Acute Gout: A Systematic Review of Randomized 
Controlled Trials. J Rheumatol. 2018 Jan;45(1):128-136. doi: 10.3899/jrheum.170137. Epub 2017 
Aug 1. PubMed PMID: 28765243. 
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5: Saglimbene V, Natale P, Palmer S, Scardapane M, Craig JC, Ruospo M, Gargano L, Lucisano G, 
Török M, Celia E, Gelfman R, Bednarek-Skublewska A, Dulawa J, Stroumza P, Leal M, Del Castillo D, 
Murgo AM, Schon S, Wollheim C, Hegbrant J, Strippoli GFM. The prevalence and correlates of low 
sexual functioning in women on hemodialysis: A multinational, cross-sectional study. PLoS One. 
2017 Jun 20;12(6):e0179511. doi: 10.1371/journal.pone.0179511. eCollection 2017. PubMed 
PMID: 28632793; PubMed Central PMCID: PMC5478101. 
6: Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto 
P, Vecchio M, Craig JC, Strippoli GF. Glucose targets for  preventing diabetic kidney disease and its 
progression. Cochrane Database Syst Rev. 2017 Jun 8;6:CD010137. doi: 10.1002/14651858. 
CD010137.pub2. Review. PubMed PMID: 28594069. 
7: Ruospo M, Palmer SC, Wong G, Craig JC, Petruzzi M, De Benedittis M, Ford P, Johnson DW, 
Tonelli M, Natale P, Saglimbene V, Pellegrini F, Celia E, Gelfman R,  Leal MR, Torok M, Stroumza P, 
Bednarek-Skublewska A, Dulawa J, Frantzen L, Del Castillo D, Schon S, Bernat AG, Hegbrant J, 
Wollheim C, Gargano L, Bots CP, Strippoli GF; ORALD Investigators. Periodontitis and early 
mortality among adults treated with hemodialysis: a multinational propensity-matched cohort 
study. BMC Nephrol. 2017 May 22;18(1):166. doi: 10.1186/s12882-017-0574-x. PubMed PMID: 
28532432; PubMed Central PMCID: PMC5440912. 
8: Palmer SC, Maggo JK, Campbell KL, Craig JC, Johnson DW, Sutanto B, Ruospo M, Tong A, 
Strippoli GF. Dietary interventions for adults with chronic kidney disease. Cochrane Database Syst 
Rev. 2017 Apr 23;4:CD011998. doi: 10.1002/14651858.CD011998.pub2. Review. PubMed PMID: 
28434208. (Chapter 6) 
9: Saglimbene V, Palmer SC, Craig JC, Ruospo M, Nicolucci A, Tonelli M, Johnson D, Lucisano G, 
Williams G, Valentini M, D'Alonzo D, Pellegrini F, Strippoli P, Salomone M, Santoro A, Maffei S, 
Hegbrant J, Tognoni G, Strippoli GF; CE-DOSE Study Investigators. Low versus high dose 
erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. 
PLoS One. 2017 Mar 1;12(3):e0172735. doi: 10.1371/journal.pone.0172735. eCollection 2017. 
PubMed PMID: 28249030; PubMed Central PMCID: PMC5332066. 
10: Saglimbene V, Palmer S, Scardapane M, Craig JC, Ruospo M, Natale P, Gargano L, Leal M, 
Bednarek-Skublewska A, Dulawa J, Ecder T, Stroumza P, Marco Murgo A, Schön S, Wollheim C, 
Hegbrant J, Strippoli GF. Depression and all-cause and cardiovascular mortality in patients on 
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haemodialysis: a multinational cohort study. Nephrol Dial Transplant. 2017 Feb 1;32(2):377-384. 
doi: 10.1093/ndt/gfw016. PubMed PMID: 28186569. 
11: Navarese EP, Gurbel PA, Andreotti F, Kołodziejczak MM, Palmer SC, Dias S, Buffon A, Kubica J, 
Kowalewski M, Jadczyk T, Laskiewicz M, Jędrzejek M, Brockmeyer M, Airoldi F, Ruospo M, De Servi 
S, Wojakowski W, O' Connor C, Strippoli GF. Prevention of contrast-induced acute kidney injury in 
patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. 
PLoS One. 2017 Feb 2;12(2):e0168726. doi: 10.1371/journal.pone.0168726. eCollection 2017. 
Review. PubMed PMID: 28151965; PubMed Central PMCID: PMC5289438. 
12: Kelly JT, Palmer SC, Wai SN, Ruospo M, Carrero JJ, Campbell KL, Strippoli GF. Healthy Dietary 
Patterns and Risk of Mortality and ESRD in CKD: A Meta-Analysis of Cohort Studies. Clin J Am Soc 
Nephrol. 2017 Feb 7;12(2):272-279. doi: 10.2215/CJN.06190616. Epub 2016 Dec 8. Review. 
PubMed PMID: 27932391; PubMed Central PMCID: PMC5293335. (Chapter 1) 
13: Iannone A, Ruospo M, Wong G, Principi M, Barone M, Strippoli GFM, Di Leo A. 
Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review 
of Randomized Trials. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1684-1697.e11. doi: 
10.1016/j.cgh.2016.11.021. Epub 2016 Nov 25. Review. PubMed PMID: 27890853. 
14: Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, French R,  Ruospo M, 
Strippoli GF. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of 
Randomized Trials. Am J Kidney Dis. 2016 Nov;68(5):691-702. doi: 10.1053/j.ajkd.2016.05.015. 
Epub 2016 Jul 22. Erratum in: Am J Kidney Dis. 2017 Sep;70(3):452. PubMed PMID: 27461851. 
(Chapter 4) 
15: Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De 
Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, 
Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N,  Strippoli GF. Comparison of Clinical Outcomes 
and Adverse Events Associated With  Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A 
Meta-analysis. JAMA. 2016 Jul 19;316(3):313-24. doi: 10.1001/jama.2016.9400. PubMed PMID: 
27434443. (Chapter 5) 
16: Palmer SC, Natale P, Ruospo M, Saglimbene VM, Rabindranath KS, Craig JC, Strippoli GF. 
Antidepressants for treating depression in adults with end-stage kidney disease treated with 
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dialysis. Cochrane Database Syst Rev. 2016 May 23;(5):CD004541. doi: 
10.1002/14651858.CD004541.pub3. Review. PubMed PMID: 27210414. 
17: Palmer SC, Ruospo M, Wong G, Craig JC, Petruzzi M, De Benedittis M, Ford P, Johnson DW, 
Tonelli M, Natale P, Saglimbene V, Pellegrini F, Celia E, Gelfman R,  Leal MR, Torok M, Stroumza P, 
Frantzen L, Bednarek-Skublewska A, Dulawa J, Del Castillo D, Bernat AG, Hegbrant J, Wollheim C, 
Schon S, Gargano L, Bots CP, Strippoli GF; ORALD Investigators. Patterns of oral disease in adults 
with chronic kidney disease treated with hemodialysis. Nephrol Dial Transplant. 2016 
Oct;31(10):1647-53. doi: 10.1093/ndt/gfv413. Epub 2015 Dec 29. PubMed PMID: 27035674. 
18: Palmer SC, Ruospo M, Barulli MR, Iurillo A, Saglimbene V, Natale P, Gargano L, Murgo AM, Loy 
C, van Zwieten A, Wong G, Tortelli R, Craig JC, Johnson DW, Tonelli M, Hegbrant J, Wollheim C, 
Logroscino G, Strippoli GF; COGNITIVE-HD Study Investigators. COGNITIVE-HD study: protocol of 
an observational study of neurocognitive functioning and association with clinical outcomes in 
adults with end-stage kidney disease treated with haemodialysis. BMJ Open. 2015 Dec 
9;5(12):e009328. doi: 10.1136/bmjopen-2015-009328. PubMed PMID: 26656022; PubMed  
Central PMCID: PMC4679889. 
19: Mathew AT, Strippoli GF, Ruospo M, Fishbane S. Reducing hospital readmissions in patients 
with end-stage kidney disease. Kidney Int. 2015 Dec;88(6):1250-1260. doi: 10.1038/ki.2015.307. 
Epub 2015 Oct 14. Review. PubMed PMID: 26466320. 
20: Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, 
Strippoli GF. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst 
Rev. 2015 Aug 3;(8):CD003965. doi: 10.1002/14651858.CD003965.pub2. Review. PubMed PMID: 
26235292. 
21: Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF. Interventions for 
preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database 
Syst Rev. 2015 Jul 14;(7):CD010294. doi: 10.1002/14651858.CD010294.pub2. Review. PubMed 
PMID: 26171904. 
22: Palmer SC, Ruospo M, Wong G, Craig JC, Petruzzi M, De Benedittis M, Ford P, Johnson DW, 
Tonelli M, Natale P, Saglimbene V, Pellegrini F, Celia E, Gelfman R,  Leal MR, Torok M, Stroumza P, 
Bednarek-Skublewska A, Dulawa J, Frantzen L, Ferrari JN, Del Castillo D, Bernat AG, Hegbrant J, 
Wollheim C, Gargano L, Bots CP, Strippoli GF; ORAL-D Study Investigators. Dental Health and 
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Landorf KB. Risk factors for foot ulceration and lower extremity amputation in adults with end-
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The main body of my work focused on investigating the potential role of new non established risk 
factors for chronic kidney disease (CKD) and adverse vascular outcomes in CKD/end stage kidney 
disease (ESKD). As several strategies to address recognized risk factors for CKD and adverse 
vascular events in CKD have not been proven to determine significant benefits, I wanted to 
evaluate the potential prognostic value of novel risk factors for CKD/adverse vascular events in 
ESKD, specifically nutritional aspects. These have been the subject of previous research in 
cardiovascular disease and the intake of certain nutrient categories proved to be protective for the 
risk of chronic degenerative diseases in general and adverse vascular outcomes (examples include 
the Mediterranean diet, the Dietary Approaches to Stop Hypertension (DASH) diet, etc.).  
Long-term hemodialysis treatment for ESKD is associated with an annual mortality of between 
15% and 35%, depending on geographies; in Italy it is between 12-15% with some variability 
between regions. Existing interventions, including management of dyslipidemia, anemia, dialysis 
adequacy among others, have unfortunately not shown to dramatically affect the risk of such 
adverse outcomes in hemodialysis. Contention exists around some interventions (phosphate 
binding agents, glucose control, antihypertensive agents), which have been a subject of study in 
my thesis. Nonetheless, overall, there is considerable evidence that treatment of established 
cardiovascular risk factors is not effective in reducing adverse vascular outcomes in hemodialysis, 
as one would, on opposite, expect. 
Nutritional intake and dietary patterns are potential determinants of health outcomes in 
hemodialysis patients. Malnutrition (commonly referred to as protein-energy wasting) frequently 
occurs in patients treated with long-term hemodialysis. The accumulation of uremic metabolites, 
metabolic acidosis, dietary restrictions, inflammation and additional frequent comorbidities, 
including cardiac dysfunction, can suppress appetite, decrease protein and energy intake, and 
increase catabolic processes in this population. Malnutrition affects 20 to 70% of dialysis patients 
in general and particularly hemodialysis and increases with duration of dialysis treatment; 
approximately 5 to 10% of people treated with hemodialysis experience severe malnutrition.  
Premature death in people with end-stage kidney disease is strongly associated with lower body 
mass, lower serum cholesterol and other markers of impaired nutrition. Several studies have 
shown a consistent association between low serum albumin, low height-adjusted body weight and 
malnutrition (assessed by subjective global assessment) and total and cardiovascular-specific 
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mortality in the hemodialysis population. In addition, protein-energy wasting (incorporating both 
malnutrition and other metabolic derangements in patients with end-stage kidney disease, such as 
inflammation) is a strong risk factor for premature death.  Other dietary and nutrition factors have 
potential clinical effects in the setting of end-stage kidney disease. The Mediterranean diet 
specifically characterized by high intake of olive oil, fruit, nuts, vegetables and cereals, more 
moderate fish and poultry intake and lower consumption of dairy foods, red and processed meats 
and sweets, prevents cardiovascular events in the general population, but this is unproven in the 
setting of ESKD/hemodialysis. In general, data evaluating the association between dietary 
composition and clinical outcomes in people treated with hemodialysis are limited and largely 
derive from small, single-center, retrospective studies. Finally, the perspective of patients on 
hemodialysis, who are recipients of a series of restrictions in their dietary activities, are perceived 
by clinicians and the patients themselves but have not been the subject of formal study. 
Therefore, in the work of my thesis, I have contributed to design and conduct a primary study, the 
largest worldwide multinational, prospective cohort study to evaluate nutrition and dietary 
patterns and their association with major health outcomes in adults treated with hemodialysis in a 
multinational setting. The intention of this study was to identify the prevalence of dietary 
patterns, and the association of specific nutrient intakes and the risk of adverse vascular outcomes 
in ESKD/hemodialysis. Subsequent to the full analysis of this study, will be the design of primary 
intervention studies based around nutritional strategies in this population.  
As one of the researchers involve in the inception, design and conduct of this study, I have not 
only contributed to the original research idea, but have been involved in the preparation of case 
report forms of the food frequency questionnaires to be received by all patients in the 11 
countries in Europe and South America involved in the study, I was responsible for recruitment, 
data collection and data entry as well as data analysis and manuscript drafting.  
The study idea generated from the previous conduct of a series of comprehensive systematic 
literature reviews including meta-analysis  both for existing cohort studies and existing 
randomized trials of interventions (the latter based upon methodology of the Cochrane 
Collaboration).   
I finally have conducted a qualitative research study in the area of nutrition and CKD/ESKD to 
understand patients perspectives, a matter of specific important in the current era of research. 
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In performing all this work, I have gained skills in the area of searching and synthesizing evidence.  
I have developed  highly sensitive search strategies for multiple databases (MEDLINE, EMBASE, 
The Cochrane Central Registry), screened thousands of scientific papers and extracted  data from 
the selected publications to identify, evaluate and synthetize a large body of evidence on: 
 association between dietary patterns and mortality or end-stage kidney disease among 
adults with chronic kidney disease (meta-analysis of cohort studies)  
 comparing and ranking phosphate binding strategies for CKD (network meta-analysis of 
randomized controlled trials (RCTs)) 
 evaluating the relative efficacy and safety of glucose-lowering drugs including insulin in 
people with type 2 diabetes (network meta-analysis of RCTs) 
 assessing the benefits and harms of dietary interventions among people with chronic 
kidney disease (meta-analysis of RCTs) 
 evaluating/eliciting patients perspective on dietary and fluid restrictions in CKD 
(qualitative meta-analysis) 
So, the overall project is based on clinical epidemiology methods and includes multiple sub-
projects: 
1. Systematic reviews/meta-analyses  
 Systematic review/meta-analysis of cohort studies evaluating association between 
nutritional exposures and the outcomes of interest 
 Systematic review/meta-analysis of randomized trials evaluating the effects of 
specific/nonspecific nutritional interventions on the outcomes of interest  
 Systematic review/meta-analysis and thematic synthesis of qualitative studies to 
describe patients’ perspectives on dietary management in chronic kidney disease 
2. A large scale ‘ad hoc designed’ prospective cohort study assessing the association 
between nutritional exposures and the outcomes of interest (first study of its kind ever 





Aim of the thesis 
Adults with chronic kidney disease treated with hemodialysis experience high mortality rates. 
Effective interventions addressing established cardiovascular risk factors to improve health 
outcomes for long-term hemodialysis patients remain unproven and novel and testable 
determinants of health in hemodialysis are needed. Nutrition and dietary patterns are potential 
factors influencing health in other settings that warrant exploration in multinational studies in 
men and women treated with hemodialysis.   
In the current PhD project entitled “Nutrition and dietary intake and their association with 
mortality and hospitalization in adults with chronic kidney disease treated with hemodialysis” I 
aimed to evaluate the association between the exposure to different nutrition and dietary 
patterns and the risk of mortality (all-cause and cause-specific) and hospital admissions (any, and 
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Background and objectives 
Patients with chronic kidney disease are advised to follow dietary recommendations that restrict 
individual nutrients. Emerging evidence indicates overall eating patterns may better predict 
clinical outcomes, however evidence for dietary patterns in kidney disease has not been previously 
synthesized.  
Design, setting, participants and measurements 
This systematic review aimed to evaluate the association between dietary patterns and mortality 
or end-stage kidney disease among adults with chronic kidney disease. Medline, Embase, and 
reference lists were systematically searched to 24 November 2015 by two independent review 
authors. Eligible studies were longitudinal cohort studies reporting the association of dietary 
patterns with mortality, cardiovascular events, or end-stage kidney disease.  
Results 
A total of seven studies involving 15,285 participants were included. Healthy dietary patterns were 
generally higher in fruit and vegetables, fish, legumes, cereals, whole grains, and fiber and lower in 
red meat, salt, and refined sugars. In six studies, healthy dietary patterns were consistently 
associated with lower mortality (adjusted relative risk 0.73, 95% confidence interval 0.63 to 0.83; 
risk difference 46 fewer (29 to 63 fewer) events per 1000 people over five years). There was no 
evidence of an association between healthy dietary patterns and risk of end-stage kidney disease 
(1.04, 0.68 to 1.40).  
Conclusions 
Thus, healthy dietary patterns are associated with lower mortality in people with kidney disease. 
Interventions to support adherence to increased fruit and vegetable, fish, legume, whole grains, 
and fiber intake and reduced red meat, sodium, and refined sugars could be effective tools to 




Chronic kidney disease affects about 10% to 13% of adults1 and represents a public health 
challenge due to the substantially increased risks of death and cardiovascular disease among 
affected people.2 3 Patients who have chronic kidney disease are advised to follow dietary 
recommendations that restrict individual nutrients such as phosphorus, salt, potassium, and 
protein to prevent short- and long-term clinical complications.4 Historically, dietary advice has 
been based on individual nutrients or food groups instead of whole eating patterns, although 
considered complex, challenging to adhere to, and an intense burden for some patients.5 In 
addition, there is limited evidence that restricting or supplementing specific nutrients or single 
food groups effectively prevents clinical complications including kidney failure or death.6-9 Fluid 
and dietary restrictions remain frequently identified as priority areas of research by patients with 
kidney disease and healthcare providers.10 
Recent evidence has linked dietary patterns rich in fruit and vegetables, fish, legumes, cereals, and 
nuts with reduced cardiovascular events and death in healthy adults and those at high risk of 
cardiovascular disease.11-14 In parallel, there is an emerging trend toward the study of whole 
dietary patterns rather than single nutrient or food group restrictions among people with kidney 
disease.15-17 However, existing cohort studies of dietary patterns in people with kidney disease 
have small sample sizes, while existing randomized trials are insufficiently powered to establish 
the role of whole dietary patterns on mortality and kidney failure limiting the impact of single 
studies to inform clinical practice and policy.18 19 Existing dietary guidelines lack robust evidence 
for effects on patient-centered outcomes.20 
The aim of this study was to conduct a meta-analysis of the evidentiary basis for the association of 
dietary patterns with mortality and cardiovascular endpoints to establish the potential role of 





Our primary aim was to assess the association of healthy dietary patterns on the risk of mortality 
and end-stage kidney disease in adults with chronic kidney disease. This systematic review 
followed a pre-specified review protocol, prospectively registered in the International Prospective 
Register of Systematic Reviews (PROSPERO)21 and reported using the preferred reporting items for 
systematic reviews and meta-analysis (PRISMA).22 
Data sources and Searches 
We searched Medline, Embase, and reference lists of retrieved studies for prospective cohort 
studies available online reporting the association between dietary patterns and clinical outcomes 
among adults who have chronic kidney disease on November 30, 2015. We did not have any 
language or date restriction for the search. The search terms are shown in Supplemental Table 1. 
Study Selection 
Dietary patterns were defined as overall habitual food intake ascertained by healthy eating 
guidelines or a priori diet quality score; dietary pattern analysis; and/or consumption of whole 
food groups such as fruit and vegetables. We excluded single nutrient or food-group based 
modifications from this review including isolated protein or sodium restriction. We required follow 
up for at least 24 weeks to ensure sufficient follow-up of dietary patterns on patient-level 
outcomes, and explicit reporting of outcomes either as raw data or adjusted effect estimates with 
95% confidence intervals. We used definitions of chronic kidney disease according to international 
clinical practice guidelines.4. 
Data Extraction and Quality Assessment 
Two authors (JK, SW) independently reviewed all retrieved records for eligibility using reference 
management software. The two authors extracted data and adjudicated risk of bias, with 
differences resolved by discussion. We contacted authors for information missing or unclear from 
included studies. The risk of bias was assessed using the Newcastle-Ottawa tool.23 We then used 
the grading of recommendations assessment, development, and evaluation (GRADE) methodology 
to rate the quality of the evidence for mortality as high, moderate, low or very low.24 
Observational studies begin as low quality evidence, but can be rated upward to moderate or high 
quality evidence if they collectively demonstrate a large magnitude of effect, or a dose-response 
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gradient. Outcomes were death, health-related quality of life, end-stage kidney disease, major 
cardiovascular events, blood pressure, serum cholesterol, and major adverse events. 
Data Synthesis and Analysis 
We carried out analyses according to a pre-defined protocol to compare healthy eating patterns 
(generally higher intake of fruit, vegetables, cereals, legumes, whole grains and fiber, and fish, and 
lower intake of red meat, salt, and refined sugar) versus dietary intake less representative of these 
eating patterns. We then summarized adjusted risks (hazard ratio, odds ratio or relative risk) 
provided in studies using random-effects inverse variance meta-analysis. A fixed-effect model was 
also used to ensure robustness of the model chosen and susceptibility to outliers. Estimated 
numbers of events incurred or avoided with dietary change was calculated as a risk difference 
based on a five year risk of mortality reported in a systematic review of cohort studies.25 We used 
the I2 statistic to assess heterogeneity – the proportion of total variation observed in the 
association of dietary intake and outcome among studies beyond that expected by chance, with an 
I2 value less than 25% considered as low heterogeneity and more than 75% as high heterogeneity. 
We assessed for small study effects in analyses for mortality by visual evaluation of the funnel plot 
for symmetry. 
Sensitivity analyses were done excluding studies in which the same cohort of participants may 
have been represented more than once and excluding studies involving adults with end-stage 
kidney disease. We planned subgroup analyses based on gender, duration of follow up, study 
quality, and geographical region. Analyses were performed using Stata 13, with 95% confidence 





Study Selection and Baseline Characteristics 
The systematic search yielded seven cohort studies (Figure 1), involving 15 285 patients with 
chronic kidney disease (Table 1).17 26-31 The participants were followed for between 4 and 13 years 
on average, totaling approximately 91 000 patient years of follow up. All but one study involved 
people with chronic kidney disease defined as an estimated glomerular filtration rate below 60-70 
ml/min per 1.73 m2 body surface area or albuminuria.17 26-30 One study enrolled adults treated with 
dialysis.31 Studies involved people living in the United States,17 26 27 29 30 Sweden,28 and Japan.31 
Healthy dietary patterns were reported as generally consistent with a higher intake of fruits and 
vegetables, legumes, cereals, whole grains and fiber, and fish, and lower intake of red meat, and 
products containing sodium and refined sugars (Table 2). All studies were published between 2013 
and 2015. There were 3983 deaths and 1027 end-stage kidney disease events recorded during 
follow up. 
Risk of Bias and Evidence Quality 
Risks of bias in the included studies is shown in Supplemental Figure 1. Overall, studies were 
considered at low risk of bias for characteristics considered important to the reliability of cohort 
studies. When GRADE (directness, precision, consistency, and study limitations) recommendations 
were considered, the evidence quality for all-cause mortality was considered low based on the 
non-randomized study design, without incurring further downgrades in evidence quality for 
indirectness, imprecise results, heterogeneity, or study reporting limitation. 
Outcomes 
All-cause mortality  
When compared with other dietary patterns, a dietary pattern richer in vegetables, fruit, fish, 
cereals, whole grains and fiber, legumes, and nuts and seeds and lower in red meat, sodium and 
refined sugars was associated with a lower risk of death. In six studies among 13 930 participants 
followed for between 4 and 13 years the relative risk of all-cause mortality was 0.73 (95% 
confidence interval 0.63 to 0.83) (figure 2).  There was no heterogeneity between studies (I2 =0%) 
and no evidence of small study effects (Supplemental Figure 2). Based on an estimated five year 
mortality of 17% in people with chronic kidney disease,25 the risk difference with a healthy dietary 
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pattern compared to other dietary patterns was 46 fewer deaths per 1000 people (29 to 63 fewer) 
over 5 years. 
End-stage kidney disease 
There was no evidence of an association between a healthy dietary pattern and risk of end-stage 
kidney disease in three studies (n=10 071 people) with follow up ranging between 4 and 6.4 years. 
The risk of end-stage kidney disease among people with chronic kidney disease was 1.04 (0.68 to 
1.40) with no evidence of statistical heterogeneity between studies (Figure 3). 
Major cardiovascular events, health-related quality of life, adverse events, blood pressure 
There were insufficient numbers of studies to conduct meta-analysis for risks of major 
cardiovascular events. In one study involving 3006 people, a healthy diet score was not associated 
with risk of atherosclerotic events (1.01, 0.47 to 2.18).17 In a single study among 1355 dialysis 
patients, an “unbalanced dietary pattern” with high sodium intake and higher vegetable and lower 
fish and meat intake, was associated with a higher risk of a composite of hospitalization due to 
cardiovascular disease or death due to any cause.31 
There was no reporting of health-related quality of life, or cardiovascular-related death, adverse 
events, or hyperkaliemia as individual endpoints. There was no information about the effects of 
healthy dietary patterns on blood pressure or serum cholesterol levels during follow up. 
Sensitivity analyses 
Results were similar when single studies were removed to exclude the possibility that participants 
had been included in analyses more than once (Supplemental Table 2). There was no evidence 
that results in meta-analyses for mortality were different based on country of origin, age, duration 





This meta-analysis comprising approximately 90 000 person years of follow up and including 3983 
mortality events showed that dietary patterns rich in vegetables and fruits, legumes, whole grains, 
and fiber together with lower consumption of red meat, sodium, and refined sugars were 
consistently associated with reduced mortality in people with chronic kidney disease. There was 
insufficient information in existing cohort studies to determine the impact of healthy dietary 
patterns on risks of end-stage kidney disease, and major cardiovascular complications, or health-
related quality of life. To our knowledge this is the first cumulative assessment of whole dietary 
patterns and their impact on mortality and clinical complications in people with chronic kidney 
disease. 
The association of healthy dietary patterns with reduced mortality in people with chronic kidney 
disease is in contrast with the lack of association between restrictions of individual dietary 
components for food groups including serum phosphorus,7 32 33 sodium6 and protein34 intake and 
mortality, although individual studies addressing these questions have had small sample sizes and 
low power to discern the relative impact of nutritional modifications. The findings of the current 
meta-analysis are consistent with accruing large-scale evidence of consistent mortality benefits 
with adherence to a plant-based dietary pattern among people without existing chronic disease35 
although in a large randomized controlled trial of Mediterranean diet, a primarily plant-based diet 
including extra virgin olive oil or nuts, there was no statistical evidence of reduced mortality alone 
in people at high risk of cardiovascular events, although a Mediterranean dietary pattern reduced 
the risk of a composite of non-fatal and fatal cardiovascular events.11 To date, randomized trials 
testing the effects of dietary patterns rich in fruits and vegetables or a Mediterranean diet in 
adults with kidney disease are preliminary and have not examined mortality as an endpoint.18 36 37 
As in our study, there is limited evidence for the impact of eating patterns on risks of end-stage 
kidney disease in the literature, although cohort studies suggest dietary patterns rich in fruit and 
vegetables may retard progression to chronic kidney disease and decrease albuminuria and blood 
pressure.38-42 
Recent research in chronic kidney disease has seen a shift from the decades-long focus on 
assessing and modifying single nutrient components of diet among people with chronic kidney 
disease reflecting in practice guidelines,4 to an increasing analysis of whole dietary patterns. As a 
result, this study shows accumulating evidence over the last five years of analyses that consider all 
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food groups thought to be important for health. While existing single-nutrient approaches have 
had limited impact on health in people with kidney disease, this study of the building evidence for 
healthy dietary patterns on mortality risk suggests that this shift to wider dietary approaches 
across several food groups is appropriate and aligns with existing patient priorities.10 Given the 
prevalence of chronic kidney disease in the community, data supporting specific dietary patterns 
potentially has an important public health impact, and warrants the prioritization of additional 
resources to support a randomized trial of dietary intake in this population. Highly-efficient trial 
design, embedded within registries or electronic health records might increase the feasibility and 
reduce the costs of an adequately powered dietary trial in the wider population with kidney 
disease. This is particularly relevant given the progressive shift toward more Western dietary 
patterns43 and the relative lack of treatments proven to reduce the burden of premature death 
and kidney failure among people with kidney disease. A recent additional cohort study showing a 
dose-dependent association between red meat intake and risk of end-stage kidney disease and 
reduced risks when other sources of protein are substituted further adds weight to the need to 
understand the impact of whole food dietary patterns on clinical outcomes in the setting of kidney 
disease.44 
While this study was prospectively planned and conducted independently by two authors, 
providing highly consistent findings among studies, and precise risk estimates for the mortality 
endpoint, some limitations of this study can be identified. First, the healthy dietary patterns we 
identified were not standardized, and represent a heterogeneous range of dietary intake. For 
example, some dietary patterns included milk products as healthy food groups27 whereas others 
defined milk and milk product intake as less desirable.26 28 30 However, the key elements of greater 
fruit and vegetable intake were present in all studies. Second, these studies were based on dietary 
self-recalls via differing methods (food frequency questionnaires versus food records), although 
the results among all studies were consistent, and not apparently influenced by this factor. Third, 
included patients had a range of kidney function, although all had an estimated glomerular 
filtration rate below 60-70 ml/min per 1.73 m2 or albuminuria. Fourth, all the studies included in 
meta-analysis for mortality were conducted in United States or Sweden, and thus the results may 
not be generalizable to other global regions including lower resourced regions. Fifth, we did not 
find any association of dietary change with end-stage kidney disease. End-stage kidney disease is a 
rarer complication of chronic kidney disease due to the competing risk of death; accumulated 
studies evaluating the impact of diet on this outcome had relatively few recorded events as would 
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be expected, even when linked to dialysis census databases. Sixth, it was not possible to assess for 
evidence of publication bias. Finally, this study is based on non-randomized data leading to the 
potential for the findings to be partly explained by residual confounding and leading to low quality 
evidence. The results are hypothesis-generating and represent an important indication for a future 
randomized trial and public policy, particularly as dietary and lifestyle interventions are highly 
ranked research priorities by patients and clinicians. 
In summary, this meta-analysis shows that adherence to dietary patterns rich in fruit and 
vegetables, fish, legumes, cereals, whole grains and fiber, and lower in red meat, and products 
containing sodium and refined sugars is associated with reduced mortality in people with chronic 
kidney disease. This finding represents a shift in evidence from management of single nutrient or 
food groups in the care of kidney disease and aligns with the experiences of patients who describe 
nutritional advice as frequently complex and difficult to follow. This evidence might prompt the 
prioritization of randomized trials of dietary patterns among people with kidney disease and re-
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Table 1: Characteristics of included studies 
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Sweden  Uppsala 
Longitudinal 
Study of Adult 
Men 
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Meat, fish and 
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Hemodialysis Not reported 
(61.4 years) 








Table 2: Characteristics of dietary exposures used in meta-analyses 




Covariates included in risk ratio 




Plant versus animal 
protein 
Plant protein ratio quartiles (grains, fruits, 







Total protein intake, age, sex, race, smoking, alcohol 
use, calorie intake, exercise, body mass index, 
hypertension, cancer, myocardial infarction, 







Plant based  Plant based defined using principal component 





Age, gender, race, geographic region, energy intake, 
lifestyle factors (self-reported frequency of exercise; 
current smoking), comorbidities (heart disease; 
hypertension), educational achievement, family 
income, urinary albumin to creatinine ratio, 









Mediterranean diet score (polyunsaturated 
fats/saturated fatty acids >0.34; vegetables and 
legumes >69 day; fruit >115 g/day; cereals and 
potatoes >361 g/day; fish >25 g/day; meat and 
meat products <92 g/day; milk and milk products 







Body mass index, physical activity, smoking status, 







Diet score  Healthy diet score based on fish (≥ servings/week), 
fruit and vegetable consumption (≥4.5 cups/day) 
and sodium (<1500 mg/day), sugar (<450 








Age, race, sex, geographic region, income, 










Healthy diet score (American Heart Association; 
fruits/vegetables>2.8 cups/day; fish >1.3 oz/week; 
whole grains >0.88 oz/day; 24-hour urine sodium 
excretion <152 mEq/day; sweets/sugar-sweetened 
beverages <571 ml/week 
Ideal (healthy 
diet score 4-5 
Dietary score 0-
3 
Clinical center; age, sex, race/ethnicity, education, 
diabetes, dyslipidemia, hypertension, any 
cardiovascular disease, angiotensin-converting 
enzyme/angiotensin receptor blocker use; 









Index based on 
Food Guide 
Pyramid  
Healthy Eating Index based on 10 dietary 
components (grains, vegetables, fruits, milk, meat, 







Age, sex, race/ethnicity, annual household income, 
education, estimated GFR, microalbuminuria, 
diabetes, cardiovascular disease, cancer, systolic 
blood pressure, serum cholesterol, use of statin, use 







Meat, fish and 
vegetable intake 
Consumption of approximately equal amounts of 
food from meat, fish, and vegetable groups. 
Well-balanced Unbalanced Age, gender, dialysis duration, serum albumin, body 
mass index, energy intake, diabetes, coronary heart 
disease, cerebrovascular disease and peripheral 
vascular disease. 
GFR = glomerular filtration rate. 
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Figure 2: Risk of all-cause mortality associated with healthy dietary patterns among adults with 
chronic kidney disease 
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Figure 3: Risk of end-stage kidney disease associated with healthy dietary patterns among adults 
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Adults with end stage kidney disease (ESKD) treated with haemodialysis experience mortality rates 
of between 15% and 20% each year. Effective interventions that improve health outcomes for 
long-term dialysis patients remain unproven. Novel and testable determinants of health in dialysis 
are needed. Nutrition and dietary patterns are potential factors influencing health in other health 
settings that warrant exploration in multinational studies in men and women treated with dialysis. 
We report the protocol of the “DIETary intake, death and hospitalisation in adults with end-stage 
kidney disease treated with haemodialysis (DIET-HD) study”, a multinational prospective cohort 
study. DIET-HD will describe associations of nutrition and dietary patterns with major health 
outcomes for adults treated with dialysis in several countries.  
Methods and Analysis 
DIET-HD will include at least 6000 adults who have ESKD treated within a collaborative network of 
clinics in Argentina, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Sweden, 
and Turkey administered by a single dialysis provider. Nutritional intake and dietary patterns will 
be measured using the Global Allergy and Asthma European Network (GA2LEN) food frequency 
questionnaire. The primary dietary exposures will be n-3 and n-6 polyunsaturated fatty acid 
consumption. The primary outcome will be cardiovascular mortality and secondary outcomes will 
be all-cause mortality, infection-related mortality and hospitalisation. 
Ethics and dissemination 
The study has been approved by the relevant Ethics Committees in Argentina, France, Germany, 
Hungary, Italy, Poland, Portugal, Romania, Spain, Sweden, and Turkey. All participants will provide 
written informed consent and will be free to withdraw their data from the study at any time. Data 
will be handled securely and anonymously. The findings of the study will be disseminated through 
peer-reviewed journals, national and international conference presentation. We expect that the 
DIET-HD study will inform large pragmatic trials of nutrition or dietary interventions in the setting 





Long-term dialysis treatment for end-stage kidney disease is associated with an annual mortality 
of between 15% and 20%, a proportion in excess of many cancers.1 Healthcare interventions have 
not been generally shown to improve clinical outcomes for adults treated with dialysis and 
additional testable strategies for improving mortality and morbidity are needed. 
Nutritional intake and dietary patterns are potential determinants of health outcomes in dialysis 
patients. Dietary restrictions aimed at keeping fluid, serum phosphorus and potassium levels 
within range often results in limited food choices and unappetising meals.2 The accumulation of 
uraemic metabolites, metabolic acidosis, inflammation and additional frequent comorbidities, 
including cardiac dysfunction, can suppress appetite, decrease protein and energy intake, and 
increase catabolic processes in this population.3 Malnutrition (commonly referred to as protein-
energy wasting4) affects 20 to 70% of dialysis patients and increases with duration of dialysis 
treatment;5-7 Approximately 5 to 10% of people treated with dialysis experience severe protein-
energy malnutrition.8  
Premature death in people with end-stage kidney disease is strongly associated with low body 
mass, low serum cholesterol and other markers of impaired nutrition. Several studies have shown 
a consistent association between low serum albumin, low height-adjusted body weight and 
malnutrition (assessed by subjective global assessment) and total and cardiovascular-specific 
mortality in the dialysis population.9-11 In addition, protein-energy wasting (incorporating both 
malnutrition and other metabolic derangements in patients with end-stage kidney disease, such as 
inflammation) is a strong risk factor for premature death.3 Data for 5058 adults in the United 
States Renal Data System (USRDS) indicated that dialysis patients who were considered 
malnourished by their physicians had a 27% greater risk of cardiovascular death. Similarly, a 
Dialysis Outcomes and Practice Patterns Study (DOPPS) cohort study comprising 7719 adult 
haemodialysis patients reported that severe malnutrition (evaluated by a modified subjective 
global assessment, recent weight loss, poor dietary intake, gastrointestinal symptoms and visual 
assessment of subcutaneous fat) was linked to a 33% higher mortality risk.11 12 
Serum n-3 and n-6 polyunsaturated fatty acid profiles are additional potential determinants of 
cardiovascular outcomes in adults treated with haemodialysis. N-3 polyunsaturated fatty acids 
such as eicosapentaenoic acid and docosahexaenoic acid may favourably influence oxidative 
stress, inflammation and thrombosis.13 14 Dialysis patients have a decreased ratio of n-3 to n-6 
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PUFAs, which independently predicts accelerated cardiovascular disease.15 However, data for 
dietary polyunsaturated fatty acid intake and associations with mortality in this clinical setting are 
sparse although n-3 polyunsaturated fatty acid supplementation may lower mortality and hospital 
admissions in other settings of chronic disease,16  including earlier stages of chronic kidney 
disease.17  
Other dietary and nutrition factors have potential clinical effects in the setting of end-stage kidney 
disease. The Mediterranean diet, characterised by high intake of olive oil fruit, nuts, vegetables 
and cereals, moderate fish and poultry intake and lower consumption of dairy foods, red and 
processed meats and sweets, prevents cardiovascular events,18 although prognostic data in the 
setting of kidney disease are rare. The average blood levels of biologically important trace 
elements including selenium and zinc (antioxidant molecules) differ in people with end-stage 
kidney disease.19 Lower zinc levels in end-stage kidney disease patients are associated with 
increased oxidative stress, lipid peroxidation and inflammation.20 Since deficiency or excess of 
trace elements is potentially harmful, the hypothesis that trace element supplementation might 
influence clinical outcomes is worthy of evaluation. Similarly, vitamin C is an antioxidant with 
several immune and regulatory functions, and levels are often depleted in end-stage kidney 
disease patients by up to 50%. A recent Cochrane review of trials investigating the use of 
antioxidants for people with chronic kidney disease found that antioxidant therapy does not 
reduce cardiovascular or all-cause death but due to the suboptimal quality of existing studies, a 
clinically important benefit cannot be excluded.21  
The quality and quantity of food intake is thought to play a major role in cardiovascular and 
infective complications of dialysis and have prognostic implications through mechanisms 
independent of overall nutrition status (lipid levels, blood pressure, thrombotic tendency, cardiac 
rhythm, endothelial function, insulin sensitivity, oxidative stress).22 23 However, data evaluating the 
association between diet and clinical outcomes in people treated with dialysis are limited and 
largely derive from small, single-centre, retrospective studies.24-27  
The prospective study described in this protocol will be the first large scale multinational cohort 
study to evaluate the association between nutrition and health outcomes in adults with end-stage 
kidney disease treated with haemodialysis. The study will assess the short and long term morbidity 
and mortality associated with dietary intake (total energy, fat (including mono- and n-3 and n-6 
polyunsaturated fatty acids; cholesterol), carbohydrates (including total sugars), protein, fibre, 
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folate, β-carotene, retinol, thiamine, riboflavin, phosphorus, magnesium, calcium, zinc, fluid), and 
specific food types (fruit, vegetable, nuts, fish, pulses)) in adults treated with haemodialysis. The 
study will also evaluate nutrient and non-nutrient antioxidants, specific food groups related to 
Mediterranean or other regionally distinctive diets, and the intake of processed food and fresh 





Study design summary 
The “DIETary intake, death and hospitalisation in adults with end-stage kidney disease treated 
with HaemoDialysis (DIET-HD) study” is a multinational, prospective, cohort study designed to 
evaluate the association between nutrition and dietary patterns and health outcomes in prevalent 
adult haemodialysis patients in Europe and South America.  
Target population, setting and inclusion/exclusion criteria 
The DIET-HD population will involve at least 6000 adults treated with long-term haemodialysis 
treatment at clinics within a multinational collaborative dialysis network administered by 
Diaverum, a provider of renal services. The clinics included in this study will be from dialysis 
communities in which the local investigators have committed to providing high quality data in 
Argentina, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Sweden, and 
Turkey. 
Participants will be eligible for DIET-HD if they meet the following inclusion criteria: (1) have end-
stage kidney disease; (2) are treated with long-term haemodialysis for at least the previous 90 
days; (3) are 18 years or older; (4) their treating team agrees to the patient’s involvement in the 
study; and (5) the participant is willing to provide written and informed consent. We will exclude 
potential participants from DIET-HD if they have: (1) significant neurocognitive disability or 
medical comorbidity that would preclude them from understanding the dietary questionnaire 
even if assisted; (2) a life expectancy less than 6 months according to their treating physician; (3) 
planned kidney transplantation within 6 months of baseline, or (4) anticipated recovery of kidney 
function.  
Study exposures and outcomes 
The primary exposure variables will be dietary consumption of n-3 and n-6 polyunsaturated fatty 
acids. The primary outcome will be cardiovascular mortality. Secondary outcomes will be all-cause 
mortality, death due to infection, and all-cause and cause-specific hospitalisation. Key secondary 
nutritional exposure variables will dietary total energy, fat (including monounsaturated fatty acids; 
cholesterol), carbohydrates (including total sugars), protein, fibre, folate, β-carotene, retinol, 
thiamine, riboflavin, phosphorus, magnesium, calcium, zinc, fluid), and specific food types (fruit, 




Assessment of dietary intake (food frequency questionnaire) 
Consecutive eligible patients in a convenient sample of selected clinics will be given a food 
frequency questionnaire to complete during dialysis treatment. The usual dietary intake will be 
ascertained using the Global Asthma and Allergy Network of Excellence (GA2LEN) food frequency 
questionnaire (FFQ).28 The GA2LEN was initially translated into 12 languages to be used as a single 
instrument in all the European centres participating in the GA2LEN follow-up survey. The FFQ has 
been tested in a sub-sample of adults from five European countries and shown to be a reliable 
instrument to estimate dietary intake in different countries.28 Translations of the FFQ have been 
carried out following the standard operating procedure of the World Health Organization. Forward 
translation from English into relevant participant languages was carried out by local research team 
members. Back translation was then carried out by an independent translator who had not seen 
the original English version. During this stage, local foods were incorporated into each of the FFQs. 
The GA2LEN has been adapted to mirror the local and staple foods of each participant country in 
this study without affecting the international comparability structure of the FFQ. The FFQ provides 
information on the frequency of a wide range of foods, which have been classified using the 
European Food Group Classification Method designed by Ireland and colleagues.29 This is an 
international classification based on the European Food Consumption Survey Method (EFCOSUM) 
designed to “define a minimum set of dietary components which are relevant determinants of 
health and to define a method for the monitoring of food consumption in national representative 
samples of all age-gender categories in Europe in a comparable way.”30  
Nutrient estimates 
Nutrient intake will be calculated using national Food Composition Tables from each participating 
country. For analyses comprising the entire study sample, we will implement the methodological 
approach used by GA2LEN,28 which employed the British Food Composition Table to describe 
nutrient composition, including data from country-specific Food Composition Tables, to calculate 
nutrient estimates of traditional or staple foods of specific countries. Current analyses in the 
GA2LEN Nutrition study show that the British Food Composition Table is the most comprehensive 
table in terms of number of nutrient data available. We have access to all the latest data within 
Food Composition Tables in European countries facilitated by EuroFir (European Food Network of 
Excellence)31 which, as GA2LEN, was an EU funded Network. This is now a non-profit consortium 
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that fosters the advancement in the knowledge of food composition in Europe and other 
countries.  
The standard food portion sizes used in the FFQ will be obtained from Food Standard Agency Food 
Portion Sizes Guidelines in the UK. The frequency of consumption will be converted into grams per 
day and then into nutrient estimates. The FFQ is designed to be answered by the participants (self-
administered). However, depending on the country and the needs of the research team, as well as 
of the participants, some centres will prefer to have the FFQ interviewer-administered, when 
necessary, or have interviewers on hand in the clinics to either administer the FFQ (for participants 
who have literacy limitations) or to verify that the FFQ has been answered in full. Participants will 
complete the dietary questionnaire during a haemodialysis treatment. 
We will calculate intake of the following macro- and micro- nutrients using estimates of the 
EuroFir Food Composition Tables: energy (kJ/day), fat (including mono- and polyunsaturated fat; 
n-3 polyunsaturated fatty acids; n-6 polyunsaturated fatty acids; trans-fatty acids; cholesterol), 
carbohydrate, glycaemic index, total sugar, protein (including sources (animal versus vegetable 
sources)), fibre, folate, beta-carotene, retinol, thiamine, riboflavin, phosphorus, magnesium, 
calcium and zinc. We will also estimate the intake of specific food groups including fruit, vegetable, 
nuts, fish and pulses. Research assistants will be trained using a step-by-step practical overview of 
the process that is to be followed in administration of the questionnaires. The protocol 
emphasises the need for assistants to avoid non-verbal cues indicating surprise or disapproval at 
the participant’s eating patterns.  
FFQ responses will be evaluated by members of the research team who are unaware of the 
participants’ identities. All FFQs with missing values will be checked and corrected for any data 
errors. After data cleaning, if more than 10% of the questionnaire remains incomplete, then the 
participant will be excluded. In addition, individuals for whom energy intake is in the upper or 
lower 2% of the intake will then checked for data entry and coding accuracy and errors will be 
corrected, if identified. Data from the FFQ will be entered into an electronic database using optical 
character recognition (OCR) and analysed using software that facilitates the collection of food 





Demographic and clinical data 
Demographic, clinical, laboratory and dialysis-related data will be obtained from a patient 
database within one month of enrolment. Relevant data will be obtained from clinical databases 
linked to the participant via a standardised identification code. Standardised data will include age, 
gender, race, country of residence, clinic attended, education, marital and occupational status, 
family income, financial stress, housing, alcohol intake, smoking history, physical activity, 
menopausal status, body mass index, protein catabolic rate, cause of kidney disease, existence of 
cardiovascular comorbidity, diabetes, or hypertension, medication prescription, dialysis 
prescription, and serum levels of haemoglobin, phosphorus, parathyroid hormone, calcium, 
ferritin, albumin, and total cholesterol. 
Outcomes 
Measurement time points 
After baseline dietary evaluation, we will measure clinical outcomes using linked data at 12 
months and thereafter at yearly intervals up to 10 years. Data for total and cause-specific 
hospitalisation and mortality are obtained through data linkages to a centralised database 
administered by Diaverum. In this database, every change in participant status is updated by the 
managing clinician on a monthly basis, including change in survival status or hospitalisation, with 
causes of death or hospital admission. 
Outcomes 
The primary study outcome will be cardiovascular mortality. Secondary outcomes will all-cause 
mortality, infection-related mortality, and all-cause and cardiovascular related hospitalisation. A 
cardiovascular-related death or hospitalisation will include death or hospitalisation attributed to 
acute myocardial infarction, pericarditis, atherosclerotic heart disease, cardiomyopathy, cardiac 
arrhythmia, cardiac arrest, valvular heart disease, pulmonary oedema, congestive cardiac failure, 
cerebrovascular accident including intracranial haemorrhage, ischemic brain damage including 
anoxic encephalopathy, or mesenteric infarction or ischemic bowel. An infection related death will 
include septicaemia due to internal vascular access, central nervous system infection (brain 
abscess, meningitis, encephalitis), septicaemia due to peripheral vascular disease or gangrene, 
cardiac infection (endocarditis), pulmonary infection (pneumonia or influenza), abdominal 
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infection (peritonitis, perforated bowel, diverticular disease, gallbladder infection), or genito-
urinary infection (urinary tract infection, pyelonephritis, renal abscess). 
Sample size 
The sample size for this study will be at least 6000 participants. Based on an anticipated mortality 
of 14% to 15% each year and a cardiovascular mortality rate of 6% per annum, we anticipate that 
recruitment and evaluation of at least 6000 participants will allow the study, with a type 1 error α= 
0.05 and power of 80% to detect a hazard ratio of at least 1.10 for each 1 standard deviation 
decrease in n-3 polyunsaturated fatty acid intake. When adjusting for the complete set of 
potentially confounding variables, assuming an R2 = 0.30, the same sample size will detect a hazard 
ratio of at least 1.12 for each standard deviation decrease in the primary exposure.  
Statistical analysis 
The initial data analysis will be descriptive. Participants’ baseline characteristics (country, clinic, 
demographics, clinical characteristics, dialysis treatment, etc.) will be described using frequencies 
for categorical variables and mean, median, range, standard deviation for continuous variables. 
Characteristics of specific dietary components will also be calculated as mean, median, range, and 
standard deviation. To evaluate associations between each individual nutrient of interest and the 
outcomes, we will conduct multivariate regression analyses using Cox proportional hazards 
analysis fitted using a shared frailty model to account for clustering within countries. Participants 
will be censored within survival analyses if they emigrate from the dialysis network, are 
transplanted, or experience recovery of their kidney function.  
Given the large number of nutritional exposures, we will control for potential false discoveries 
using the Simes’ procedure allowing for a 5% false discovery rate while controlling for potential 
confounding variables. Similarly we will explore associations between groups of foods (e.g., 
vegetables or fruits) and nutrients using similar techniques. We will then explore the association 
between dietary or nutritional exposures (foods, single or grouped or nutritional components) 
with the outcomes of interest within countries using logistic or linear regression adjusted by 
confounding variables) and then combine data from all countries using meta-analysis. We will also 
calculate weighting of the sample to make it representative of the source population within each 
country. We will conduct analyses in STATA (www.stata.com) using existing routines available for 
the GA2LEN study. 
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Ethics and dissemination 
Ethical considerations 
DIET-HD has received ethics approval from the following responsible Human Research Ethics 
Committees in France, Germany, Hungary, Portugal, Romania, Spain, Sweden, and Turkey. Ethics 
approval was not required for this type of study in Argentina, Italy or Poland. The study is based on 
informed written consent, and participants can withdraw from the study at any point in time. The 
study is non-invasive and imposes no significant risks to participants. Data material will be 
managed confidentially and anonymously. 
Dissemination 
The findings of the study will be disseminated through peer-reviewed journals, national and 
international conference presentations and to the participants through communication within the 




We have designed DIET-HD to evaluate whether dietary patterns and nutritional intake are 
associated with mortality and hospitalisation in adults with end-stage kidney disease treated with 
haemodialysis. This study will generate potential testable diet and nutrition targets for evaluation 
in pragmatic multicentre trials and meta-analyses. 
Our study design, while incorporating data from several countries and using validated and robust 
multinational dietary analysis tools from the GA2LEN network collaboration, has potential 
limitations. To ensure sufficient data from a broad range of participants, we have used a 
convenient sample of clinics within the participating countries to maximise recruitment without 
stratification by key clinic demographic or clinical characteristics. This may limit our ability to 
provide data representative of source populations but will still be the largest in depth nutritional 
survey of adults treated with haemodialysis to date. Mortality and other endpoint data will be 
obtained using linkages to a data registry. There will not be adjudication of clinical endpoints by 
personnel blinded to exposure and there will be some misclassification of clinical outcomes.  
Effective strategies to improve health outcomes in this population are scarce and urgently needed. 
We expect that the results of the DIET-HD study will inform large pragmatic trials of nutrition or 
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Background & Aims: Patients on hemodialysis suffer from high risk of premature death, which is 
largely attributed to cardiovascular disease, but interventions targeting traditional cardiovascular 
risk factors have made little or no difference. Long chain n-3 polyunsaturated fatty acids (n-3 
PUFA) are putative candidates to reduce cardiovascular disease. Diets rich in n-3 PUFA are 
recommended in the general population, although their role in the hemodialysis setting is 
uncertain. We evaluated the association between the dietary intake of n-3 PUFA and mortality for 
hemodialysis patients. 
Methods: The DIET-HD study is a prospective cohort study (January 2014-June 2017) in 9757 
adults treated with hemodialysis in Europe and South America. Dietary n-3 PUFA intake was 
measured at baseline using the GA2LEN Food Frequency Questionnaire. Adjusted Cox regression 
analyses clustered by country were conducted to evaluate the association of dietary n-3 PUFA 
intake with cardiovascular and all-cause mortality. 
Results: During a median follow up of 2.7 years (18,666 person-years), 2087 deaths were 
recorded, including 829 attributable to cardiovascular causes. One third of the study participants 
consumed sufficient (at least 1.75 g/week) n-3 PUFA recommended for primary cardiovascular 
prevention, and less than 10% recommended for secondary prevention (7-14 g/week). Compared 
to patients with the lowest tertile of dietary n-3 PUFA intake (<0.37 g/week), the adjusted hazard 
ratios (95% confidence interval) for cardiovascular mortality for patients in the middle (0.37 to 
<1.8 g/week) and highest (≥1.8 g/week) tertiles of n-3 PUFA were 0.82 (0.69-0.98) and 1.03 (0.84-
1.26), respectively. Corresponding adjusted hazard ratios for all-cause mortality were 0.96 (0.86-
1.08) and 1.00 (0.88-1.13), respectively.  
Conclusions: Dietary n-3 PUFA intake was not associated with cardiovascular or all-cause mortality 
in patients on hemodialysis. As dietary n-3 PUFA intake was low, the possibility that n-3 PUFA 








Approximately 1 in 10 people on dialysis die every year, and 40% of these deaths are attributable 
to cardiovascular disease (1-3). The pathogenesis of cardiovascular disease is different in dialysis 
patients from for the general population, driven largely by non-traditional risk factors, including 
oxidative stress, inflammation, endothelium dysfunction and altered mineral metabolism leading 
to medial arterial calcification (4-7). Consequently, the benefits of interventions targeting 
traditional cardiovascular risk factors, such as statins, blood-pressure lowering, and anti-platelet 
therapy, have been shown to have lower effectiveness for preventing adverse cardiovascular 
outcomes in hemodialysis patients (8-12).  
Long chain n-3 polyunsaturated fatty acids (n-3 PUFA) are recommended to prevent 
cardiovascular disease in the general population (13-15). n-3 PUFA, present mostly in oily fish and 
in smaller amount in meat, eggs and dairy products, have potential anti-thrombotic, anti-oxidative, 
anti-inflammatory and anti-arrhythmic effects on cardiac myocytes (16-19). Informed by a number 
of randomized controlled trials and systematic reviews (20-25), the current recommendations by 
the American Heart Association and World Health Organization suggest an intake of at least 1.75 
grams per week of n-3 PUFA (achieved by at least two servings of fish per week, especially oily 
fish) for primary cardiovascular prevention and 7-14 grams per week (which could require 
supplementation) for secondary prevention (13-15).  
In patients on hemodialysis, data for the effects of n-3 PUFA on mortality are sparse and limited to 
small-scale observational studies (26-33). Results to date have been inconclusive. Accordingly, 
recommendations for n-3 PUFA intake in the hemodialysis population have been extrapolated 
from evidence in the general population (34).  
The aim of this study was to ascertain the association of dietary n-3 PUFA intake with 




The “DIETary intake, death and hospitalization in adult with end-stage kidney disease treated with 
HemoDialysis” (DIET-HD) study is a multinational, prospective, cohort study to evaluate the 
association between nutrition and dietary patterns with major health outcomes in prevalent adult 
patients treated with hemodialysis. The study protocol has been detailed elsewhere (35). This 
study is reported according to the Strengthening the Reporting of Observational studies in 
Epidemiology (STROBE) guidelines (36).  
Study Population 
Consecutive patients were invited from a convenience sample of clinics within a private dialysis 
provider network in Europe (France, Germany, Italy, Hungary, Poland, Portugal, Romania, Spain, 
Sweden, and Turkey) and South America (Argentina). Eligible patients were 18 years or older with 
end-stage kidney disease treated with hemodialysis (any number of treatments per week and any 
duration per treatment) for at least the previous 90 days. Patients were excluded if they had 
significant neurocognitive disability that precluded them from completing the Food Frequency 
Questionnaire (FFQ), a life expectancy less than six months, or anticipated kidney transplantation 
within six months of baseline data collection. Ethics approval was obtained from all relevant 
institutional ethics committees and the study was conducted in accordance with the Declaration 
of Helsinki. All participants provided written and informed consent. 
Covariates of interests 
Socio-demographic, clinical and dialysis characteristics at baseline were obtained from an 
administrative database that stored relevant data on incident patients requiring hemodialysis 
within all facilities of the private dialysis provider. This database was linked to the participants via 
a unique identification code. All participating clinics used the same standard operating procedures 
to assess and record baseline variables including age, gender, country of treatment, education 
attainment, marital status and living situation, occupation, smoking history, physical activity, Body 
Mass Index,comorbidities (including diabetes  and previous cardiovascular disease), use of 
medications, laboratory parameters (including hemoglobin, albumin, phosphorus and calcium) and 






The dietary intake of n-3 PUFA was ascertained using the Global Allergy and Asthma European 
Network (GA2LEN) Food Frequency Questionnaire (FFQ) (37). During the dialysis treatment, 
participants answered the FFQ, either independently or assisted by an interviewer, depending on 
the severity of their clinical condition. Data from the FFQ were entered into an electronic database 
using optical character recognition and linked to the baseline and outcomes data via a unique 
identification code. The GA2LEN FFQ was specifically designed as the first single, standardized 
instrument to assess dietary intake across countries and was particularly validated for n-3 PUFA 
dietary intake. Patients reported how often they had consumed the foods over the previous year, 
using eight predefined options (rarely or never, 1-3 times per month, once, 2-4, or 5-6 times per 
week, once, 2-3 or 4 or more times per day). Standard food portion sizes were used to quantify 
the intake following the recommendations from the UK’s Food Standards Agency, and daily food 
intake (grams) was calculated. Macro- and micronutrient intake were derived using the latest 
available McCance & Widdowson’s Food Composition Tables. 
Outcomes 
The primary outcome was time to death due to cardiovascular causes. Cardiovascular mortality 
was defined as sudden death or death attributed to acute myocardial infarction, pericarditis, 
atherosclerotic heart disease, cardiomyopathy, cardiac arrhythmia, cardiac arrest, valvular heart 
disease, pulmonary edema, or congestive cardiac failure. Outcomes data were obtained from data 
linkage with the administrative database and adjudicated by the participants’ treating clinicians, 
who were unaware of the dietary n-3 PUFA intake. The secondary outcome was death from any 
cause. 
Statistical analysis 
The a priori sample size calculation has been reported in detail in the published study protocol 
(35). Participants were excluded if their FFQ contained erroneous or missing identification code 
(after optical character recognition) that prevented the data linkage with their clinical baseline and 
outcomes data, 20% or more missing answers, or biologically implausible values for total energy 
intake (above or below 3 standard deviations from the log transformed mean). 
Baseline variables were calculated as mean and standard deviation or median and interquartile 
range for continuous variables, depending upon their distribution, and as frequencies and 
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percentages for categorical variables. Restricted cubic splines were used to determine the linearity 
between n-3 PUFA intake and mortality (no evidence of non-linearity was identified). The follow-
up period was defined from the time of the inclusion in the study to the time of cardiovascular or 
all-cause mortality. Patients who left the dialysis network, underwent kidney transplantation, 
were transferred to peritoneal dialysis, withdrew dialysis, had kidney function recovery, went on 
vacation, were lost to follow-up or survived until the end of the follow-up period were censored. 
Univariate and multivariate Cox proportional hazard regression analyses were fitted using a 
random effects shared frailty model and stratified by country to account for clustering of mortality 
risk and dietary exposure within countries. Dietary intake of n-3 PUFA was entered as tertiles in 
the random effect shared frailty model and as continuous variable in the analysis stratified by 
country. Results were expressed as a hazard ratio and the associated 95% confidence interval. The 
proportional hazards assumption in Cox models was assessed by fitting log (time)-dependent 
covariates in the multivariable model and no deviation from the assumption was found. Effect 
modification between dietary n-3 PUFA intake and covariates were tested in the multivariable 
model and no effect modification was observed. 
Analyses of cardiovascular mortality were adjusted for gender, education (secondary versus 
none/primary), smoke (former or current versus never), diabetes, myocardial infarction, vascular 
access type (arterio-venous fistula versus graft/catheter), Body Mass Index (categories according 
to WHO), albumin (tertiles), Charlson comorbidity score (quartiles), age (standard deviation 
increase), phosphorus, calcium, haemoglobin, KTV (index to quantify hemodialysis treatment 
adequacy), fiber daily intake (tertiles) and energy intake (1000 kcal per day increase). Analyses of 
all-cause mortality were adjusted as above except for fiber intake and with the addition of time on 
dialysis and being wait-listed for renal transplantation. Variables included in the multivariate 
models were selected by backwards elimination retaining those (a part from energy intake and 
gender) that were significantly associated with mortality (p < 0.05) or changed the hazard ratio of 
mortality for dietary n-3 PUFA by a clinically relevant amount (≥ 10%). For each categorical 
variable, an extra category was included for missing data in the multivariate model, when 
necessary (education, smoking, diabetes, myocardial infarction, serum albumin, Body Mass Index). 
A complete-case analysis was also conducted including only those patients with complete data as 
sensitivity analyses. In subgroup analysis the association between dietary n-3 PUFA intake and 
cardiovascular mortality was assessed among patients achieving levels of n-3 PUFA recommended 
for secondary cardiovascular prevention. The potential relevance of competing events (death from 
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other causes and kidney transplantation for the analysis of cardiovascular mortality; kidney 
transplantation for the analysis of all-cause mortality) was considered using a stratified 
proportional sub-distribution hazard model. All analyses were conducted using SAS 9.4. (Inc, Gary 




Overall, 9757 patients on hemodialysis were enrolled from 5 January 2014 through 22 January 
2015 in the DIET-HD study and followed through 27 June 2017. Of these, 8110 (83%) were 
included in the analysis. Patients with an erroneous or missing identification code to allow data 
linkage [n = 1224 (13%)] and those with insufficient or implausible dietary responses [n = 423 (4%)] 
were excluded (Figure 1). 
Baseline characteristics  
The mean age of the cohort was 63.1 years (standard deviation 15.0 years). Overall, 4691 (58%) 
were men, 2068 (33%) were former or current smokers, 934 (15%) engaged in daily physical 
activity, 2332 (32%) had diabetes, 838 (12%) had experienced myocardial infarction and 634 (9%) 
had experienced stroke. Participants had been treated with hemodialysis for a median period of 
3.6 years (interquartile range 1.7 to 6.8) (Table 1).  
The median intake of n-3 PUFA was 1.2 (0.3 to 2.4) grams per week. Overall, 31% of participants 
did not consume any fish on a weekly basis, 46% consumed ≤1 serving, and 23% ≥ 2 servings each 
week. There was substantial variability in the dietary intake of n-3 PUFA across countries (Table 2). 
The median weekly intake of n-3 PUFA ranged from 0.2 (0.1 to 0.6) grams in Argentina and 3.1 (2.1 
to 4.3) grams in Sweden. The median country-level n-3 PUFA intake was lower than the minimum 
recommended value for cardiovascular prevention (1.75 grams per week) in nine out of eleven 
countries. 
Cardiovascular and all-cause mortality  
During a median follow up of 2.7 years (18,666 person-years), 2087 deaths (26%) were recorded, 
of which 829 (40%) were attributable to cardiovascular causes.  The incidence of cardiovascular 
and all-cause mortality varied considerably by country and was highest among patients in Eastern 
European countries (Hungary, Poland, Romania, Turkey) and Argentina and lower among patients 
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in Northern, Central and Western European countries (Sweden, Germany, Portugal, Spain, France, 
Italy) (Table 2). In general, patients in countries with lower incidence of cardiovascular and all-
cause mortality, such as Sweden (5 and 16 deaths per 100,000 person-days, respectively) and 
Portugal (7 and 26 deaths per 100,000 person-days) reported a higher median intake of n-3 PUFA 
(3.1 [interquartile range 2.1-4.3] and 2.4 [1.2-6.9] g per week, respectively), while patients in 
countries with higher incidence of cardiovascular and all-cause mortality, including Hungary (25 
and 46 deaths per 100,000 person-days) and Argentina (16 and 38 deaths per 100,000 person-
days) reported lower intake of n-3 PUFA (0.4 [0.2-1.3] and 0.2 [0.1-0.6] grams per week 
respectively) (Figure 2).  
Association between dietary n-3 PUFA intake and cardiovascular mortality 
There was no association between dietary intake of n-3 PUFA and cardiovascular mortality. The 
adjusted hazard ratio (95% CI) for cardiovascular death among patients in the highest (≥1.8 grams 
per week) and middle tertile (0.37 to <1.8 grams per week) of dietary n-3 PUFA intake was 0.99 
(0.83 to 1.19) and 0.84 (0.71 to 1.00), respectively, compared with patients in the lowest tertile 
(<0.37 grams per week). Similar findings were observed when considering the competing risk of 
other causes of death and kidney transplantation on cardiovascular mortality (Table 3). In 
subgroup analysis including only patients (N=725) achieving levels of n-3 PUFA recommended for 
secondary prevention (≥ 7 grams per week), no significant association between n-3 PUFA and 
cardiovascular mortality was observed [adjusted hazard ratio among patients in the highest (≥8.9 
grams per week) and middle tertile (7.5 to <8.9 grams per week) was 1.26 (0.58-2.72) and (1.16 
(0.56-2.4) respectively, compared with patients in the lowest tertile (<7.5 grams per week)]. There 
was no association between dietary n-3 PUFA intake and cardiovascular mortality within individual 
countries (Figure 3). Risk factors for cardiovascular mortality included older age, lower education, 
smoking, presence of comorbidities and higher level of phosphorus and calcium. Arterio-venous 
fistula vascular access, dietary fiber, serum albumin, BMI, hemoglobin and Kt/V were inversely 
associated with cardiovascular mortality (Table S1). 
Association between dietary n-3 PUFA intake and all-cause mortality 
Compared with patients in the lowest dietary intake of n-3 PUFA, the adjusted hazard ratio (95% 
CI) for all-cause mortality among those in the highest and middle n-3 PUFA tertile was 1.00 (0.88 
to 1.13) and 0.96 (0.86 to 1.08), respectively. Similar findings were observed when considering the 
competing risk of kidney transplantation on all-cause mortality (Table 3). There was no association 
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between dietary intake of either n-3 PUFA and all-cause mortality within countries (Figure 3). Risk 
factors for all-cause mortality were older age, being male, lower education, smoking, presence of 
comorbidities, longer time on dialysis and serum levels of phosphorus and calcium. Arterio-venous 
fistula vascular access, being wait-listed for renal transplantation, and higher levels of albumin, 
BMI, hemoglobin and Kt/V were associated with lower risks of all-cause mortality (Table S1).  
Complete-case analysis 
Similar findings were observed in complete-case analysis. 3981 participants had complete data for 
dietary n-3 PUFA, as ascertained by the FFQ, and for covariates and clinical outcomes, as collected 
within the administrative database. In this subsample of patients, the adjusted hazard ratio (95% 
CI) for cardiovascular death among patients in the highest and middle tertiles of n-3 PUFA intake 
was 1.12 (0.82 to 1.53) and 0.89 (0.66 to 1.18), respectively, compared with those in the lowest 
tertile. The adjusted hazard ratios (95% CI) for all-cause mortality among patients in the highest 
and middle tertiles of n-3 PUFA intake were 1.04 (0.87 to 1.25) and 1.02 (0.86 to 1.20), 






In this large, multinational cohort study of dietary n-3 PUFA intake, dietary intake was generally 
below recommended levels for primary and secondary prevention of cardiovascular mortality. No 
association between the dietary n-3 PUFA intake with cardiovascular or all-cause mortality was 
observed among adults treated with hemodialysis. When considering an ecological approach, 
there was considerable variation in the dietary intake of n-3 PUFA among participating countries 
with an apparent inverse relationship between country-level median dietary intake of n-3 PUFA 
and mortality incidence. However, such ecological inferences between n-3 PUFA dietary intake 
and mortality were not present at the individual patient level, when controlling for clinical 
characteristics and energy intake.  
The absence of an observed relationship between dietary n-3 PUFA intake and mortality has a 
number of possible interpretations, including insufficient power, duration of follow up, dietary n-3 
PUFA intake below levels considered sufficient for mortality prevention, or the absence of a true 
relationship between n-3 PUFA dietary intake and mortality in the dialysis setting. Chief among 
these putative explanations may be the insufficient level of n-3 PUFA, particularly in hemodialysis 
patients whose mortality risk is similar in magnitude to those requiring secondary prevention and 
whose dietary n-3 PUFA intake in this cohort was lower than recommended for primary 
cardiovascular prevention. Previous interventions studies in the general population have 
suggested a threshold of at least 1.75 g per week of n-3 PUFA (achieved by at least two servings of 
fish per week) is needed to achieve any cardiovascular benefits (38) and higher doses n-3 PUFA 
supplementations (≥ 7 g per week) are required for secondary cardiovascular prevention strategy 
(20, 21). Only one third of the present study population consumed recommended levels of n-3 
PUFA as to achieve primary cardiovascular prevention, and less than 10% of study participants 
achieved the level of n-3 PUFA recommended for secondary prevention. The risk of cardiovascular 
disease within the hemodialysis population is very high, and might therefore require higher dose 
n-3 PUFA, analogous to secondary prevention, and which could only be achieved through 
supplementation. Although no significant association between n-3 PUFA and cardiovascular 
mortality was observed in our subgroup analysis including patients with secondary prevention 
levels of n-3 PUFA, the number of observations within this subgroup was too small to exclude a 
beneficial effect of higher dose n-3 PUFA. Existing randomized controlled trials of higher dose n-3 
PUFA supplementation in patients on hemodialysis have reported no significant effect on all-cause 
63 
 
mortality and arteriovenous fistula failure, but reduced risk of thrombosis in arteriovenous grafts 
and cardiovascular events (39-42). None have assessed the impact of n-3 PUFA supplementation 
on cardiovascular mortality as the primary outcome in this population (26, 27).   
The finding of low dietary intake of n-3 PUFA in our cohort is consistent with previous studies 
reporting a lower intake of n-3 PUFA in the hemodialysis setting compared to the dietary 
guidelines for cardiovascular risk reduction (43, 44). Low dietary n-3 PUFA intake is also consistent 
with lower energy and other nutrient intake, including protein and fiber, by hemodialysis patients 
as compared to recommendations for cardiovascular prevention in the general population, and 
renal nutrition recommendations (45-47). Impaired appetite caused by uremia and comorbid 
illness (48), and financial constraints (49) experienced by hemodialysis patients can contribute to 
these deficiencies in nutritional intake.  
The present study has several strengths. It is the primary analysis of the DIET-HD study, a large 
multinational prospective cohort study investigating putative determinants of adverse clinical 
outcomes for patients on hemodialysis. In particular, the DIET-HD study examines the role of diet 
in the hemodialysis setting that is an important area of research uncertainty prioritized by 
healthcare professionals and patients (50). The population was geographically diverse thereby 
enhancing the generalizability of the findings. To date, no data are available on dietary intake of n-
3 PUFA and its association with mortality in hemodialysis patients across different countries using 
a common FFQ.  This was the first FFQ specifically designed to allow international comparisons 
and that included local foods for each participant country. 
Limitations of the study should be also considered. First, ascertainment errors were possible due 
to the use of a self-reported questionnaire. Second, despite the high response rate to the FFQ, the 
exclusion of patients with erroneous or missing identification code (13%) raised the potential for 
selection bias. Third, information regarding the potential consumption of PUFA supplementation 
was not available. In addition, the single baseline measurement of dietary n-3 PUFA intake may be 
not reflective of the actual cumulative intake over time both before the study commended and 
during follow up. Moreover, blood levels of n-3 PUFA were not measured and may reflect more 
accurately longer term consumption and myocardial n-3 PUFA composition. However, the 
correlation between dietary intake of n-3 PUFA ascertained by the GA2LEN FFQ and corresponding 
levels in plasma has been validated in a previous pilot study (37) reporting results in agreement 
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with those of other validation studies of dietary n-3 PUFA intake from FFQs with plasma levels (51, 
52). 
In summary, the dietary intake of n-3 PUFA in adults treated with hemodialysis is below the 
recommended levels for primary and secondary cardiovascular prevention. At these levels of n-3 
PUFA intake, there was no demonstrable association between dietary n-3 PUFA and mortality 
which may indicate either that n-3 PUFA does not improve cardiovascular outcomes in 
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cardiovascular and all-cause mortality 






Table 1: Baseline characteristics of participants  
Variable Overall (N=8110) 
Demographics  
Age (years) (n=8110) 63.1 (15.0) 
Male (n=8110) 4691(57.8) 
Country (n=8110)  
Portugal 1777 (21.9) 
Argentina 1204 (14.9) 
Turkey 1107 (13.7) 
Spain 1041 (12.8) 
Romania 1000 (12.3) 
Hungary 554 (6.8) 
Italy 543 (6.7) 
Poland 434 (5.4) 
France 221 (2.7) 
Germany 178 (2.2) 
Sweden 51 (0.6) 
Socio-economic characteristics  
Married/life partner (n=6095) 4127 (67.7) 
Secondary education (n=6090) 2699 (44.3) 
Daily physical activity (n=6199) 934 (15.1) 
Wait-listed for transplant (n=8094) 1496 (18.5) 
Current or former smoker (n=6280) 2068 (32.9) 
Clinical characteristics  
Body-Mass Index (kg/m2) (n=7872)  
Underweight (<18.5) 365 (4.6) 
Normal range (18.5-24.9) 3309 (42.0) 
Pre-obese (25.0-29.9) 2659 (33.8) 
Obese (≥30.0) 1539 (19.6) 
Hypertension (n=7317) 6219 (85.0) 
Diabetes (n=7280) 2332 (32.0) 
Congestive heart failure (n=7272) 1388 (19.1) 
Myocardial infarction (n=7236) 838 (11.6) 
Stroke (n=7230) 634 (8.8) 
Pulmonary disease (n=8108) 940 (11.6) 
Depression (n=7218) 757 (10.5) 
Gastrointestinal disease (n=8108) 1763 (21.7) 
Charlson comorbidity score (n=8108) 6 (4-8) 
Laboratory variables  
Albumin, g/L (n=6167) 39.8 (3.8) 
Phosphorus, mg/dL (n=7869) 4.7 (1.4) 
Calcium, mg/dL (n=7870) 8.9 (0.7) 
Hemoglobin, g/dL (n=7869) 11.1 (1.3) 
Dialysis characteristics   
Arterio-venous fistula (n=8051) 6481 (80.5) 
Time on dialysis (years) (n=8108) 3.6 (1.7-6.8) 
Kt/V urea (n=7818) 1.7 (0.3) 
Continuous data are expressed as mean (standard deviation), median (25th, 75th quartile) or number (percentage). 
Body Mass Index categories are defined according to the World Health Organization. Anti-hypertensive includes 
angiotensin converting enzyme or angiotensin II receptor blocker. 
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Table 2. Country-specific dietary n-3 PUFA intake and incidence (per 100,000 person-days) of 






n-3 PUFA  
Median, grams per week (IQR) 
Argentina 16 38 0.2 (0.1-0.6) 
France 9 32 1.5 (0.5-2.5) 
Germany 4 29 1.4 (0.3-2.2) 
Hungary 25 46 0.4 (0.2-1.3) 
Italy 8 27 1.4 (0.3-2.7) 
Poland 15 35 1.3 (0.3-2.4) 
Portugal 7 26 2.4 (1.2-6.9) 
Romania 18 32 1.3 (0.2-1.8) 
Spain 7 32 1.5 (0.5-3.4) 
Sweden 5 16 3.1 (2.1-4.3) 
Turkey 11 22 1.2 (0.3-1.5) 
n-3 PUFA: long chain n-3 polyunsaturated fatty acids (calculated as sum of eicosapentaenoic acid, docosapentaenoic 
acid and docosahexaenoic acid). IQR: interquartile range. 
 
 
Table 3: Mortality hazard ratios (95% confidence interval) by tertiles of weekly grams n-3 
PUFA intake  
 n-3 PUFA, grams per week 
Model ≤ 0.37 0.37 to <1.8 ≥1.8 
Cardiovascular mortality    
Univariate random effect 1.00 0.84 (0.71-1.00) 0.99 (0.83-1.19) 
*Multivariate random effect 1.00 0.82 (0.69-0.98) 1.03 (0.84-1.26) 
*Multivariate competing risk 1.00 0.82 (0.68-0.97) 1.05 (0.85-1.29) 
All-cause mortality    
Univariate random effect 1.00 0.99 (0.89-1.10) 1.00 (0.89-1.12) 
≠Multivariate random effect 1.00 0.96 (0.86-1.08) 1.00 (0.88-1.13) 
≠Multivariate competing risk 1.00 0.97 (0.87-1.09) 1.01 (0.89-1.15) 
*Adjusted for gender, education (secondary versus none/primary), smoke (former or current versus never), 
diabetes, myocardial infarction, vascular access type (arterio-venous fistula versus graft/catheter), Body Mass Index 
(categories according to WHO), albumin (tertiles), Charlson comorbidity score (quartiles), age (standard deviation 
increase), phosphorus, calcium, haemoglobin, KTV, fiber daily intake (tertiles), energy intake (1000 kcal per day 
increase). ≠As above but excluding fiber daily intake and plus time on dialysis and being wait-listed for transplant 
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the Food Frequency Questionnaire 
N= 9757
Participants included in the analyses 
N= 8108
CENSORED
• Transferred to out of network center N = 287
• Kidney transplantation N = 446
• Transferred to peritoneal dialysis N = 9
• Withdrawal dialysis N = 30
• Kidney function recovery N = 13
EXLCUDED 
• Missing identification code N = 1226
• ≥ 20% missing answers N = 338
• Implausible energy intake values N = 85
All-cause mortality N=1214
Cardiovascular mortality N= 515
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Figure 2. Unadjusted incidence (per 100,000 person-days) of cardiovascular and all-cause mortality plotted against dietary n-3 PUFA intake by 
country 
 
IR: incidence rate per 100,000 person-days; n-3 PUFA: long chain n-3 polyunsaturated fatty acids (calculated as sum of eicosapentaenoic, docosapentaenoic and docosahexaenoic 
acids). The area of the circles is proportional to the number of participants in each country. 
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Figure 3. Association between dietary n-3 PUFA intake and cardiovascular and all-cause 
mortality by country 
 
*
Hazard ratio adjusted for gender, education (secondary versus none/primary), smoke (former or current versus 
never), diabetes, myocardial infarction, vascular access type (arterio-venous fistula versus graft/catheter), Body 
Mass Index (categories according to WHO), albumin (tertiles), Charlson comorbidity score (quartiles), age (standard 
deviation increase), phosphorus, calcium, haemoglobin, KTV, fiber daily intake (tertiles), energy intake (1000 kcal 
per day increase). #As above except for fiber daily intake and plus wait-listed for transplant and time on dialysis. CI: 
confidence interval. 





CHAPTER IV: PHOSPHATE-BINDING AGENTS IN ADULTS WITH CKD: A 
NETWORK META-ANALYSIS OF RANDOMIZED TRIALS 
 
Suetonia C. Palmer, Sharon Gardner, Marcello Tonelli, Dimitris Mavridis, David W. Johnson, 
Jonathan C. Craig, Richard French, Marinella Ruospo, Giovanni F.M. Strippoli.  





Guidelines preferentially recommend non-calcium phosphate binders in adults with CKD. We 
compare and rank phosphate binder strategies for CKD. 
Study Design 
Network meta-analysis 
Setting & Population 
Adults with CKD  
Selection Criteria for Studies 
Randomized trials with allocation to phosphate binders. 
Interventions 
Sevelamer, lanthanum, iron, calcium, colestilan, bixalomer, nicotinic acid, magnesium. 
Outcomes 
The primary outcome was all-cause mortality. Additional outcomes were cardiovascular 
mortality, myocardial infarction, stroke, adverse events, serum phosphorus and calcium levels, 
and coronary artery calcification. 
Results 
77 trials (12,562 participants) were included. Most studies (62 trials in 11,009 patients) were 
performed in a dialysis population. Trials were generally of short duration (median 6 months) 
and had high risks of bias. All-cause mortality was ascertained in 20 studies during 86,744 
patient-months of follow up. There was no evidence that any drug class lowered mortality or 
cardiovascular events when compared with placebo. Compared with calcium, sevelamer 
reduced all–cause mortality (odds ratio 0.39, 95% CI 0.21–0.74), while treatment effects of 
lanthanum (0.78, 0.16–3.72), iron (0.37, 0.09–1.60) and colestilan (0.55, 0.07–4.43) were not 
significant. Lanthanum caused nausea, while sevelamer posed the highest risk of constipation, 
and iron caused diarrhea. All phosphate binders lowered serum phosphorus to a greater 
extent than placebo, with iron ranked as the best treatment. Sevelamer and lanthanum posed 
substantially lower risks of hypercalcemia than calcium. 
Limitations 




There is currently no evidence that phosphate binder treatment reduces mortality compared 
with placebo in adults with CKD. It is not clear whether the higher mortality with calcium 
versus sevelamer reflects whether there is net harm associated with calcium, net benefit with 
sevelamer, both, or neither. Iron-based binders show evidence of greater phosphate lowering 





Chronic kidney disease (CKD) caused 20 million years of life to be affected by premature 
mortality or meaningful disability in 2010.1 CKD is characterized by premature vascular 
disease2 in part due to accelerated vascular calcification. Phosphorus accumulation – due to 
impaired kidney excretion – drives transformation of vascular smooth muscle cells toward a 
phenotype similar to bone-forming osteoblasts.3 Accordingly, oral phosphate binders are 
prescribed to reduce intestinal phosphorus uptake and lower serum levels. Guidelines 
recommend serum phosphorus levels within or toward the normal range.4 In the United 
States, phosphate binders contribute $0.5 billion in health spend annually.5 
Many different classes of phosphate binders are available. Although drugs have been 
compared head-to-head in randomized trials and meta-analyses,6 7 uncertainty remains about 
which treatment option is the most effective at lowering mortality and cardiovascular 
complications, and whether drugs are better than placebo. A previous meta-analysis 
concluded that non-calcium binders reduced mortality compared to calcium-based treatments, 
but comparative effects of specific phosphate binder classes against each other or placebo 
could not be discerned due to a lack of head-to-head trials.7 Current evidence has resulted in 
weak guideline recommendations4 and considerable uncertainty about efficacy and harms of 
specific phosphate binders.  
Network meta-analysis can evaluate all available phosphate binders within a coherent 
framework and rank treatments even when drugs have not been compared in head-to-head 






This systematic review with network meta-analysis was conducted according to a pre-specified 
protocol, and was reported using PRISMA guidelines.9 
Search strategy and selection criteria 
Cochrane, MEDLINE, and Embase databases were searched on May 18, 2016 without language 
restriction. Randomized trials from a previous Cochrane review were also included.6 We 
included parallel-group randomized clinical trials (RCTs) with follow up of ≥4 weeks allocating 
adults with CKD to a phosphate binder, placebo, or standard care. 
Study Selection and data extraction 
Two reviewers (SP and SG) independently screened titles and abstracts of the retrieved 
citations and reviewed the full text of all citations considered potentially eligible. Reviewers 
resolved any disagreements through discussion. Two reviewers (SP and SG) extracted and 
double-checked data extraction. 
Risk of bias assessment 
Two reviewers (SP and SG) critically appraised risks of bias using the Cochrane tool.10  
Statistical Analysis 
The primary outcome was all–cause mortality. Secondary outcomes were cardiovascular 
mortality, myocardial infarction, stroke, nausea, abdominal pain, constipation, diarrhea, 
achievement of a serum phosphorus target, serum phosphorus levels, hypercalcemia, and 
coronary artery calcification.  
First, random-effects pairwise meta-analysis was used to assess treatment effects.11 Then, 
random-effects network meta-analysis in a frequentist environment was conducted. The 
following were evaluated when considering the appropriateness of combining studies for 
network meta-analysis: clinical setting, age, stage of kidney disease, follow up duration, and 
serum phosphorus. A fixed-effect model was to check for the robustness of the results for all-
cause mortality. Binary outcomes were expressed as odds ratios and continuous outcomes 
were calculated as standardized mean differences, together with their 95% confidence 




The extent of network heterogeneity was estimated by comparing a common heterogeneity 
variance (tau [τ]) within each network with an empirical distribution of heterogeneity 
variances.13 A loop-specific approach was then used to compare the difference between direct 
and indirect estimates for a treatment effect (inconsistency factor) within triangular or 
quadrilateral loops within a network.14 The ‘design-by-treatment’ interaction model was also 
used to draw a single inference about the plausibility of assuming consistency within a 
network.15 16  
Pre-specified sensitivity analyses were restricted to studies in dialysis, younger patients (<60 
years), follow up ≥12 months, and baseline serum phosphorus ≤1.8 mmol/l. Additional 
analyses were done removing one study at a time from the network for all-cause mortality and 
restricted to studies at low risk of bias for allocation concealment. A post-hoc analysis of the 
comparative effectiveness between sevelamer and calcium for all-cause mortality was done 
that included published longer term follow up of the Dialysis Clinical Outcomes Revisited 
(DCOR) study.17  
All analyses were generated in Stata 13 using the network command19 and previously reported 
routines.20 To rank treatments according to their probability of being the best treatment for a 
specific outcome, the surface under the cumulative ranking (SUCRA) curve was estimated 
using the network rank command. We assumed that the relative effects of each intervention 
compared to placebo followed a multivariate normal distribution.18 We generated 1000 
relative effects and in each replicate, the treatment effects were ranked; finally, the 
percentages of assuming any of the possible ranks for all interventions was computed. 
Statistical testing was two-tailed. A p value <0.05 was taken to indicate statistical significance. 
Role of the funding source 
There was no funder for this study. SCP and GFMS had full access to all the data in the study 





77 studies involving 12,562 adults were eligible (Figure 1 and Table S1). 62 trials involved 
11,009 dialysis patients. Eight phosphate binder classes were evaluated: sevelamer 
(hydrochloride or carbonate), lanthanum carbonate, calcium (carbonate or acetate), iron (iron 
magnesium hydroxycarbonate, ferric citrate, SBR759, sucroferric oxyhydroxide), colestilan, 
bixalomer, nicotinic acid and magnesium carbonate. Median duration was three months 
(interquartile range [IQR], 1.8-6 months), with a median age of 56.7 years (IQR, 53.5-60.3), and 
median serum phosphorus of 6.5 mg/dl (IQR 5.3-7.7). The median (IQR) follow-up duration in 
months for each drug was: placebo 1.8 (1-3); sevelamer 3 (2-11); lanthanum 3 (1.5-9); calcium 
6 (3-12); iron 1.8 (1-3); colestilan 3 (1-3); bixalomer 2 (1-3); nicotinic acid 1.9 (1.4-2.4). Twenty 
studies involving 6376 patients reported 770 deaths during 86,744 patient-months (Table 1).21-
39  
Risks of bias 
The risks of bias were frequently high (Figures S1 and S2). 16 studies (20.8%) reported low risk 
methods for random sequence generation and eight (10.4%) adequately concealed allocation. 
24 studies (31.1%) masked participants and investigators and two trials (3.0%) masked 
outcome assessment. 18 (23.3%) studies included 90% or more participants in analyses 
according to their randomized treatment allocation. 26 (33.8%) reported all clinically relevant 
outcomes (mortality and/or cardiovascular events and adverse events). Analyses were 
reported as intention–to–treat in 12 studies (15.6%) and adverse events were systematically 
captured in 14 (18.2%) studies. Published studies tended to favor newer drug classes 
(sevelamer, lanthanum, iron) for all-cause mortality (Figure S3). 
Study consistency and heterogeneity 
When considering potential effect modifiers in assessing consistency, nearly all studies (88%) 
included patients with end-stage kidney disease. 51 (76%) studies enrolled patients with a 
mean age between 50 and 70 years. Baseline serum phosphorus levels were variable (3.1-9.0 
mg/dl) but less diverse in studies included in the network analysis for all-cause mortality (5.0-
7.8 mg/dl). Dosing regimens for phosphate binders were similar among trials (Table S1). For 
studies reporting all-cause mortality, over half included follow up 12 months or longer (Table 
1). Studies were deemed sufficiently comparable for key effect modifiers to justify the 
consistency assumption that meta-analysis was reasonable. 
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The network for cardiovascular mortality indicated the presence of substantial heterogeneity 
(τ=1.20), while networks for all-cause mortality (τ=0.74), hypercalcemia (τ=0.94) and diarrhea 
(τ=0.81) showed moderate-high heterogeneity, and networks for nausea (τ=0.55), abdominal 
pain (τ=0.41), constipation (τ=0.34), serum phosphorus target (τ=0.44), serum phosphorus 
values (τ=0.51), and coronary artery calcification (τ <0.001) showed low-moderate 
heterogeneity. Treatment estimates from direct and indirect evidence did not show loop-
specific inconsistency except for serum phosphorus values, however, the results of testing 
were very imprecise in some cases and so inconsistency could not be excluded (Table S2). 
There was no evidence of global network inconsistency except for the outcome of diarrhea 
(Table S3). 
Treatment outcomes  
Overall results of pairwise meta-analyses for binary outcomes are given in the Table S4. 
Definitions of biochemical outcomes are described in Table S5. 
All-cause mortality, cardiovascular mortality, stroke and myocardial infarction 
The network for all-cause mortality is shown in Figure S4. Median follow up was 15 months for 
trials comparing sevelamer versus calcium, three months for sevelamer versus iron, and 12 
months for lanthanum versus calcium.  
There was no evidence of different odds of all-cause mortality between any phosphate binder 
and placebo (iron OR 0.45, CI 0.08−2.66, sevelamer 0.47, 0.08−2.56, colestilan 0.66, 0.10−4.31, 
lanthanum 0.93, 0.11−8.00, calcium 1.20, 0.21−6.75), although placebo-controlled trials were 
of short duration (4 weeks to 3 months) (Table 2).  
Sevelamer appeared to reduce all-cause mortality compared with calcium (0.39, 0.21–0.74) 
and was ranked best for this outcome, while the effects of lanthanum (0.78, 0.16–3.72), iron 
(0.37, 0.09–1.60) and colestilan (0.55, 0.07–4.43) compared with calcium were not significant 
(Table 2). When a fixed effect model was used to estimate odds of all-cause mortality, the ORs 
for therapies when compared with calcium were 0.74 (0.62−0.89) for sevelamer, 0.67 
(0.26−1.72) for iron, and 0.87 (0.16−4.76) for colestilan. The non-calcium binders did not differ 
statistically from each other for all-cause mortality.  
Data for cardiovascular mortality, myocardial infarction and stroke were sparse due to few 





Side-effects (nausea, constipation, diarrhea, abdominal pain) 
The networks for adverse events are shown in Figure S6. Lanthanum ranked as the treatment 
with the highest probability of causing nausea (Figure 2). Lanthanum increased nausea 
compared to calcium (2.18, 1.00–4.74) and iron (4.07, 1.15–14.3) (Table 3). Sevelamer 
increased constipation compared to calcium (2.12, 1.01–4.45), lanthanum (3.03, 1.31–7.02) 
and iron (3.15, 1.73–7.53) and was ranked worst for this side-effect (Table 4). Iron increased 
diarrhea compared with calcium (3.30, 1.02–10.8), but differences between all other 
phosphate binders were not significant (Table 4). No drug increased abdominal pain (Table 3). 
Serum calcium and phosphorus 
Networks for serum phosphorus and calcium are shown in Figure S7. Iron increased odds of 
achieving serum phosphorus targets compared with sevelamer, lanthanum, calcium, and 
placebo (Table 5). All phosphate binders except colestilan significantly lowered serum 
phosphorus levels compared to placebo (Table 5). Iron lowered serum phosphorus levels to a 
greater extent than lanthanum, sevelamer, and calcium, and was ranked as the best treatment 
(Figure 2). Sevelamer (0.14, 0.07–0.29) and lanthanum (0.09, 0.03–0.25) were associated with 
significantly lower odds of hypercalcemia compared with calcium. 
Coronary artery calcification 
Sevelamer reduced coronary artery calcification scores compared with calcium (SMD -0.20, -
0.40 to -0.01) (Table S8 and Figure S8). 
Sensitivity analyses 
Treatment estimates were similar when restricted to studies reporting low risk methods of 
allocation concealment, involving dialysis patients, with longer duration of follow up, or with 
lower baseline serum phosphorus levels (Table S9). When removing one study at a time, the 
estimated odds of mortality with sevelamer compared to calcium was no longer significant 
when the INDEPENDENT study26 was excluded (Table S10; 0.61, 0.37−1.01) and the 
heterogeneity tau in the mortality network with this study removed was reduced from 0.73 
(moderate–high heterogeneity) to 0.35 (low heterogeneity). There was no evidence of 
treatment differences based on the individual phosphate binder formulation (sevelamer 
[hydrochloride or carbonate] or calcium [acetate or carbonate]) although there were 
frequently few observations leading to low power in the analyses (Table S11). The treatment 
estimates for all-cause mortality repeated including extended follow up for the DCOR study17 




This systematic review included 77 studies involving 12,562 adults with CKD, predominantly in 
dialysis populations. There was no evidence that any phosphate binder lowered mortality 
compared with placebo. Sevelamer was associated with lower all-cause mortality when 
compared to calcium-based binders. Estimated effects of other non-calcium binding agents 
compared to calcium-based treatment were non-significant and there were no statistical 
differences in mortality risk between different non-calcium containing binders (sevelamer, 
lanthanum, iron). Overall, these data cannot establish whether there is net harm associated 
with calcium-based phosphate binders, net benefit associated with sevelamer, both, or 
neither. Existing trials of phosphate binders on all-cause mortality were of short duration with 
those evaluating iron-based treatment lasting generally 3 months or fewer. Coronary artery 
calcification (a putative mechanism for death related to high serum calcium and phosphorus) is 
not clinically apparent for most patients until at least 10 years of dialysis,40 indicating that 
currently-available phosphate binder therapy trials may be of insufficient duration to provide 
definitive information about treatment effects on mortality, cardiovascular events, or vascular 
calcification, although sevelamer appeared to prevent coronary artery calcification compared 
with calcium binders in the short-term.  
Lanthanum and colestilan had the highest probability of nausea, sevelamer ranked worst for 
constipation, and iron-based binders conferred greatest odds of diarrhea. Iron lowered serum 
phosphorus levels compared to other binders including sevelamer and lanthanum. All 
phosphate binders except colestilan lowered serum phosphorus compared with placebo. As 
expected, calcium was ranked as most likely to cause hypercalcemia.  
These findings extend those of an previous pairwise meta-analysis7 – which concluded that 
sevelamer or lanthanum should be first line therapy in the management of phosphorus in CKD 
– in three ways. First, by integrating direct and indirect evidence, the benefits of non–calcium 
binders in the previous review might have been principally attributable to sevelamer, whereas 
comparative effects of other non-calcium-based agents including lanthanum were not 
significant compared to calcium or placebo for mortality. In the previous pairwise meta-
analysis, evidence for non-calcium based agents (sevelamer and lanthanum) were combined to 
identify a risk reduction in mortality with non-calcium binders of 22%, but study data were 
insufficient to evaluate treatment effects for individual drug classes. Importantly, due to a lack 
of placebo-controlled trials, comparisons of phosphate binders with placebo has not been 
previously possible. This network meta-analysis indicates that there is no evidence that any 
phosphate binder improves life expectancy when compared with placebo in trials of short 
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duration. Second, this review identifies adverse events attributable to phosphate binder 
classes that can facilitate decision-making aligned with patient preferences. Third, iron–based 
binders lowered serum phosphorus to a greater extent than other phosphate binder classes, 
indicating these are an important candidate intervention for larger studies against sevelamer 
and/or calcium, to evaluate impact on mortality and cardiovascular endpoints. 
Proponents of non–calcium binders might argue that these findings indicating an association of 
sevelamer with lower all-cause mortality support the need to update existing guidelines, which 
cited insufficient comparative efficacy data on clinical outcomes rather than recommending a 
specific phosphate binder for patients with CKD.4 However, there are several issues that 
preclude a preferential recommendation for sevelamer compared to other binders based on 
the current evidence. First, the available studies have important methodological limitations, 
meaning that bias could have affected the results. Smaller studies may have influenced the 
estimated benefit of sevelamer over calcium-based binders, indicated by the smaller benefit of 
treatment observed using a fixed-effect model and the absence of smaller trials with more 
favorable effects for calcium-based treatment. Second, after exclusion of a single study (the 
INDEPENDENT trial26), the reduction in all-cause mortality with sevelamer compared to calcium 
was no longer significant. Removing the INDEPENDENT study involving 466 incident dialysis 
patients substantially reduced heterogeneity between studies. It is not clear why the results of 
the INDEPENDENT study differed so markedly favoring sevelamer than other trials in this meta-
analysis. Third, due to imprecision, it is possible that non–calcium binders other than 
sevelamer are also associated with better (or worse) associations with clinical outcomes 
compared to calcium. Finally, it is important to note that none of the available calcium or non–
calcium agents lowered mortality compared with placebo – in other words whether calcium-
based agents are harmful or non-calcium based agents are beneficial. Placebo-controlled trials 
lasted 3 months on average, precluding robust inferences about treatment effects.  
Given the widespread use of phosphate binders in clinical practice, randomized trials are an 
urgent priority to support and inform the extensive prescribing of these medications. Such 
trials should include comparisons of phosphate binders with placebo (perhaps with rescue 
treatment for severe hyperphosphatemia and or hyperparathyroidism) and head–to–head 
comparisons between available agents – focusing on clinically relevant outcomes such as 
mortality and cardiovascular events. Given the significantly lower phosphorus levels associated 
with iron, and the potential association of sevelamer with lower mortality, future trials should 
focus on these two classes of agent, compared to placebo, calcium, or each other. Finally, the 
high absolute risk of adverse events with all binders suggests that there is value to considering 
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patient preferences when selecting an approach to phosphorus control in kidney patients, 
especially those who are concerned about treatment harms. Further, the failure of any agent 
to reduce mortality versus placebo suggests that a less aggressive approach to phosphate-
lowering treatment may be entirely appropriate in all patients pending the availability of new 
evidence.  
The results of this network meta–analysis contrasts with those of the largest randomized study 
to compare sevelamer with calcium (the Dialysis Clinical Outcomes Revisited (DCOR) trial), 
which found no effect of sevelamer compared with calcium on total death in hemodialysis 
patients treated for approximately 20 months.35 First, it is possible that DCOR had insufficient 
statistical power to identify treatment benefit, particularly as about half of the 2103 
randomized participants left the study early. The current meta–analysis potentially had greater 
power to discern a significant association for mortality between treatments due to a larger 
sample size, as well as draw inferences from both direct and indirect treatment comparisons. A 
second interpretation is that benefits of sevelamer might be limited to older participants as 
was identified in the DCOR study in participants who were 65 years or older in pre–specified 
subgroup analyses. However, it was unlikely that the reduction in mortality with sevelamer 
that was found in this meta-analysis was because of a preponderance of older participants as 
the mean age for participants in most included studies was 60 years or younger. Alternatively, 
it is possible that this meta-analysis found treatment benefits for sevelamer due to the 
inclusion of smaller studies at higher risk of bias for important methodological features within 
network meta-analyses, which may have resulted in overestimated effects on mortality that 
are discordant with the largest existing randomized trial. When the INDEPENDENT study was 
removed from analyses, the beneficial effect of sevelamer on all-cause mortality compared 
with calcium was not significant, indicating that evidence of efficacy for sevelamer in this 
analysis may be reliant on the results of this single study.26 
The strengths of this meta-analysis include the use of network meta-analyses to draw 
inferences about the comparative effects of phosphate binders with clinical outcomes that 
have not been directly compared in existing randomized trials including against placebo and 
permit greater precision for treatment effects on mortality and adverse events than has 
previously been possible. The analyses are drawn from a highly-sensitive literature search and 
included assessments of study risks of bias.  
The study has limitations which reduce the applicability of the findings to clinical practice, 
related principally to the extent and quality of information in individual trials. First, reporting 
risks of bias were often high or not reported sufficiently to make a judgment, lowering 
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confidence in the results of contemporary trials of phosphate binders. Lack of reporting of 
many outcomes in many studies was a potential limitation. Second, most contributing trials 
were of short duration. This was particularly the case for trials of iron-based binders, which 
were commonly continued for 3 months or less. Given the natural history of vascular 
calcification as clinically evident after many years of end-stage kidney disease,40 it is likely that 
existing trials do not have sufficient longevity to identify definitive treatment effects, and trials 
of iron-based binders will need to be longer to identify treatment effects on hypercalcemia, 
adverse events (especially iron overload), and patient-level outcomes including mortality. Such 
trials may benefit from efficient trial design, such as follow up embedded within a data 
registry, to enable long-term follow up for sufficient numbers of participants. Trials of placebo 
were often of short duration (3 months or shorter). The longer-term benefits of treatment 
against placebo remain uncertain for many outcomes. Third, while meta-analysis assumes that 
contributing studies were sufficiently similar in most respects other than the treatments under 
study, statistical assessment of this assumption was limited by low power, although little 
evidence of network inconsistency was found. There was also no evidence of different 
treatment associations for individual drugs within binder classes, but few data reduced 
confidence in these assumptions. Fourth, data for cardiovascular events were rarely reported. 
As the assumed mechanism of benefit for these drugs is by reducing vascular calcification to 
prevent vascular injury, these outcomes must be considered as core outcomes in future trials 
and systematically captured in ongoing studies and prescribing surveillance. Finally, most 
studies involved participants with end-stage kidney disease. The findings of this review may 
not be generalizable across the full range of kidney function.  
In conclusion, there is no evidence that phosphate binder treatment reduces mortality 
compared to placebo in adults with CKD.  It is not clear whether the higher mortality with 
calcium versus sevelamer reflects whether there is net harm associated with calcium, net 
benefit with sevelamer, both, or neither. Iron lowered serum phosphate to the greatest 
extent, indicating future studies might prioritize evaluation of this treatment class. All available 
phosphate binders display distinct adverse event profiles that can inform treatment decisions 
for individual patients. 
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Table 1. Trials ascertaining treatment effects on all-cause mortality 
Study Intervention drug 
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Table 1. Trials ascertaining treatment effects on all-cause mortality 
Study Intervention drug 








Location Stage of chronic 
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Mean age (SD), 
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Abbreviations: CKD = chronic kidney disease. 5D = chronic kidney disease treated with dialysis. NI = not indicated. P = phosphorus.  PTH = parathyroid hormone. *Patient-months follow 





Table 2: Network estimated odds ratios (95% confidence intervals) of phosphate binders on all-cause mortality 
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(0.09, 2.65) 


































The table should be read from left to right. The risk estimate is for the column-defining treatment compared with the row-defining treatment. An odds ratio <1 indicates the column 
treatment was associated with a lower odds of mortality than the row treatment.  For example, sevelamer treatment lowered the odds of all-cause mortality compared to calcium 
treatment (odds ratio 0.39, 95% confidence interval 0.21, 0.74). Bold and underlined results are statistically significant. The heterogeneity tau (τ) for the network analysis was τ = 0.74 
(indicative of moderate-high heterogeneity). There were 20 studies involving 6376 participants included in the network 
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Table 3. Network estimated odds ratios (95% confidence intervals) of phosphate binders on nausea and abdominal pain 
 
































































































The lower part of the table reporting treatment estimates for nausea should be read from left to right. The risk estimate is for the column-defining treatment compared with the row-
defining treatment. An odds ratio <1 indicated the column treatment was associated with a lower odds of nausea than the row treatment.  For example, lanthanum-based treatment 
was associated with increased odds of nausea compared to calcium-based treatment (2.18, 1.00 to 4.74). The upper part of the table reporting estimates for abdominal pain should be 
read from left to right. The risk estimate was for the row-defining treatment compared with the column-defining treatment. An odds ratio <1 indicated the row treatment was 
associated with a lower odds of abdominal pain than the column treatment. For example, the odds of abdominal pain with sevelamer was 1.25 (0.46 to 3.42) compared with calcium 
treatment. Bold and underlined results are statistically significant. The heterogeneity tau (τ) for each network analysis was: nausea τ = 0.55 (indicative of moderate heterogeneity), 
abdominal pain τ = 0.41 (indicative of low-moderate heterogeneity). There were 26 trials involving 7265 patients in the network for nausea and 18 trials involving 3235 patients in the 
network for abdominal pain 
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The lower part of the table reporting treatment estimates for constipation should be read from left to right. The risk estimate is for the column-defining treatment compared with the 
row-defining treatment. An odds ratio <1 indicates the column treatment is associated with a lower odds of constipation than the row treatment.  For example, sevelamer based 
treatment is associated with increased odds of constipation compared to calcium-based treatment (odds ratio 2.12, 95% confidence interval 1.01, 4.45). The upper part of the table 
reporting estimates for diarrhea should be read from left to right. The risk estimate is for the row-defining treatment compared with the column-defining treatment. An odds ratio <1 
indicates the row treatment is associated with a lower odds of diarrhea than the column treatment. For example, sevelamer is associated with a lower odds of diarrhea than iron 
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treatment (odds ratio 0.30, 95% confidence interval 0.09, 0.99). Bold and underlined results are statistically significant. The heterogeneity tau (τ) for each network analysis was: 
constipation τ = 0.34 (indicative of low heterogeneity), diarrhea τ = 0.81 (indicative of moderate-high heterogeneity). There were 27 trials involving 7862 patients in the network for 
constipation and 23 trials involving 4894 patients in the network for diarrhea. 
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Table 5 Summary network treatment estimates of the comparative efficacy and safety of phosphate binding agents on serum phosphorus targets 
and hypercalcemia 





























































































































The lower part of the table reporting treatment estimates for hypercalcemia should be read from left to right. The risk estimate is for the column-defining treatment compared with 
the row-defining treatment. An odds ratio <1 indicates the column treatment is associated with a lower odds of hypercalcemia than the row treatment.  For example, sevelamer based 
treatment is associated with lower odds of hypercalcemia compared to calcium-based treatment (odds ratio 0.14, 95% confidence interval 0.07, 0.29). The upper part of the table 
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reporting estimates for achieving a serum phosphorus target should be read from left to right. The risk estimate is for the row-defining treatment compared with the column-defining 
treatment. An odds ratio <1 indicates the row treatment is associated with lower odds of achieving a serum phosphorus target than the column treatment. For example, sevelamer is 
associated with lower odds of achieving a serum phosphorus target than iron treatment (odds ratio 0.55, 95% confidence interval 0.30, 0.99). Bold and underlined results are 
statistically significant. The heterogeneity tau (τ) for each network analysis was: hypercalcemia τ = 0.94 (indicative of high heterogeneity), and achieving serum phosphorus target τ = 
0.44 (indicative of low-moderate heterogeneity). There were 21 trials involving 5159 patients in the network for hypercalcemia and 21 trials involving 2382 patients in the network for 
achieving target serum phosphorus levels. 
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Figure 2: Rankings for efficacy and toxicity of phosphate binders 
 
The graph displays distribution of probabilities for efficacy (all-cause mortality, serum phosphorus levels) and safety 
(nausea, constipation, hypercalcemia). Ranking indicates probability that drug class is first “best”, second “best”, 
etc. For example, sevelamer showed a 25.8% probability of ranking the best treatment for all-cause mortality, while 
calcium showed a 0.0% probability of ranking the best treatment for all-cause mortality. 
107 
 
CHAPTER V: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS 
ASSOCIATED WITH GLUCOSE-LOWERING DRUGS IN PATIENTS WITH TYPE 2 
DIABETES. A META-ANALYSIS 
 
Suetonia C. Palmer, Dimitris Mavridis, Antonio Nicolucci, David W. Johnson, Marcello Tonelli, 
Jonathan C. Craig, Jasjot Maggo, Vanessa Gray, Giorgia De Berardis, Marinella Ruospo, Patrizia 
Natale, Valeria Saglimbene, Sunil V. Badve, Yeoungjee Cho, Annie-Claire Nadeau-Fredette, 
Michael Burke, Labib Faruque, Anita Lloyd, Nasreen Ahmad, Yuanchen Liu, Sophanny Tiv, 
Natasha Wiebe, Giovanni FM. Strippoli.  





Numerous glucose−lowering drugs are used to prevent complications of type 2 diabetes. 
Objective: 
To estimate the relative efficacy and safety of glucose-lowering drugs including insulin. 
Data Sources: 
Cochrane, Medline, and EMBASE databases through March 21, 2016. 
Study Selection: 
Randomized clinical trials ≥24 weeks’ duration.  
Data Extraction and Synthesis: 
Random-effects network meta-analysis. 
Main Outcomes and Measures: 
Cardiovascular mortality, all-cause mortality, serious adverse events, myocardial infarction, 
stroke, glycated hemoglobin (HbA1C), treatment failure (rescue treatment or lack of efficacy), 
hypoglycemia, and weight, as individual endpoints. 
Results: 
A total of 301 clinical trials (1,417,367 patient-months) were included; 177 trials (56,598 
patients), drugs given as monotherapy; 109 trials (53,030 patients), drugs added to metformin 
(dual therapy); and 29 trials (10,598 patients), drugs added to metformin and sulfonylurea 
therapy (three-drug therapy). The association between drug classes and cardiovascular deaths 
was evaluated in 25 trials of drug monotherapy (14,477 patients; 67 events during 197,763 
patient-months); 26 trials of dual therapy (20,690 patients; 45 events during 286,157 patient-
months); and 5 trials of three drug therapy (3267 patients; 6 events during 37,223 patient-
months). There were no differing associations between drug classes and cardiovascular or all-
cause mortality. Compared with metformin, sulfonylurea (standardized mean difference (SMD) 
0.18, 95% CI 0.01 to 0.34), thiazolidinedione (SMD 0.16, 0.00 to 0.31), DPP-4 inhibitor (SMD 
0.33, 0.13 to 0.52), and alpha glucosidase inhibitor (SMD 0.35, 0.12 to 0.58) monotherapy were 
associated with higher HbA1C levels. Compared to metformin, SGLT-2 inhibitors were 
associated with lower odds of treatment failure (odds ratio (OR) 0.47, 0.31 to 0.71; risk 
difference (RD) -0.3%, -4% to 3%). Sulfonylurea (OR 3.13, 2.39 to 4.12; RD 10%, 7% to 13%) and 
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basal insulin (OR 17.9, 1.97 to 162; RD 10%, 0.08% to 20%) were associated with greatest odds 
of hypoglycemia. When added to metformin, drugs were associated with similar HbA1C levels, 
while SGLT-2 inhibitors offered the lowest odds of hypoglycemia (OR 0.12, 0.08 to 0.18; RD -
22%, -27% to -18%). When added to metformin and sulfonylurea, basal insulin was associated 
with the lowest odds of treatment failure (OR 0.44, 0.20 to 0.99; RD -5%, -20% to 9%), while 
GLP-1 receptor agonists were associated with the lowest odds of hypoglycemia (OR 0.60, 0.39 
to 0.94, RD -10%, -18% to -2%).  
Conclusions and Relevance: 
Among adults with type 2 diabetes, there were not significant differences in the associations 
between any of nine available classes of glucose-lowering drugs (alone or in combination) and 
the risk of cardiovascular or all-cause mortality. Metformin was associated with lower HbA1C 
levels or no significant difference in HbA1C levels than any of the other drug classes. All drugs 
were estimated to be effective when added to metformin. These findings are consistent with 
ADA recommendations for using metformin monotherapy as initial treatment for patients with 




Diabetes was estimated to account for approximately 1.3 million deaths in 2010, with more 
than 80% of diabetes−related deaths occurring in low− and middle−income countries.1,2 In 
addition, diabetes was estimated to cause disability (blindness, limb amputation, kidney 
failure, cardiovascular events) among 47 million people in 2010.3 Lifestyle modification and 
glucose−lowering drug treatment are the mainstay of therapy to prevent and delay 
diabetes−related complications. A large number of glucose-lowering drug classes are approved 
for type 2 diabetes including metformin, insulins, sulfonylureas, thiazolidinediones, dipeptidyl 
peptidase-4 (DPP-4) inhibitors, sodium−glucose−linked cotransporter-2 (SGLT-2) inhibitors, 
glucagon−like peptide-1 (GLP-1) receptor agonists, meglitinides, and alpha−glucosidase 
inhibitors.  
American Diabetes Association (ADA) guidelines suggest metformin as first−line drug 
treatment, and, if glycemic control is not achieved, the addition of a second drug (often 
sulfonylurea) is recommended.4 Triple therapy with two drugs added to metformin is 
suggested when glycemic control is no longer sustained with two drugs. Annual drug 
expenditure for glucose-lowering therapy doubled to $12.5 billion between 2001 and 2007 in 
the United States, with most patients receiving at least dual therapy.5 However, despite the 
widespread use of these drugs, the comparative effects of glucose−lowering strategies on hard 
clinical outcomes, especially mortality and cardiovascular events, are uncertain.6,7 Emerging 
evidence suggests SGLT-2 inhibitors lower a composite of cardiovascular outcomes and death 
when the drug is added to standard care in high-risk patients.8 However randomized clinical 
trials of diabetes medications have been generally insufficiently powered to establish the role 
of drug treatment on preventing cardiovascular death, limiting the ability of single studies to 
inform practice and policy.  
Head−to−head trials and standard meta−analysis do not allow all treatments to be compared 
simultaneously, constraining the comparative assessment of longer term benefits and risks 
associated with available medications.7 Therefore, a systematic review with network 






A systematic review with network meta−analysis was conducted with a frequentist approach 
using a pre−specified study protocol. Additional post-hoc analyses and changes to the protocol 
are described in eMethods 1. The study was reported according to the PRISMA extension 
statement for network meta−analysis.9 
Search strategy and selection criteria 
Randomized clinical trials publically available on March 21, 2016 comparing two individual 
glucose−lowering drug classes for treatment of type 2 diabetes were identified. The Cochrane 
Library Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase were searched 
using a highly−sensitive search strategy developed by an experienced trials search coordinator 
for each database (eTable 1).  
Study selection and data extraction 
Parallel−group randomized clinical trials in which treatment was given for 24 weeks or longer 
were included. Comparisons of the following drug classes were considered: metformin, 
sulfonylurea, thiazolidinedione, dipeptidyl−peptidase-4 (DPP-4) inhibitor, sodium−glucose 
cotransporter-2 (SGLT2) inhibitor, glucagon−like peptide-1 (GLP-1) receptor agonist, basal 
insulin, meglitinide, and alpha−glucosidase inhibitor. Trials in which basal−bolus and prandial 
insulin regimens were compared with the specified drug classes of interest or placebo or 
standard therapy were also included. Trials were considered within separate analytical 
networks based on whether drugs were given as monotherapy, added to metformin (dual 
therapy), or added to metformin and sulfonylurea (triple therapy). Metformin plus 
sulfonylurea was chosen a priori as the baseline therapy for three−drug combinations, as this 
has been most widely used.10 Studies evaluating treatments that were no longer available or 
withdrawn from the market (e.g., phenformin and troglitazone) were excluded, as were those 
that did not principally act to lower blood glucose. Studies evaluating treatment in children 
(age 18 years or younger) and pregnant women were ineligible.  
Two investigators screened the title and abstracts of retrieved citations independently (GDB 
and SP) to identify potentially eligible trials. Any discrepancies were discussed between 
researchers until a consensus occurred. Any potentially relevant citation was then retrieved in 
full−text and reviewed by the same two investigators against the eligibility criteria and 
decisions about eligibility were double−checked independently by a third author (VG). 
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Information in non−English language studies was formally translated before assessment. At 
least two investigators (SCP, DWJ, JM, VG, GDB, MR, PN, VS, SB, YC, AN, MB, LF, AL, NA, YL, and 
ST) independently reviewed the main reports and supplementary materials including data 
reported in the www.clinicaltrials.gov portal, and extracted study and patient characteristics, 
and treatment strategies. All extracted data were independently checked by two authors (SP, 
JM). 
Outcomes 
The association of drug treatment with cardiovascular mortality was the primary endpoint. 
Secondary individual efficacy endpoints were all−cause mortality, myocardial infarction, 
stroke, glycated hemoglobin (HbA1C), and treatment failure (lack of efficacy or need for rescue 
treatment). Secondary individual safety endpoints were serious adverse events, hypoglycemia, 
and body weight.  
Quality assessment – risk of bias 
Two investigators (JM, VG) used the Cochrane tool to assess study risks of bias.11  
Statistical analysis 
Detailed methods for statistical analysis were described in eMethods 1. The clinical setting and 
characteristics of the trials (considering age, proportion of men, HbA1C, body weight, duration 
of diagnosed diabetes, duration of follow-up, and year of publication) reporting each drug 
class were evaluated to consider whether the included trials were sufficiently similar that a 
network meta−analysis approach was appropriate. Treatment effects were then estimated by 
random−effects pair−wise meta−analysis.12 The association between treatment and outcomes 
was estimated using standardized mean differences (SMD) for HbA1C and body weight and 
odds ratios (OR) for cardiovascular mortality, all−cause mortality, myocardial infarction, stroke, 
serious adverse events, treatment failure, and hypoglycemia, together with 95% confidence 
intervals. In general, a standardized mean difference of 0.2 is considered small, 0.5 medium, 
and 0.8 large.13 
Frequentist network meta−analysis was then used to compare available treatment strategies 
within a single analytical framework.14,15 Odds ratios were also accompanied by absolute risk 
differences (RD). Network meta−analysis was done in Stata version 13 (www.stata.com) using 
the network command and self−programmed Stata routines.16,17 The relative ranking 
probability of each treatment was estimated and the treatment hierarchy of competing 
interventions was obtained using rankograms, surface under the cumulative ranking (SUCRA) 
curves, and mean ranks. The restricted maximum likelihood method was used to estimate 
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heterogeneity, assuming a common estimate for heterogeneity variance across different 
comparisons for a single clinical outcome.18 The extent of heterogeneity in each network 
analysis was evaluated by comparing the magnitude of a common heterogeneity variance for 
the network (tau [τ]) with an empirical distribution of heterogeneity variances, considering the 
range of expected treatment estimates (odds ratios and standardized mean differences), in 
which values of τ from 0.1 to 0.5 were reasonable, 0.5 to 1.0 were considered fairly high, and 
above 1.0 represented fairly extreme heterogeneity.19-21 
To explore for evidence of within−network inconsistency, the loop−specific approach was used 
initially.22 To check the assumption of consistency in the entire analytical network, a 
‘design−by−treatment’ approach was then used.23 A comparison-adjusted funnel plot of 
treatment estimates for drug classes as monotherapy on cardiovascular mortality was used to 
assess for evidence of small-study effects. In addition, random−effects bivariable network 
meta−regression analyses were conducted to assess baseline HbA1C, body weight, duration of 
diabetes, and age as effect modifiers on estimates for end of treatment HbA1C, body weight, 
and hypoglycemia. Post-hoc sensitivity analysis was done to assess for intra-class variation in 
the effect of individual sulfonylurea drugs as monotherapy on odds of hypoglycemia. 
Additional post-hoc sensitivity analyses were conducted restricted to studies of monotherapy 
in which allocation concealment was at low risk of bias. Statistical testing was 2-sided with p 




Electronic searching through March 21, 2016 retrieved 9819 citations (Figure 1). Overall, 301 
randomized clinical trials involving 118,094 patients were eligible for inclusion in the review. In 
177 trials (56,598 patients), drugs were given as monotherapy, in 109 trials (53,030 patients), 
drugs were added to metformin, and in 29 trials (10,598 patients), drugs were added to 
metformin and sulfonylurea therapy (eTables 2-4). The number of patients allocated to each 
treatment in trials ranged between 824-26 and 156227 (median 104 adults, IQR 46−190). The 
mean HbA1C level at randomization was 8.2% (SD 1.1%) in monotherapy trials, 8.2% (SD 0.6%) 
in dual therapy trials, and 8.4% (SD 0.6%) in triple therapy trials. Mean body weight at baseline 
was 81.9 (SD 8.9) kilograms in monotherapy trials, 83.8 (SD 15.7) kilograms in dual therapy 
trials, and 84.1 (SD 9.5) kilograms in triple therapy trials. The median duration of diagnosed 
diabetes at randomization was 5.7 (IQR 3.3−7.0) years. Mean study follow-up ranged between 
24 weeks and 76.8 months (median, 6 months, IQR 5.5 to 12 months). The clinical trials were 
deemed sufficiently similar on the basis of study-level age, gender, HbA1C, body weight, 
duration of diagnosed diabetes, and duration of follow-up that a network analysis was 
appropriate although newer drug classes (DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 
receptor antagonists) were evaluated in trials published somewhat more recently (eFigure 1). 
Risks of bias 
Overall, the risk of bias was high or unclear for random sequence generation in 208 trials 
(69.1%), concealment of treatment allocation in 232 trials (77.1%), masking of participants 
and/or investigators in 96 trials (31.9%), masking of outcome assessment in 281 trials (93.4%), 
completeness of outcome reporting in 179 trials (59.5%) and selective reporting of outcomes 
in 172 trials (57.5%) (eTables 5-7). The trial sponsor was involved in authorship and/or data 
management in 190 trials (63.1%). 
Network consistency 
The networks of individual treatment endpoints are shown in Figure 2 and eFigure 2. 
Inconsistencies between direct and indirect evidence were noted for some drug comparisons 
(eFigures 3-5), assessing dual therapy (for treatment failure, hypoglycemia and body weight) 
and triple therapy (HbA1C and hypoglycemia). The design−by−treatment interaction model did 
not identify global inconsistency in treatment networks (except treatment failure with dual 
therapy and HbA1C with three-drug therapy) (eTable 8). However, the confidence intervals for 
inconsistency in loops of drug comparisons were often very wide and robust conclusions about 
inconsistency could not be drawn. When assuming a common heterogeneity variance within 
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treatment networks for binary outcomes, there was evidence of low levels of heterogeneity in 
all networks with the exception of HbA1C for dual therapy, in which there was evidence of 
fairly high network heterogeneity (tau, 0.5 to 1.0) (eTable 9). Definitions of treatment failure in 
the included studies were generally lack of efficacy or need for additional glucose-lowering 
therapy (eTable 10). Contributions of direct evidence to network analyses were reported in 
eTable 11. 
Treatment outcomes 
Treatment effects in pairwise meta-analyses are shown in eFigures 6-8. 
Monotherapy 
Primary outcome: cardiovascular mortality 
25 studies involving 14,477 adults evaluated the association of drug classes as monotherapy 
with cardiovascular death, including a total of 67 events during 197,763 patient−months of 
follow-up (Figure 2). There were no significant differences in the associations between any 
drug class as monotherapy with odds of cardiovascular mortality (Table 1 and eTable 12). Data 
were absent for basal insulin and GLP-1 receptor agonist monotherapy and rankings of drug 
classes for cardiovascular mortality were very imprecise (Figure 3).  
Secondary outcomes: all-cause mortality, serious adverse events, myocardial infarction, stroke, 
HbA1C, treatment failure, hypoglycemia, body weight 
All monotherapies had uncertain comparative associations with all-cause mortality, serious 
adverse events, myocardial infarction, and stroke (Table 1 and eTable 12). All drug classes as 
monotherapy were associated with lower HbA1C levels than placebo (standardized mean 
difference (SMD) ranging from −0.66, CI -0.88 to -0.44 for alpha glucosidase inhibitors to -1.11, 
-1.44 to -0.77 for meglitinides). Compared to metformin, sulfonylurea (SMD 0.18, 0.10 to 0.34), 
thiazolidinedione (SMD 0.16, 0.00 to 0.31), DPP-4 inhibitor (SMD 0.33, 0.13 to 0.52), and alpha 
glucosidase inhibitor (SMD 0.35, 0.12 to 0.58) monotherapy were associated with higher 
HbA1C levels, while SGLT-2 inhibitors (SMD 0.18, -0.15 to 0.51), basal insulin (SMD 0.13, -0.24 
to 0.51), GLP-1 receptor agonists (SMD -0.04, -0.31 to 0.23), and meglitinides (SMD -0.09, -0.42 
to 0.24) showed no significant difference in HbA1C levels. There was limited confidence in 
hierarchical treatment rankings for HbA1C levels (Figure 3).28  
Placebo was associated with the greatest odds of treatment failure (odds ratio (OR) versus 
metformin 3.83, 2.88 to 5.10; risk difference (RD) 11%, 8% to 14%), while DPP-4 inhibitor (OR 
1.53, CI 1.16 to 2.01; RD 3%, 1% to 6%) and meglitinide (OR 2.58, 1.43 to 4.66; RD 5%, 1% to 
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9%) monotherapies were also associated with higher odds of treatment failure than 
metformin. SGLT-2 inhibitor (OR 0.47, 0.31 to 0.71; RD -0.3%, -4% to 3%) treatment was 
associated with the lowest odds of treatment failure. 
Basal insulin (OR 17.9, 1.97 to 162; RD 10%, 0.08% to 20%) or sulfonylurea (OR 3.13, 2.39 to 
4.12; RD 10%, 7% to 13%) monotherapy were hierarchically the worst for an association with 
hypoglycemia while placebo (OR 0.58, 0.40 to 0.83; RD -3%, -5% to -0.2%) was the only 
intervention associated with lower odds of hypoglycemia than metformin. Thiazolidinediones 
(OR 0.67, 0.50 to 0.88; RD -4%, -7% to -1%) and DPP-4 inhibitors (OR 0.69, 0.50−0.94; RD -1%, -
4% to 1%) were also associated with a lower risk of hypoglycemia than metformin. Compared 
with metformin, GLP-1 receptor agonist monotherapy was associated with a lower body 
weight (SMD -0.28, -0.52 to -0.04) while sulfonylurea (SMD 0.19, 0.04 to 0.33) and 
thiazolidinedione (SMD 0.24, 0.04 to 0.43) monotherapy were associated with higher body 
weight.  
Drugs added to metformin 
Primary outcome: cardiovascular mortality 
26 trials involving 20,690 adults evaluated dual therapy (drugs added to metformin) including 
45 cardiovascular deaths during 286,157 patient−months of dual therapy (Figure 2). There was 
no significant association between any drug class and odds of cardiovascular mortality (Table 1 
and eTable 13). Data for basal insulin or alpha glucosidase inhibitors added to metformin were 
absent and rankings of drug classes for cardiovascular mortality were very imprecise (Figure 3). 
Secondary outcomes: all-cause mortality, serious adverse events, myocardial infarction, stroke, 
HbA1C, treatment failure, hypoglycemia, body weight 
There were no significant differences between any drug class when added to metformin for 
odds of all−cause mortality, serious adverse events, myocardial infarction, or stroke (Table 1 
and eTable 13) with the exception of a lower odds of stroke associated with DPP-4 
inhibitor/metformin versus sulfonylurea/metformin (OR 0.47, 0.23 to 0.95; RD -0.2%, -0.4% to 
-0.04%). When considering efficacy, all drug classes as dual therapy regimens lowered HbA1C 
to a similar extent, although there was fairly high statistical heterogeneity in this network. 
Direct and indirect evidence tended to indicate similar results with the exception of the 
comparison between sulfonylurea and placebo therapy when added to metformin (eFigure 7). 
Compared with sulfonylurea/metformin, SGLT-2 inhibitor/metformin ranked the best for 
avoiding treatment failure (OR 0.68, 0.48 to 0.96; RD -3%, -6% to -0.8%) while alpha 
glucosidase inhibitor/metformin (OR 12.4, 1.84 to 83.3; RD 9%, 1% to 17%) and DPP-4 
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inhibitor/metformin (OR 1.37, 1.07 to 1.76; RD 1%, -1% to 3%) strategies were associated with 
higher odds of treatment failure. 
All dual therapy classes were associated with lower odds of hypoglycemia than 
sulfonylurea/metformin dual therapy, with mean odds of hypoglycemia ranging from 0.56 
(0.32 to 0.98; RD -4%, -12% to 5%) for basal insulin/metformin to 0.12 (0.08 to 0.18; RD -22%, -
27% to -18%) for SGLT-2 inhibitor/metformin, which was ranked as the best option to avoid 
hypoglycemia (Figure 3). Sulfonylurea/metformin dual therapy was ranked worst for body 
weight. Compared with sulfonylurea/metformin treatment, DPP-4 inhibitor/metformin (SMD -
0.58, -1.06 to -0.11), SGLT-2 inhibitor/metformin (SMD -0.96, -1.46 to -0.47) and GLP-1 
receptor agonist/metformin (SMD -1.05, -1.54 to -0.57) were associated with significantly 
lower body weight at the end of treatment.  
Drugs added to metformin and sulfonylurea: secondary outcomes 
Primary outcome: cardiovascular mortality 
Five trials involving 3267 adults evaluated triple therapy (drugs added to metformin and 
sulfonylurea) (Figure 2) including 6 cardiovascular deaths during 37,223 patients−months of 
triple therapy. There was no evidence of an association of any drug class with cardiovascular 
mortality (Table 1 and eTable 14). Data for meglitinides and alpha glucosidase inhibitors added 
to metformin and sulfonylurea were absent and rankings of drug classes cardiovascular death 
were very imprecise (Figure 3). 
Secondary outcomes: all-cause mortality, serious adverse events, myocardial infarction, stroke, 
HbA1C, treatment failure, hypoglycemia, body weight 
There was no evidence of significantly different associations with all-cause mortality or serious 
adverse events between any of the drug classes given as triple therapy (Table 1 and eTable 14). 
Insufficient observations were available to generate evidence networks for myocardial 
infarction or stroke. 
As add-ons to metformin/sulfonylurea, alpha glucosidase inhibitors ranked worst for lowering 
HbA1C whereas thiazolidinediones or basal insulin were best (Figure 3 and eTable 14). Alpha 
glucosidase inhibitors were associated with higher HbA1C levels than thiazolidinediones (SMD 
1.42, 0.57 to 2.26), GLP-1 receptor agonists (SMD 1.34, 0.37 to 2.32) and basal insulin (SMD 
1.42, 0. 44 to 2.39) when added to metformin/sulfonylurea. Basal insulin plus 
metformin/sulfonylurea ranked best for avoiding treatment failure whereas DPP-4 inhibitor 
plus metformin/sulfonylurea was the worst (Figure 3 and Table 1). Compared with 
thiazolidinedione given as triple therapy, basal insulin was associated with lower odds of 
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treatment failure (OR 0.44, 0.20 to 0.99; RD -5%, -20% to 9%) while DPP-4 inhibitor plus 
metformin/sulfonylurea was associated with higher odds of treatment failure (OR 2.20, 1.32 to 
3.68; RD 21%, 7% to 35%). 
When added to metformin/sulfonylurea, GLP-1 receptor agonists were ranked best for 
avoiding hypoglycemia while thiazolidinediones ranked worst. GLP-1 receptor agonists were 
associated with lower odds of hypoglycemia than thiazolidinediones (OR 0.60, 0.39 to 0.94; -
10%, -18% to 2%) in triple therapy. When added to metformin/sulfonylurea, SGLT-2 inhibitors 
were ranked best for minimizing weight gain while thiazolidinediones and basal insulin ranked 
worst. All other drug classes except basal insulin were associated with a lower body weight 
than thiazolidinediones when added to metformin/sulfonylurea (SMD ranging from -0.23, -
0.46 to -0.00 for DPP-4 inhibitors and SMD -0.23, -0.39 to -0.06 for GLP-1 receptor agonists to 
SMD -0.33, -0.59 to -0.07 for SGLT-2 inhibitors). 
Meta-regression and sensitivity analysis 
Network meta-regression analyses were used to assess whether treatment effects for HbA1C, 
hypoglycemia and body weight were modified by study−level age, HbA1C, body, duration of 
diagnosed diabetes and duration of treatment. Generally, regression analyses were 
non−significant or had limited associations with estimated treatment effects (eTable 15). There 
was no evidence of different associations between drug classes as monotherapy between 
small and large trials for the primary outcome of cardiovascular mortality (Figure 4). In 
additional analyses, all sulfonylureas as monotherapy ranked similarly and among the worst 
treatments for odds of hypoglycemia (eTable 16 and eFigure 9). There were no substantive 
differences in the findings for drug classes as monotherapy when analyses were restricted to 
trials at low risk of bias from allocation concealment (eTable 17). DPP-4 inhibitors were 
associated with moderately higher HbA1C levels than metformin and higher odds of treatment 
failure, while being association with lower risks of hypoglycemia. Sulfonylurea monotherapy 
was associated with higher odds of hypoglycemia compared with metformin. Treatment 
estimates for mortality and cardiovascular events in high quality trials were uninterpretable 





This network meta−analysis evaluated the association with efficacy and safety endpoints of 
nine classes of glucose-lowering drugs for type 2 diabetes. Considering cumulative trial data 
from 114,962 adults, there was no evidence of differences in the associations between any of 
the available drug classes (alone or in combination) on cardiovascular mortality, all-cause 
mortality, serious adverse events, myocardial infarction, or stroke (with the exception of a 
lower association of DPP-4 inhibitor therapy with stroke compared with sulfonylurea 
treatment when added to metformin). Considerable uncertainty about the association of drug 
treatment with cardiovascular mortality occurred largely because of the small number of 
events, despite evidence networks that included 15,000 to 20,000 patients.   
All monotherapies were associated with large proportional reductions in HbA1C levels 
compared with placebo (standardized mean differences ranging between -0.66 and -1.11), 
while metformin was associated with small to moderately lower HbA1C levels versus 
sulfonylurea, thiazolidinedione, DPP-4 inhibitor, and alpha glucosidase inhibitor monotherapy 
(standardized mean differences ranging between -0.16 and -0.35). All drugs were associated 
with less treatment failure than placebo. Compared with metformin, SGLT-2 inhibitors 
performed the best with significantly lower odds of treatment failure, although this translated 
to a small and non-significant absolute risk difference of -0.3%. Basal insulin and sulfonylurea 
monotherapy were associated with greatest odds of hypoglycemia with absolute risk 
difference of 10% compared with metformin. Individual sulfonylurea drugs as monotherapy 
were associated with similar odds of hypoglycemia. Metformin was associated with small 
relative reductions in body weight compared with sulfonylurea (-0.19) and thiazolidinedione (-
0.24) treatment but moderately higher body weight than GLP-1 receptor agonists (0.28), which 
performed the best. Metformin was a reasonable first−line agent for type 2 diabetes, while 
sulfonylureas and basal insulin might be avoided in patients for whom hypoglycemia was 
particularly hazardous. SGLT-2 inhibitors might be considered as an alternative first−line agent 
given lower odds of treatment failure compared to other available drug classes.  
When drug classes were added to metformin as dual therapy, all were associated with large 
reductions in HbA1C levels (mean differences ranging between -0.67 and -2.07), although 
heterogeneity in this network lowered confidence in the results. SGLT-2 inhibitors had the 
highest probability of avoiding treatment failure; SGLT-2 inhibitors were associated with lower 
odds of treatment failure than sulfonylureas with an absolute risk reduction of 3%. 
Sulfonylurea therapy added to metformin was associated with the greatest odds of 
hypoglycemia and performed significantly worse than all other treatments, while SGLT-2 
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inhibitors added to metformin ranked the best. SGLT-2 inhibitors and GLP-1 receptor agonists 
added to metformin had the highest probabilities of being the best treatment for body weight 
while sulfonylurea therapy as dual treatment was the worst. Considering the balance of 
treatment benefits and harms, adding SGLT-2 inhibitors to metformin among patients needing 
additional glucose−lowering therapy might be the preferred treatment option to offer the 
lowest odds of treatment failure and minimize risks of hypoglycemia and weight gain. 
Otherwise, addition of basal insulin to metformin appeared to be a reasonable alternative. In 
contrast, although it is commonly used, sulfonylurea treatment added to metformin was 
associated with the least favorable side effect profile. Given the lack of evidence that any 
regimen was superior for hard clinical outcomes, decision−makers (especially within 
lower−resource settings) may consider whether the advantages of SGLT-2 inhibitors outweigh 
their generally higher costs compared to sulfonylureas or basal insulin. 
When efficacy and safety of available agents used as part of a three−drug regimen added to 
metformin plus sulfonylurea were compared, alpha glucosidase inhibitors were associated 
with highest HbA1C levels while there were no significant differences in HbA1C levels between 
any other treatment classes. Basal insulin ranked the best for avoiding treatment failure while 
DPP-4 inhibitors were the worst. GLP-1 receptor agonists as three-drug therapy posed the 
lowest risks of hypoglycemia, associated with a 10% absolute risk reduction compared with 
thiazolidinedione therapy, although due to rare events for some treatments, this risk 
difference was not significant. SGLT-2 inhibitors were the best ranked for weight gain. 
Thiazolidinediones posed the greatest risks of hypoglycemia and were ranked worst for body 
weight. Considering these results, SGLT-2 inhibitors, GLP-1 receptor agonists and basal insulin 
might be considered as preferred options when adding a third agent to metformin and 
sulfonylurea, while alpha glucosidase inhibitors and thiazolidinediones might be less favorably 
considered. 
A central finding in this meta−analysis was that despite over 300 available clinical trials 
involving nearly 120,00 adults and 1.4 million patient-months of treatment, there was little or 
no evidence that specific glucose−lowering drugs as one, two, or three drug regimens 
prolonged life−expectancy or prevented cardiovascular−related deaths or events. This finding 
might have been due to the lack of statistical power in available trials, with only approximately 
70 cardiovascular deaths reported among monotherapy trials. Although recruitment to several 
large and principally placebo−controlled studies is ongoing,6 all of these studies plan composite 
primary outcomes that include cardiovascular mortality, myocardial infarction, and stroke, and 
may not draw definitive conclusions about the individual components of the combined patient 
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outcomes. In addition, it also remained possible that there were no clinically important 
comparative differences between specific glucose−lowering drugs on mortality risk. A recent 
trial involving 14,671 adults adding sitagliptin or placebo to existing therapy over 3 years 
observed no difference in the risk of cardiovascular mortality between treatment groups,29 
while a placebo−controlled trial of saxagliptin among nearly 17,000 adults observed no 
differences in mortality with treatment.30 Notably, the EMPA-REG OUTCOME trial8 evaluating 
the SGLT-2 inhibitor empagliflozin was not eligible for this meta-analysis because background 
treatment that included other antidiabetic therapies. Together, our findings and EMPA-REG 
OUTCOME concluding that 3 years of SGLT-2 inhibitor treatment reduced cardiovascular and 
all-cause mortality in adults with diabetes and cardiovascular disease, suggested that future 
trials should compare the risk of mortality for SGLT-2 inhibitors against metformin or basal 
insulin or in dual therapy regimens. Cumulative network meta−analysis of any available 
additional studies should be conducted as results become available to ensure any evidence for 
survival benefits or harms is rapidly identified. 
The finding that metformin monotherapy was an appropriate first−line pharmacological 
treatment for initial treatment of type 2 diabetes was consistent with the American Diabetes 
Association (ADA) recommendations.4 However, these guidelines also suggested a 
patient−centered approach ─ considering efficacy, weight gain, hypoglycemia, and 
comorbidities ─ when selecting treatment. Therefore, clinicians and patients may prefer to 
avoid sulfonylurea or basal insulin as initial therapy to avoid hypoglycemia, choose GLP-1 
receptor agonists when weight management is a priority, or consider SGLT-2 inhibitors based 
on a favorable combined safety and efficacy profile. When considering the addition of a 
second agent to metformin (one of six treatment options of sulfonylurea, thiazolidinedione, 
DPP-4 inhibitor, SGLT2 inhibitors, GLP-1 receptor agonist, or basal insulin), the present findings 
suggested a potential treatment hierarchy with sulfonylurea therapy least preferred (due to an 
unfavorable side effect profile); SGLT-2 inhibitors can be suggested for patients wishing to 
avoid hypoglycemia; and SGLT-2 inhibitors or GLP-1 receptor agonists for those in whom 
weight gain is a higher priority. There was little evidence to guide the choice of third drug in 
triple therapy regimens, although clinicians might consider SGLT-2 inhibitors, GLP-1 receptor 
agonists, or basal insulin based on efficacy and safety, while thiazolidinediones might be less 
favored due to their side effect profile, and alpha glucosidase inhibitors lack efficacy. In 
addition, metformin plus sulfonylurea as the two−drug basis for a third agent appeared to be 
least favorable, and three−drug combinations that use other oral agents (particularly 
metformin plus SGLT-2 inhibitor) warranted further evaluation. 
122 
 
The present systematic review and network analysis extended findings from a 2011 pairwise 
meta−analysis of 166 randomized clinical trials and observational studies examining 
medications for type 2 diabetes that included assessments of one− and two−drug 
combinations.7 The network approach allowed greater statistical power to compare all single 
and two−drug treatments with each other, confirmed the hazards of sulfonylureas alone and 
when combined with metformin for hypoglycemia, and indicated the beneficial associations of 
GLP-1 receptor agonists on body weight. The network analysis extended understanding about 
comparative effectiveness and safety for all other treatment options and combinations, based 
on metformin as initial treatment, even though these have not been directly evaluated in 
head−to−head trials. The consistency of many findings between the two reviews despite the 
differing analytical methods strengthened the conclusions of both studies. 
Thiazolidinediones (including rosiglitazone and pioglitazone) have been linked to increased 
edema and heart failure without evidence of a corresponding excess in cardiovascular 
mortality in previous meta−analyses.31,32 This increased risk is recommended as being 
considered when patients make treatment decisions about dual therapy for type 2 diabetes.4 
Because of limited trial data for heart failure was not included as an outcome in this analysis, 
and network analysis did not demonstrate different comparative effects between 
thiazolidinediones and other drug classes on other cardiovascular complications such as 
myocardial infarction and stroke.  
The strengths of this review included the comprehensive systematic search that considered 
trials published in languages other than English and those published only as conference 
proceedings, the use of a pre−specified protocol, and double−checking of data extraction. 
However, there were several limitations. First, analyses were limited by the amount of data in 
the included studies. While cardiovascular mortality was included as an outcome because of its 
central clinical importance and the ongoing uncertainty about drug effectiveness for this 
endpoint, only a minority of studies reported this outcome and most had few or zero events. 
Meta-analysis resulted in treatment estimates with wide confidence intervals for this and 
other outcomes, leading to low confidence in drug effects and non-significant absolute risk 
differences. In the network analysis for cardiovascular mortality for monotherapy, the 
mortality rate was considerably lower than that in a recent pragmatic trial among adults with 
previously undetected diabetes,33 suggesting future trial investigators need to consider drug 
evaluations in real−world settings with higher morbidity and mortality risks. Randomized trials 
of sufficient duration and with adequate statistical power are needed to detect treatment 
effects of diabetes drugs on mortality,6 and include consideration of disruptive trial designs 
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such as registry−based trials to maximize trial efficiency and feasibility. In addition, statistical 
inconsistency between direct and indirect comparisons in some networks, including dual 
therapy associations with HbA1C levels, diminished the ability to draw confident conclusions 
for some treatment effects. Second, triple therapy regimens evaluated in this study were 
limited to individual drugs added to metformin and sulfonylurea therapy and the comparative 
effectiveness of other three−drug combinations were not assessed. Third, analyses have not 
been adjusted for baseline kidney function, and thus findings may not have been applicable to 
patients who have chronic kidney disease. A recent trial of empagliflozin added to standard 
therapy (EMPA-REG OUTCOME)8 which included a subgroup of nearly 2000 adults who had 
chronic kidney disease found no evidence of different risks of cardiovascular death with 
treatment among people with kidney failure.8 Fourth, many of the trials were conducted in 
higher income countries. Medication use in lower resource settings may be limited by cost and 
drug availability. Fifth, most studies were short−term and the longer term safety of the 
available drugs alone and in combination was incompletely understood. Finally, while there 
were no clinically important associations between drug effects and patient or study 
characteristics, there was limited power in these analyses.  
Conclusions  
Among adults with type 2 diabetes, there were not significant differences in the associations 
between any of nine available classes of glucose-lowering drugs (alone or in combination) and 
the risk of cardiovascular or all-cause mortality. Metformin was associated with lower HbA1C 
levels or no significant difference in HbA1C levels than any of the other drug classes. All drugs 
were estimated to be effective when added to metformin. These findings are consistent with 
ADA recommendations for using metformin monotherapy as initial treatment for patients with 
type 2 diabetes and selection of additional therapies based on patient-specific considerations. 
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Table 1: Summary effects of glucose-lowering interventions in people with type 2 diabetes 
 Drugs given as monotherapy 
















1.25 (0.59 to 
2.67) 
0.87 (0.30 to 2.49) 
1.00 (0.37 to 
2.65) 
0.75 (0.14 to 
3.96) 
-- -- 
0.55 (0.07 to 
4.61) 
0.92 (0.13 to 
6.38) 





1.19 (0.81 to 
1.75) 
1.09 (0.72 to 1.65) 
0.73 (0.41 to 
1.30) 
0.84 (0.22 to 
3.21) 
-- 
0.91 (0.18 to 
4.46) 
1.10 (0.17 to 
7.05) 
0.79 (0.17 to 
3.79) 





0.96 (0.83 to 
1.12) 
1.00 (0.86 to 1.16) 
1.08 (0.87 to 
1.34) 
1.24 (0.81 to 
1.92) 
-- 
0.86 (0.62 to 
1.20) 
1.65 (0.82 to 
3.30) 
0.73 (0.31 to 
1.71) 





0.94 (0.58 to 
1.50) 
0.99 (0.62 to 1.59) 
0.90 (0.36 to 
2.23) 
0.63 (0.06 to 
6.24) 
-- 
0.80 (0.15 to 
4.17) 
-- 
0.87 (0.03 to 
26.4) 
1.15 (0.35 to 
3.74) 
Stroke Referent 
1.08 (0.67 to 
1.76) 
1.04 (0.60 to 1.80) 
1.43 (0.50 to 
4.09) 
0.70 (0.05 to 
9.71) 
-- 
0.74 (0.17 to 
3.21) 
-- -- 
1.35 (0.33 to 
5.46) 
HbA1C Referent 
0.18 (0.01 to 
0.34) 
0.16 (0.00 to 0.31) 
0.33 (0.13 to 
0.52) 




-0.04 (-0.31 to 
0.23) 
-0.09 (-0.42 to 
0.24) 
0.35 (0.12 to 
0.58) 
1.01 (0.84 to 
1.18) 
Treatment failure Referent 
1.18 (0.86 to 
1.65) 
1.21 (0.87 to 1.67) 
1.53 (1.16 to 
2.01) 




0.62 (0.37 to 
1.04) 
2.58 (1.43 to 
4.66) 
2.54 (0.67 to 
9.60) 
3.83 (2.88 to 
5.10) 
Hypoglycemia Referent 
3.13 (2.39 to 
4.12) 
0.67 (0.50 to 0.88) 
0.69 (0.50 to 
0.94) 




1.06 (0.74 to 
1.52) 
2.16 (1.49 to 
3.12) 
0.65 (0.37 to 
1.13) 
0.58 (0.40 to 
0.83) 
Body weight Referent 
0.19 (0.04 to 
0.33) 
0.24 (0.04 to 0.43) 






-0.28 (-0.52 to 
-0.04) 
-0.09 (-0.30 to 
0.13) 




 Drugs given as dual therapy (in addition to metformin) 

















 Referent 2.10 (0.48 to 9.15) 
0.81 (0.36 to 
1.82) 
0.86 (0.14 to 
5.27) 
-- 
0.52 (0.08 to 
3.43) 
1.03 (0.10 to 
10.9) 
-- 




 Referent 1.29 (0.39 to 4.23) 
0.75 (0.45 to 
1.24) 




0.87 (0.39 to 
1.91) 
1.20 (0.25 to 
5.72) 
-- 




 Referent 1.23 (0.92 to 1.65) 
0.94 (0.82 to 
1.07) 




1.13 (0.91 to 
1.41) 
0.87 (0.46 to 
1.63) 
2.11 (0.73 to 
6.09) 




 Referent 1.59 (0.43 to 5.91) 
0.59 (0.32 to 
1.09) 




0.89 (0.35 to 
2.22) 
-- -- 
1.00 (0.36 to 
2.79) 
Stroke  Referent 0.81 (0.20 to 3.29) 
0.47 (0.23 to 
0.95) 




0.88 (0.26 to 
2.97) 
-- -- 
1.40 (0.50 to 
3.89) 
HbA1C  Referent 








0.10 (-0.41 to 
0.62) 
-0.83 (-1.80 to 
0.14) 
0.58 (-0.22 to 
1.37) 
1.24 (0.76 to 
1.72) 
Treatment failure  Referent 1.18 (0.70 to 1.98) 
1.37 (1.07 to 
1.76) 




0.84 (0.54 to 
1.30) 
1.16 (0.59 to 
2.26) 
12.4 (1.84 to 
83.3) 
3.43 (2.50 to 
4.72) 
Hypoglycemia  Referent 0.14 (0.09 to 0.24) 
0.12 (0.10 to 
0.16) 




0.19 (0.13 to 
0.27) 
0.55 (0.32 to 
0.93) 
0.13 (0.05 to 
0.40) 













-1.05 (-1.54 to 
-0.57) 
-- 




 Drugs given as triple therapy (in addition to metformin + sulfonylurea) 












inhibitor Placebo  
Cardiovascular 
mortality 
  Referent 
0.73 (0.00 to 
136) 




2.13 (0.04 to 
108) 
-- -- 




  Referent 
0.44 (0.02 to 
11.6) 




0.15 (0.01 to 
2.22) 
-- -- 




  Referent 
0.62 (0.32 to 
1.20) 
0.53 (0.27 to 
1.06) 
0.73 (0.42 
to 1. 27) 
0.64 (0.39 to 
1.07) 
-- -- 






  Referent -- -- -- -- -- -- -- 
Stroke   Referent -- -- -- -- -- -- -- 
HbA1C   Referent 
0.23 (-0.62 to 
1.08) 
0.12 (-1.12 to 
1.35) 





1.42 (0.57 to 
2.26) 
0.86 (0.25 to 
1.48) 
Treatment failure   Referent 
2.20 (1.32 to 
3.68) 




0.95 (0.60 to 
1.50) 
-- -- 
4.66 (3.04 to 
7.17) 
Hypoglycemia   Referent 
0.87 (0.50 to 
1.51) 




0.60 (0.39 to 
0.94) 
-- -- 
0.37 (0.24 to 
0.57) 







-0.23 (-0.39 to 
-0.06) 
-- 




Treatment effects are shown as odds ratios from indirect and direct evidence (all-cause mortality, cardiovascular mortality, serious adverse effects, myocardial infarction, stroke, 
hypoglycemia, or treatment failure) or standardized mean differences (HbA1C or body weight) together with the corresponding 95% confidence intervals. An odds ratio >1 indicates 
the outcome is more likely with treatment than the reference intervention.  An SMD above 0 indicates a higher body weight or HbA1C at end of treatment with the drug being 
considered compared to the reference treatment. Standardized mean difference of 0.2 is considered to indicate a small difference between treatments, 0.5 a moderate difference, and 
0.8 a large difference. For example, sulfonylurea monotherapy was associated with a small increase in mean HbA1C levels (standardized mean difference 0.18) compared to metformin 
monotherapy, and this difference had a 95% probability of ranging between 0.01 and 0.34. The statistically significant results are shown in bold and underlined. -- indicates treatment 
effects were not estimable due to an insufficient number of observations. Insufficient data were available to generate networks for drug classes used as triple therapy and outcomes of 
myocardial infarction and stroke. Mean odds ratios or standardized mean differences with wide confidence intervals should be interpreted with caution (e.g., the estimated odds of 
hypoglycemia associated with basal insulin compared to metformin was 17.9 and included a confidence interval of 1.97 to 162). The true odds of hypoglycemia associated with 
treatment might be considerably different than the mean estimated effect (odds ratio 17.9) and range from a small increase in hypoglycemia (odds ratio 1.97) to a very high odds of 
hypoglycemia (odds ratio 162). Wide confidence intervals were present for many drug comparisons and outcomes. 
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Figure 1: Summary of study retrieval and identification for network meta-analysis 
 
*Fourteen studies evaluated glucose–lowering strategies as both monotherapy and dual therapy. 
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Figure 2: Graphic representation of available glucose-lowering drugs on cardiovascular 
mortality in clinical trials involving people with type 2 diabetes. 
 
Nodes indicate the drug treatments which are evaluated in clinical trials. Lines represent head-to-head comparisons 
of the two drug classes indicated by the connected nodes. Numbers on the connecting lines between nodes 
represent the number of studies/number of adults in trials directly comparing the two treatments. The thickness of 
the line connecting two nodes is proportional to the number of clinical trials directly evaluating the two connected 
drug classes. For example, the most common head-to-head drug comparison for monotherapy is a sulfonylurea 
compared with a thiazolidinedione. The size of the node is proportional to the number of trials evaluating the 
treatment. For example, the most commonly evaluated monotherapy for glucose−lowering in adults with diabetes 
was metformin, followed by sulfonylurea, then placebo. 
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Figure 3: Rankings of available glucose-lowering drugs for treatment of type 2 diabetes. 
 
 
Drug classes are stratified according to administration as monotherapy, as dual therapy in addition to metformin, or 
as triple therapy in addition to metformin and sulfonylurea. The upper panel (A) indicates drug rankings for efficacy 
(cardiovascular mortality, treatment failure, and HbA1C levels). The lower panel (B) indicates drug rankings for 
adverse effects (serious adverse effects, hypoglycemia, and weight gain). The lines show the probability of the drug 
ranking for each outcome between best and worst (ranking 1st, 2nd, 3rd, etc.) and the peak indicates the ranking 
with the highest probability for the corresponding drug class. For example, for treatment failure, SGLT-2 inhibitor 
monotherapy demonstrates a higher probability of ranking best than thiazolidinedione (TZD) monotherapy. Basal 
insulin monotherapy has a 50% probability of ranking as the best drug for avoiding treatment failure and a 100% 
probability of ranking the worst (13th best) for hypoglycemia. Rankogram lines without marked peaks (for example 
for all drug classes as monotherapy and their association with odds of cardiovascular mortality) indicate similar 
probabilities of all rankings and lower confidence in comparative ranking of the relevant drug class for that 
outcome. Rankograms showing no data indicate observations were insufficient to generate a rankogram for the 
drug class for the corresponding outcome. For example, there were insufficient data for meglitinides as triple 
therapy to infer drug rankings for any outcome. Similarly, there were insufficient data to infer drug rankings for 
alpha glucosidase inhibitor treatment in triple therapy for the outcome of cardiovascular mortality. The peak of the 
rankogram curve can be used to assess probabilities of drug classes between best and worst (for example, for 
treatment failure, SGLT-2 inhibitors and GLP-1 receptor agonists were most likely to be among the best treatments 
and had similar ranking). 
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Abbreviations: AGI = alpha glucosidase inhibitor. BASAL = basal insulin. DPP-4-i = dipeptidyl peptidase-4 inhibitor.  
GLITINIDE = Meglitinide. GLP-1RA = glucagon-like peptide-1 agonist. MET = metformin. PCO = placebo. SGLT-2-i = 
sodium-glucose linked transporter-2 inhibitor. SU = sulfonylurea. TZD = thiazolidinedione. 
 
 
Figure 4: Funnel plot for cardiovascular mortality when glucose-lowering drugs were used as 
monotherapy. 
 
The red line represents the null hypothesis that the study-specific effect sizes do not differ from the respective 
comparison-specific pooled effect estimates.  The two black dashed lines represent a 95% confidence interval for 
the difference between study-specific effect sizes and comparison-specific summary estimates.  yixy is the noted 
effect size in study i that compares x with y. μxy is the comparison specific summary estimate for x versus y. The 
treatments are ordered by the surface under the cumulative ranking curve (SUCRA).  A=GLITINIDE; B=SGLT-2-I; 
C=TZD; D=AGI; E=DPP-4-i; F=MET; G=SU; H=PCO; I=BASAL-BOLUS.  
A funnel plot is a scatterplot of the study effect size versus some measure of its precision, in this the standard error. 
A funnel plot which is asymmetrical with respect to the line of the summary effect (vertical red line) implies there 
are differences between the estimates derived from small and large studies. The studies are ordered from “best” to 
“worst” according to effects on cardiovascular mortality. Missing (small) studies lying on the right side of the zero 
line suggest that small studies tend to exaggerate the effectiveness of higher ranked treatments compared to lower 
ranked treatments.  The cause of any small study effects is explored by meta-regression and is not necessarily due 
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Dietary changes are routinely recommended in people with chronic kidney disease on the 
basis of randomised evidence in the general population and non-randomised studies in chronic 
kidney disease that suggest certain healthy eating patterns may prevent cardiovascular events 
(CVE) and lower mortality. People who have kidney disease have prioritised dietary 
modifications as an important treatment uncertainty. 
Objectives 
This review evaluated the benefits and harms of dietary interventions among adults with CKD 
including people with end-stage kidney disease (ESKD) treated with dialysis or kidney 
transplantation. 
Search methods 
We searched the Cochrane Kidney and Transplant Specialised Register (up to 31 January 2017) 
through contact with the Information Specialist using search terms relevant to this review. 
Studies contained in the Specialised Register are identified through search strategies 
specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference 
proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and 
ClinicalTrials.gov. 
Selection criteria 
Randomised controlled trials (RCTs) or quasi-randomised RCTs of dietary interventions versus 
other dietary interventions, lifestyle advice, or standard care assessing mortality, 
cardiovascular events, health-related quality of life, and biochemical, anthropomorphic, and 
nutritional outcomes among people with CKD. 
Data collection and analysis 
Two authors independently screened studies for inclusion and extracted data. Results were 
summarised as risk ratios (RR) for dichotomous outcomes or mean differences (MD) or 
standardised MD (SMD) for continuous outcomes, with 95% confidence intervals (CI) or in 
descriptive format when meta-analysis was not possible. Confidence in the evidence was 






We included 17 studies involving 1639 people with CKD. Three studies enrolled 341 people 
treated with dialysis, four studies enrolled 168 kidney transplant recipients, and 10 studies 
enrolled 1130 people with CKD stages 1 to 5. Eleven studies (900 people) evaluated dietary 
counselling with or without lifestyle advice and six evaluated dietary patterns (739 people), 
including one study (191 people) of a carbohydrate-restricted low-iron, polyphenol enriched 
diet, two studies (181 people) of increased fruit and vegetable intake, two studies (355 people) 
of a Mediterranean diet and one study (12 people) of a high protein/low carbohydrate diet. 
Risks of bias in the included studies were generally high or unclear, lowering confidence in the 
results. Participants were followed up for a median of 12 months (range 1 to 46.8 months). 
Studies were not designed to examine all-cause mortality or cardiovascular events. In very-low 
quality evidence, dietary interventions had uncertain effects on all-cause mortality or ESKD. In 
absolute terms, dietary interventions may prevent one person in every 3000 treated for one 
year avoiding ESKD, although the certainty in this effect was very low. Across all 17 studies, 
outcome data for cardiovascular events were sparse. Dietary interventions in low quality 
evidence were associated with a higher health-related quality of life (2 studies, 119 people: 
MD in SF-36 score 11.46, 95% CI 7.73 to 15.18; I2 = 0%). Adverse events were generally not 
reported. 
Dietary interventions lowered systolic blood pressure (3 studies, 167 people: MD -9.26 mm Hg, 
95% CI -13.48 to -5.04; I2 = 80%) and diastolic blood pressure (2 studies, 95 people: MD -8.95, 
95% CI -10.69 to -7.21; I2 = 0%) compared to a control diet. Dietary interventions were 
associated with a higher estimated glomerular filtration rate (eGFR) (5 studies, 219 people: 
SMD 1.08; 95% CI 0.26 to 1.97; I2 = 88%) and serum albumin levels (6 studies, 541 people: MD 
0.16 g/dL, 95% CI 0.07 to 0.24; I2 = 26%). A Mediterranean diet lowered serum LDL cholesterol 
levels (1 study, 40 people: MD -1.00 mmol/L, 95% CI -1.56 to -0.44). 
Authors' conclusions 
Dietary interventions have uncertain effects on mortality, cardiovascular events and ESKD 
among people with CKD as these outcomes were rarely measured or reported. Dietary 
interventions may increase health-related quality of life, eGFR, and serum albumin, and lower 
blood pressure and serum cholesterol levels. 
Based on stakeholder prioritisation of dietary research in the setting of CKD and preliminary 
evidence of beneficial effects on risks factors for clinical outcomes, large-scale pragmatic RCTs 




Description of the condition 
Chronic kidney disease (CKD) is a disorder resulting from structural changes to the kidney 
(cysts, loss of tissue, or masses) and/or urinary tract leading to changes in the composition of 
the urine, reduced kidney function or both. The kidney is a target organ injured in diseases 
primary to the kidney (such as glomerulonephritis or polycystic kidney disease) and secondary 
diseases (including cardiovascular disease, metabolic syndrome, diabetes (predominantly type 
2), obesity, and arterial hypertension). Secondary causes of kidney failure now dominate the 
global epidemiology of kidney disease - diabetes and hypertension are the leading causes of 
CKD in middle and higher income countries worldwide, accounting for approximately 35% and 
25% of kidney disease (Jha 2013). Kidney tissue in systemic diseases is injured by accelerated 
vascular damage, glomerular hypertension, and increased cellular glycosylation and oxidation. 
Overall, CKD affects an estimated 10% to 15% of people around the world (Chadban 2003; 
Singh 2009; Zhang 2012) and leads to poorer health outcomes for affected individuals and 
communities. Among people who have moderate to severe CKD, early death and 
cardiovascular complications are two to three times more likely than for people without 
kidney disease and quality of life is reduced (Go 2004; Hemmelgarn 2010; Wyld 2012). 
Description of the intervention 
Dietary modifications (dietary intake of whole foods rather than single dietary nutrients, such 
as sodium or protein) may play an important and complex role in the aetiology and 
progression of CKD, in part through modification of systemic disease processes affecting 
kidney function (arterial hypertension, tissue glycosylation, glomerular injury, and 
macrovascular and microvascular diseases) and in part through altering the risks of non-
communicable diseases such as diabetes that play such an important role in the prevalence of 
kidney disease in developed and developing nations. Individual dietary components may 
influence blood lipid levels, oxidative stress, insulin sensitivity, blood pressure, systemic 
inflammatory responses, pro fibrotic processes, thrombosis risk, and endothelial function to 
modify clinical outcomes (Abiemo 2012; Nakayama 1996; Peters 2000; Stamler 1996; van Dijk 
2012). 
How the intervention might work 
While the exact mechanisms through which dietary modifications might act to prolong life 
expectancy and kidney function are likely to be multifactorial, there is emerging evidence 
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showing the impact of dietary changes on risk factors for kidney injury and cardiovascular 
disease. In recent Cochrane reviews of dietary advice in primary and secondary prevention 
studies - predominantly through reduction of salt and fat intake and increased fruit, 
vegetables, and fibre intake - dietary changes reduced arterial blood pressure by up to 10 mm 
Hg on average, as well as serum cholesterol and sodium excretion (Hartley 2013; Rees 
2013a; Rees 2013b). 
Combined dietary and exercise interventions among people at risk of diabetes, many of whom 
have kidney disease, reduce weight and body mass and have modest effects on blood lipids 
and blood pressure, while altered carbohydrate or energy intake plus exercise improves 
glycaemic control in people with type 2 diabetes (Nield 2008; Orozco 2008). Intensive advice 
and support to reduce salt intake may have small and unsustained effects on blood pressure 
(Adler 2014) of uncertain clinical importance. Among people at high cardiovascular risk, a 
Mediterranean diet increases circulating anti-oxidant levels, which has been proposed as one 
possible mechanism for improved survival (Zamora-Ros 2013). Whether dietary alteration of 
risks factors for cardiovascular events including blood pressure, serum lipids, or anti-oxidant 
levels modify clinical outcomes for people with CKD remains uncertain. 
Why it is important to do this review 
Although numerous randomised controlled trials (RCTs) in people with CKD have evaluated 
single nutrient management (such as protein intake or salt intake), there is relatively less 
information about the impact of whole dietary modifications - for example, the Mediterranean 
diet or Dietary Approaches to Stop Hypertension (DASH) diet - on clinical outcomes in people 
with CKD. Clinical studies in this area have been largely restricted to modifying protein, 
sodium, and phosphorus dietary intake as well as antioxidant supplementation (Fouque 
2009; Jun 2012; Liu 2015; McMahon 2015). Among people with CKD, lowered dietary salt 
intake reduced blood pressure and the amount of protein excreted by the kidney (an indicator 
of cardiovascular risk) (McMahon 2015), although there was no high-quality evidence this 
translated to slower kidney disease progression or fewer cardiovascular complications. 
Although dietary interventions in the setting of CKD have commonly focused on protein 
restriction as a mechanism to slow kidney failure, there is limited evidence that this dietary 
strategy is effective and safe and the impact of different protein sources on clinical outcomes 
is poorly understood (Robertson 2007; Fouque 2009). 
Global clinical guidelines recommend dietary strategies in the management of CKD (KDIGO 
2012). Specifically, guidelines suggest lower protein intake with appropriate education and 
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avoiding high protein intake for people at risk of kidney disease progression, lower salt intake, 
and increased physical activity (aiming for at least 30 minutes, 5 times/week). Guidelines 
recommend that people with CKD receive dietary advice and information in the context of an 
education program that is tailored to the severity of their CKD and the need to modify salt, 
phosphate, potassium, and protein intake. Given these guidelines, up to date evidence of the 
benefits and harms of dietary management is needed to inform practice and policy. 
In addition, patients, caregivers and health professionals consider the effects of dietary 
management as important and a priority treatment uncertainty in CKD (Manns 2014). When 
speaking about dietary changes, some patients experience dietary restrictions as an intense 
and unremitting burden (Palmer 2015), while at the same time offering them greater self-
efficacy in the management of their CKD. In general, patients value better understanding of 
the role of lifestyle management as a research priority (Tong 2015). Dietary management is 
therefore an important potential intervention for improving clinical outcomes in CKD that 
aligns with patient priorities. 
Objectives 
This review evaluated the benefits and harms of dietary interventions among adults with 





Criteria for considering studies for this review 
Types of studies 
We included RCTs and quasi-RCTs (in which allocation to treatment was obtained by 
alternation, use of alternate medical records, date of birth, or other predictable methods) 
measuring the effect of dietary interventions in adults with CKD. 
Types of participants 
Inclusion criteria 
Adults with any stage of CKD (any structural kidney or urine abnormality with or without 
reduced glomerular filtration rate below 60 mL/min/1.73 m² as defined by the Kidney Disease: 
Improving Global Outcomes (KDIGO 2012)) including people with end-stage kidney disease 
treated with dialysis, kidney transplantation or supportive care. 
Exclusion criteria 
Pregnant women and children younger than 18 years. 
Types of interventions 
Inclusion criteria 
We evaluated the following dietary modifications (including dietary advice or lifestyle 
management) compared with any other dietary pattern or standard care (including lifestyle 
advice). 
 Dietary patterns (e.g. DASH diet; Mediterranean diet, American Heart Association diet) 
 Nutritional counselling and education about food-based dietary interventions 
We included studies evaluating interventions for at least one month and studies in which 
concomitant non-randomised interventions such as antihypertensive medication, sodium 
restriction, or other co-interventions including supplements were used during the study period 
(e.g. specific blood pressure targets), providing that these interventions were administered to 
all treatment groups. We included studies of dietary modifications regardless of whether other 
dietary changes such as salt or phosphorus dietary intake were adjusted. We did not include 






We excluded dietary interventions that were "single-nutrient" or nutrient-focused 
interventions (including supplementation). This included the following dietary management 
interventions. 
 Dietary management of specific dietary factors including sodium, phosphorus, and 
protein (as these are evaluated in other Cochrane reviews (Fouque 2009; Jun 2012; Liu 
2015; McMahon 2015)) 
 Probiotics, prebiotics or synbiotics 
 Implementation strategies for dietary or lifestyle management 
Types of outcome measures 
We categorised outcomes according to length of follow up (< 6 months and ≥ 6 months). We 
extracted and analysed data for shorter (< 6 months) and longer (≥ 6 months) term outcomes 
separately. 
Primary outcomes 
1. All-cause mortality 
2. Major adverse cardiovascular events (as defined by study investigators) 
3. Health-related quality of life (as defined and measured by investigators) 
Secondary outcomes 
1. Withdrawal from dietary intervention 
2. Cause-specific death (cardiovascular mortality, sudden death, infection-related 
mortality) 
3. Progression to ESKD (as defined by the investigators including estimated glomerular 
filtration rate below 15 mL/min/1.73 m² or requiring treatment with long-term dialysis 
or kidney transplantation) 
4. Participant adherence to intervention 
5. Myocardial infarction 
6. Kidney function measures (creatinine clearance or estimated glomerular filtration rate, 
doubling of serum creatinine, serum creatinine) 
7. Serum lipids (total cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides) 
142 
 
8. Blood pressure 
9. Blood glucose control (glycated haemoglobin; fasting plasma glucose) 
10. Global measures of nutritional status (body mass index; body weight; waist 
circumference; subjective global assessment; malnutrition screening tool; mini 
nutritional assessment; skin-fold measurements; bioelectrical impedance analysis; 
albumin; prealbumin) 
Search methods for identification of studies 
Electronic searches 
We searched the Cochrane Kidney and Transplant Specialised Register (up to 12 January 2016) 
through contact with the Information Specialist using search terms relevant to this review. The 
Cochrane Kidney and Transplant Specialised Register contains studies identified from several 
sources. 
1. Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) 
2. Weekly searches of MEDLINE OVID SP 
3. Handsearching of kidney-related journals and the proceedings of major kidney 
conferences 
4. Searching of the current year of EMBASE OVID SP 
5. Weekly current awareness alerts for selected kidney and transplant journals 
6. Searches of the International Clinical Trials Register (ICTRP) Search Portal and 
ClinicalTrials.gov. 
Studies contained in the Specialised Register are identified through search strategies for 
CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. 
Details of these strategies, as well as a list of handsearched journals, conference proceedings 
and current awareness alerts, are available in the Specialised Register section of information 
about Cochrane Kidney and Transplant. 
Searching other resources 
1. Reference lists of review articles, relevant studies and clinical practice guidelines. 
2. Letters seeking information about unpublished or incomplete trials to investigators 




Data collection and analysis 
Selection of studies 
The search strategy was used to obtain titles and abstracts of studies that might have been 
relevant to the review. The titles and abstracts were screened independently by at least two 
authors (SP and JM), who discarded studies that were not eligible; however, studies and 
reviews that might have included relevant data or information on studies were retained 
initially. Two authors (SP and JM) independently assessed retrieved abstracts and, if necessary 
the full text, of these studies to determine which studies satisfied the inclusion criteria. Any 
uncertainties about study eligibility were discussed between authors and if necessary with a 
third author (KC). 
Data extraction and management 
Data extraction was carried out independently by two authors using pre-specified standard 
data extraction forms. Studies reported in non-English language journals were electronically 
translated before assessment. Where more than one publication of one study exists, study 
reports were grouped together and the publication with the most complete data was used in 
the analyses. Where relevant outcomes are only published in earlier publications of the study, 
these data were used. Any discrepancy between published versions were evaluated and 
highlighted. 
Assessment of risk of bias in included studies 
The following reporting items were independently assessed by two authors (SP and JM) using 
the Cochrane risk of bias assessment tool (Higgins 2011): 
 Was there adequate sequence generation (selection bias)? 
 Was allocation adequately concealed (selection bias)? 
 Was knowledge of the allocated interventions adequately prevented during the study? 
o Participants and personnel (performance bias) 
o Outcome assessors (detection bias) 
 Were incomplete outcome data adequately addressed (attrition bias)? 




 Was the study apparently free of other problems that could put it at a risk of bias? 
These were pre-specified as: baseline imbalance, interim reporting, deviation from 
study protocol in a way that does not reflect clinical practice, pre-randomisation 
administration of an intervention that could enhance or diminish the effects of a 
subsequent randomised intervention, contamination, occurrence of 'null bias' due to 
interventions being insufficiently well delivered or overly wide inclusion criteria, 
selective reporting of subgroups, reporting of trial registration, reporting of funding 
source(s), publication as full journal report, and fraud. 
Measures of treatment effect 
For dichotomous outcomes (total and cause-specific mortality, myocardial infarction, 
progression to ESKD, doubling of serum creatinine, participant adherence, withdrawal from 
intervention), the treatment effects of dietary management were expressed as a risk ratio (RR) 
together with 95% confidence intervals (CI). Where continuous scales of measurement are 
used to assess the effects of dietary management (health-related quality of life, blood 
pressure, lipids (total cholesterol, LDL cholesterol, triglycerides), kidney function (serum 
creatinine, creatinine clearance, glomerular filtration rate), body composition (weight, waist 
circumference, body mass index)), the mean difference (MD) between treatment groups were 
used, or the standardised mean difference (SMD) if different measurement scales have been 
reported. A standardised mean difference of 0.2 indicated a small difference, 0.5 a moderate 
difference and 0.8 a large difference. We evaluated mean end of treatment values for 
continuous outcomes together with the reported standard deviation in meta-analyses for 
these continuous outcomes. 
Unit of analysis issues 
Studies with more than two interventions were evaluated in this review. We used 
recommended methods for data extraction and analysis described by the Cochrane 
Collaboration (Higgins 2011). 
Cross-over studies 
There were no cross-over studies included in this meta-analysis. 
Studies with more than two interventions 
Studies with multiple intervention groups were included. When a study was a 'multi-arm' 
study, and all treatment arms provided data for eligible interventions, the study was described 
and included in the systematic review. If there were adequate data from the study, then 
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treatment arms relevant to the treatment comparisons of interest were included in applicable 
meta-analyses. 
Cluster randomised studies 
We planned to include information from cluster randomised studies. We planned to divide the 
effective sample size for each data point by a quantity called the design effect calculated as 1 + 
(M - 1) ICC, where M was the average cluster size and ICC was the intra-cluster correlation 
coefficient. In this calculation, a common design effect was assumed across all intervention 
groups. The intra-cluster coefficient (ICC) is seldom available in published reports. We 
therefore planned to adopt a common approach to use external estimates obtained from 
similar studies. For dichotomous outcomes, we planned to divide the number of participants 
and the number experiencing the event by the design effect. For continuous endpoints only 
the sample size was planned to be divided by the design effect with means and standard 
deviations remaining unchanged. 
Dealing with missing data 
Any further information required from the original author was requested by electronic mail 
and any relevant information obtained in this manner was included in the review. Evaluation 
of important numerical data such as screened, randomised patients as well as intention-to-
treat, as-treated and per-protocol population were carefully performed. Attrition rates, for 
example drop-outs, losses to follow-up and withdrawals were investigated. Issues of missing 
data and imputation methods (for example, last-observation-carried-forward) was critically 
appraised (Higgins 2011). 
Assessment of heterogeneity 
Statistical heterogeneity in treatment effects among studies was analysed using a Chi² test on 
N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² 
test (Higgins 2003). We considered I² values of 25%, 50% and 75% as corresponding to low, 
medium and high levels of heterogeneity. 
Assessment of reporting biases 
There were insufficient data to generate funnel plots to assess for the potential existence of 
small study bias for the outcome of all-cause mortality. 
Data synthesis 
We grouped studies by dietary modifications into similar interventions (e.g. counselling; 
Mediterranean; fruits and vegetables). Treatment estimates for the specified were 
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summarised within groups of dietary modifications and treatment effects were summarised 
using random-effects meta-analysis. Effects were reported as the relative risk (RR) and 95% 
confidence interval (CI) for binary outcomes and mean difference (MD) and 95% CI for 
continuous outcomes. 
We summarised information for outcomes in which meta-analysis is not possible due to 
insufficient observations using narrative tables. Narrative outcome reporting included health-
related quality of life domains described in the studies and nutrition assessments. The dietary 
interventions and associated implementation strategies were described using the "Better 
reporting of interventions: Template for Intervention Description and Replication (TIDieR) 
checklist and guide" (Hoffmann 2014) and tabulated in the review. 
Subgroup analysis and investigation of heterogeneity 
There were insufficient extractable data to conduct subgroup and univariate meta-regression 
analysis to explore the following variables as possible sources of heterogeneity: mean study 
age, mean proportion of men, energy intake, study-level mean blood pressure or cholesterol at 
baseline, proportion with diabetes, adequacy of allocation concealment, sample size, and 
duration of follow up (< 12 months versus ≥ 12 months). 
Sensitivity analysis 
There were insufficient extractable data to perform the following sensitivity analyses in order 
to explore the influence of the following factors on effect size: 
 Repeating the analysis excluding unpublished studies 
 Repeating the analysis taking account of risk of bias, as specified above 
 Repeating the analysis excluding any very long or large studies to establish how much 
they dominated the results 
 Repeating the analysis excluding studies using the following filters: diagnostic criteria, 
language of publication, source of funding (industry versus other), and country. 
'Summary of findings' tables 
We presented the main results of the review in a 'Summary of findings' table for the outcomes 
of all-cause mortality, cardiovascular mortality, end-stage kidney disease, and health-related 
quality of life. 'Summary of findings' tables present key information concerning the quality of 
the evidence, the magnitude of the effects of the interventions examined, and the sum of the 
available data for the main outcomes (Schunemann 2011a). The 'Summary of findings' tables 
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also included an overall grading of the evidence related to each of the main outcomes using 
the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach 
(GRADE 2008). The GRADE approach defines the quality of a body of evidence as the extent to 
which one can be confident that an estimate of effect or association is close to the true 
quantity of specific interest. The quality of a body of evidence involves consideration of within-
trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of 




Description of studies 
Results of the search 
The electronic search strategy of the Cochrane Kidney and Transplant specialised register on 
January 11, 2016 identified 824 records (Figure 1). On title and abstract screening, 754 records 
were excluded (seven were not related to people with chronic kidney disease, 732 did not 
evaluate a dietary pattern, 10 were not randomised clinical trials, and five were duplicate 
publications). Seventy records were evaluated in full-text detail. Fifty-eight were excluded (21 
were not in people with chronic kidney disease, 33 were not evaluating dietary patterns, three 
were not randomised clinical trials and one was of short duration (<1 month of follow up). 
Included studies 
Overall, 17 studies reported in 20 publications involving 1639 people with chronic kidney 
disease were eligible (Campbell 2008; Chanwikrai 2012; DIRECT 2012; Facchini 2003; Flesher 
2011; Goraya 2013; Goraya 2014; Leon 2006; Mekki 2010; Orazio 2011; Riccio 
2014; Stachowska 2005; Sutton 2007; Teng 2013; Tzvetanov 2014; Whittier 1985; Zhou 
2011b). The study characteristics are summarised in Table 1. Studies were published between 
2003 and 2014, with all but five (Facchini 2003; Leon 2006; Stachowska 2005; Sutton 
2007; Whittier 1985) of the studies published since 2008. 
Three studies involved 341 people treated with long-term dialysis (1 in haemodialysis and 2 in 
peritoneal dialysis), four studies involved 168 recipients of a kidney transplant, and 10 studies 
involved 1130 people with chronic kidney disease stages 1 to 5. In the studies involving people 
with chronic kidney disease, the average estimated glomerular filtration rate ranged between 
21.6 and 75 ml/min per 1.73 m2. Most participants with chronic kidney disease had an 
estimated GFR below 60 ml/min per 1.73 m2.The mean study eGFR ranged between 22.8 and 
70 ml/min per 1.73 m2. In people with a kidney transplant, the estimated glomerular filtration 
rate at baseline in the 2 studies reporting this was between 48 and 54 ml/min per 1.73 m2 on 
average. Studies had generally small sample sizes (including a median 73 participants, range 12 
to 318 patients). Participants were followed up for between 1 month and 3.9 years (median 12 
months). 




One study was conducted in Algeria (Mekki 2010), two in Australia (Campbell 2008; Orazio 
2011), one in Canada (Flesher 2011), one in China (Zhou 2011b), one in Israel (DIRECT 2012), 
one in Italy (Riccio 2014), one in Poland (Stachowska 2005), one in Taiwan (Teng 2013), one in 
Thailand (Chanwikrai 2012), one in the United Kingdom (Sutton 2007), and six in the United 
States (Facchini 2003; Goraya 2013; Goraya 2014; Leon 2006; Tzvetanov 2014; Whittier 1985). 
The mean age in the included studies ranged between 41 years (Stachowska 2005) and 69.5 
years (Campbell 2008). The mean body mass index at baseline ranged between 22.8 and 38.6 
kg/m2(median 28.5 kg/m2). 
Dietary interventions 
Dietary interventions included dietary counselling with or without physical activity and lifestyle 
advice in ten studies (860 patients) (Campbell 2008; Chanwikrai 2012; Flesher 2011; Leon 
2006; Orazio 2011; Riccio 2014; Sutton 2007; Teng 2013; Tzvetanov 2014; Zhou 2011b), a 
Mediterranean diet in three studies (395 patients) (DIRECT 2012; Mekki 2010; Stachowska 
2005), increased fruit and vegetable intake in two studies (179 participants) (Goraya 
2013; Goraya 2014), and a carbohydrate-restricted, low-iron available, polyphenol enriched 
(CR-LIPE) diet in one study (191 patients) (Facchini 2003) and a high protein/low carbohydrate 
diet in one study (Whittier 1985). A high fruit and vegetable intake was compared with oral 
bicarbonate supplementation in the setting of chronic kidney disease. A Mediterranean diet 
was compared with a control diet, a low fat diet, or a low carbohydrate diet. In general, dietary 
modifications tended to include increased intake of fish and poultry, fruit and vegetables, olive 
oil, and nuts, and lower intake of carbohydrates, red meat, sodium, and sugars. 
The aims of the dietary counselling studies were generally to assess whether dietary advice 
could improve nutritional status and body composition (Campbell 2008; Zhou 2011b), slow 
progression of chronic kidney disease (Chanwikrai 2012; Flesher 2011) or decrease biochemical 
derangement in kidney disease (Riccio 2014; Teng 2013). Studies of dietary patterns were 
primarily aimed at assessing effects of dietary intake on kidney function (DIRECT 2012; Facchini 
2003; Goraya 2013; Goraya 2014) or dyslipidaemia (Mekki 2010). Among people treated with 
dialysis, the interventions were aimed at increasing serum albumin levels (Leon 2006), 
supporting adjusted energy intake (Sutton 2007) and improving under nutrition (Zhou 2011b). 
Dietary interventions for transplant recipients aimed to modify cardiovascular risk factors 
(Orazio 2011; Stachowska 2005), provide lifestyle advice including nutrition guidance 
(Tzvetanov 2014), or reduce cushingoid side-effects. 
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Two studies reported three treatment groups. In the DIRECT 2012 study, a calorie restricted 
Mediterranean diet was compared with a calorie restricted low fat diet or calorie unrestricted 
low carbohydrate diet. In the Goraya 2014 study, increased fruit and vegetable intake was 
compared with oral bicarbonate supplementation and standard care. 
Excluded studies 
The one study which meet our population and intervention criteria was excluded as it was only 
for a short duration (10 days) (Parillo 1988). 
Risk of bias in included studies 
Reporting of details of study methodology was incomplete for most studies. The summary risks 
of bias are shown in Figure 2. 
Allocation (selection bias) 
Three studies reported adequate (low risk) random sequence generation (Campbell 2008; Leon 
2006; Sutton 2007). The risk of bias from random sequence generation methods was unclear in 
the remaining 14 studies. 
Blinding (performance bias and detection bias) 
Dues to the nature of the interventions, performance bias was judged as high risk in all 17 
studies. Detection bias was judged to be low risk in DIRECT Study 2013 and high in Zhou 2011b. 
Risk of detection bias was unclear in the remaining 15 studies. 
Incomplete outcome data (attrition bias) 
Attrition bias was low risk in seven studies (Campbell 2008; Chanwikrai 2012; DIRECT Study 
2013; Facchini 2003; Flesher 2011; Teng 2013; Zhou 2011b) and high risk in three studies (Leon 
2006; Sutton 2007; Tzvetanov 2014). Risks from attrition bias were unclear in the remaining 
seven studies. 
Selective reporting (reporting bias) 
Three studies were at low risk of reporting bias (Campbell 2008; Facchini 2003; Flesher 2011), 
and the remaining 14 studies were at high risk of reporting bias. 
Other potential sources of bias 
Eight studies were judged to be at low risk of other potential biases (Campbell 2008; Flesher 
2011; Goraya 2013; Goraya 2014; Mekki 2010; Orazio 2011; Teng 2013; Whittier 1985); five 
studies were judged to be high risk of bias (Chanwikrai 2012; DIRECT Study 2013; Leon 2006; 
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Riccio 2014; Stachowska 2005), and risks of bias were unclear in four studies (Facchini 2003; 
Sutton 2007; Tzvetanov 2014; Zhou 2011b). 
Effects of interventions 
Data for health-related quality of life are shown in Table 2.  Adverse event data are reported 
in Table 3. Adverse events were rarely reported. 
Primary outcomes 
No included studies were designed to examine effects of dietary interventions on all-cause 
mortality or major cardiovascular events. The confidence in the results for these outcomes was 
very low. 
All-cause mortality 
Five studies (Campbell 2008; Facchini 2003; Flesher 2011; Leon 2006; Sutton 2007) reported 
the number of deaths. Of these, four studies (Campbell 2008; Flesher 2011; Leon 2006; Sutton 
2007) reported deaths as part of the information provided about participant recruitment or 
attrition from study follow-up which lasted between 12 weeks and 12 months. Dietary 
counselling had uncertain effects on all-cause mortality (Analysis 1.1.1 (4 studies, 371 
participants): RR 1.59, 95% CI 0.60 to 4.21; I2 = 0%). 
In one study comparing a low-iron-available, polyphenol enriched carbohydrate-restricted (CR-
LIPE) diet with control over 3.9 years (Facchini 2003), mortality was reported as a patient 
outcome. A CR-LIPE diet had uncertain effects on all-cause mortality compared with standard 
care (Analysis 1.1.2 (1 study, 170 participants): RR 0.50, 95% CI 0.22 to 1.12). The confidence in 
the evidence for all-cause mortality was very low (Summary of findings table 1). 
Major adverse cardiovascular events 
Campbell 2008 death from cardiovascular causes was described by investigators when 
reporting study loss to follow-up during the 12 month study. Dietary counselling had very 
uncertain effects on cardiovascular mortality (Analysis 1.2.1 (1 study, 62 participants): RR 6.58, 
95% CI 0.35 to 122.21). The confidence in the evidence for cardiovascular events was very low 
(Summary of findings table 1). 
Health-related quality of life 
Only six studies included quality of life measures (Table 3). Of these, four studies used the 
Kidney Disease Quality of Life questionnaire and/or the Short Form-36 (Campbell 2008; Leon 
2006; Tzvetanov 2014; Zhou 2011b). In two studies (Tzvetanov 2014; Zhou 2011b), dietary 
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counselling was associated with a higher score on the SF-36 questionnaire than standard care 
(Analysis 1.3.1 (2 studies, 119 participants): MD 11.46, 95% CI 7.73 to 15.18; I2 = 0%). The 
confidence in the evidence for health-related quality of life was low (Summary of findings table 
1). 
Secondary outcomes 
End-stage kidney disease 
No included studies were designed to examine ESKD or risks of doubling of serum creatinine. 
The confidence in the results for ESKD was very low. Two studies reported the number of 
participants experiencing ESKD (Campbell 2008; Facchini 2003). In one of these studies 
comparing dietary counselling with standard care, the number of people starting dialysis was 
reported as part of participant progression in the 12-week study (Campbell 2008). In one 
study, a CR-LIPE diet had uncertain effects on ESKD compared with standard care. In the two 
studies combined, dietary interventions did not have statistically significant effect on risks of 
ESKD ((Analysis 1.4 (2 studies, 232 participants): RR 0.53, 95% CI 0.26 to 1.07; I2 = 0%). The 
confidence in the evidence for ESKD was very low (Summary of findings table 1). 
Doubling of serum creatinine 
Facchini 2003 reported that a CR-LIPE diet was associated with lower risks of doubling of 
serum creatinine ((Analysis 1.5 (1 study, 170 participants): RR 0.53, 95% CI 0.33 to 0.86). 
Employment 
Dietary counselling had uncertain effects on employment during a single 12 month study 
involving recipients of a kidney transplant (Analysis 1.6 (1 study, 17 participants): RR 6.22, 95% 
CI 0.96 to 40.22). 
Dietary adherence 
Dietary counselling had uncertain effects on dietary adherence compared with standard care, 
in a single study (Analysis 1.7 (1 study 54 participants): RR 1.58, 95% CI 0.97 to 2.58). 
Worsening nutrition 
In two studies, the proportion of participants with worsening nutritional status was measured 
using subjective global assessment (SGA) (Campbell 2008; Leon 2006). Compared with usual 
care, dietary counselling had uncertain effects on nutritional status as measured by SGA 






Dietary intervention was associated with a higher eGFR (Analysis 1.9 (5 studies, 219 
participants): SMD 1.08; 95% CI 0.20 to 1.97; I2 = 88%) than standard care, although there was 
very marked heterogeneity in treatment effects between the four studies evaluating dietary 
counselling and this may have been due to the different strategies used in participant 
counselling. 
Fruits and vegetables had uncertain effects on the eGFR compared with oral bicarbonate 
supplementation (Analysis 3.1 (2 studies, 143 participants); MD 0.84 mL/min/1.73 m2, 95% CI -
0.84 to 2.53; I2 = 0%). 
Serum creatinine 
Dietary interventions had uncertain effects on serum creatinine when compared to control 
(Analysis 1.10 (3 studies 112 participants): MD 0.83 µmol/L, 95% CI -16.57 to 18.23; I2 = 0%). 
In Goraya 2013, fruits and vegetables had very uncertain effects on serum creatinine 
compared with oral bicarbonate supplementation (Analysis 3.2 (1 study, 71 participants): MD -
9.00 µmol/L, 95% CI -39.11 to 21.11). 
Blood pressure 
Systolic blood pressure 
Dietary interventions lowered systolic blood pressure compared with standard care (Analysis 
1.11 (3 studies, 167 participants): MD -9.26 mm Hg, 95% CI -13.48 to -5.04; I2 = 80%). There 
was heterogeneity in the effects between the two different dietary approaches (I2=88.7%). 
Fruits and vegetables lowered systolic blood pressure compared to oral bicarbonate 
supplementation (Analysis 3.3 (2 studies, 143 participants): MD -5.81 mm Hg, 95% CI -8.84 to -
2.77) although there was high heterogeneity between studies (I2 = 79%). 
Diastolic blood pressure 
Dietary counselling lowered diastolic blood pressure compared with standard care (Analysis 







Different dietary interventions had statistically heterogeneous effects on energy intake and 
therefore the results of all available dietary approaches compared with standard care were not 
combined within a single analysis. 
Dietary counselling had uncertain effects on energy intake compared to standard care 
(Analysis 1.13.1 (4 studies, 340 participants); SMD 1.54, 95% CI -0.87 to 3.95). There was very 
high heterogeneity in this analysis (I2 = 99%) likely due to the differing counselling approaches 
in the included studies. 
A Mediterranean diet was associated with higher energy intake than standard care in Mekki 
2010 (Analysis 1.13.2 (1 study, 40 participants): SMD 1.86, 95% CI 1.11-2.61). 
A high nitrogen and low carbohydrate diet had uncertain effects on energy intake in Whittier 
1985 (Analysis 1.13 (1 study, 12 participants): SMD -0.65, 95% CI -1.82 to 0.53). 
Body weight, body mass index, waist circumference, waist-to-hip ratio and arm 
circumference 
Body weight 
Dietary interventions had uncertain effects on body weight compared with control (Analysis 
1.14 (6 studies, 454 participants): MD -0.44 kg, 95% CI -1.46 to 0.58; I2 = 15%). 
A higher fruit and vegetable intake was associated with a lower body weight than oral 
bicarbonate supplementation (Analysis 3.4 (2 studies, 143 participants):; MD -5.09 kg, 95% CI -
7.73 to -2.44; I2 = 56%). 
BMI 
Dietary interventions had uncertain effects on BMI compared with control (Analysis 1.15 (2 
studies, 119 participants): MD -1.70 kg/m2, 95% CI -5.23 to 1.82; I2 = 14%). 
Waist-to-hip ratio, waist circumference, and arm circumference 
In Orazio 2011, dietary interventions had uncertain effects on waist-to-hip ratio compared 
with control (Analysis 1.16 (1 study, 82 participants): MD -1.05, 95% CI -5.92 to 3.82). In the 
same study, dietary interventions had uncertain effects on the waist circumference (Analysis 
1.17 (1 study, 82 participants): MD -0.46 cm, 95% CI -2.05 to 1.13). 
Dietary interventions had uncertain effects on arm circumference compared with control 




Dietary interventions increased serum albumin levels compared with control (Analysis 1.19 (6 
studies, 541 participants): MD 0.16 g/dL, 95% CI 0.07 to 0.24; I2 = 26%). 
Serum low density lipoprotein cholesterol 
In Mekki 2010, a Mediterranean diet lowered serum LDL cholesterol levels compared with a 
control diet (Analysis 1.20.1 (1 study, 40 participants): MD -1.00 mmol/L, 95% CI -1.56 to -
0.44). 
In Facchini 2003, a CR-LIPE diet had uncertain effects on serum LDL cholesterol levels 
compared with a control diet (Analysis 1.20.2 (1 study, 148 participants): MD 0.21 mmol/L, 
95% CI -0.38 to 0.81). 
In Stachowska 2005, a Mediterranean diet lowered serum LDL cholesterol levels compared 
with a low fat diet (Analysis 2.1 (1 study, 38 participants): MD -0.60 mmol/L, 95% CI -1.15 to -
0.05). 
Investigation of publication bias, sub-group analyses and sensitivity analyses 
Investigation of publication bias, sub-group analyses and sensitivity analyses were not possible 
due to a lack of data observations. In particular there were insufficient data observations to 






Summary of main results 
This review summarises 17 studies of dietary interventions involving 1639 people with CKD 
that took place in a wide variety of global regions and health systems. Dietary interventions 
were evaluated for a median of 12 months. Dietary interventions were counselling, or a dietary 
pattern (Mediterranean; low fat; low carbohydrate; high fruit and vegetable; carbohydrate-
restricted, low-iron available, polyphenol-enriched; low carbohydrate-high nitrogen) compared 
with standard care, low protein intake, low fat or low carbohydrate intake, or oral bicarbonate 
supplementation. The studies included people with stages 1-5 CKD, kidney transplant 
recipients, and people with ESKD requiring dialysis. There was considerable heterogeneity in 
dietary interventions and their implementation, together with differences in tailoring of 
dietary management to individual requirements and methods to support adherence. Risks of 
bias in the included studies were often high or unclear, and these risks combined with 
imprecision in effect estimates led to low or very low confidence in the results. 
Studies were not designed to assess dietary effects on risks of death or cardiovascular events. 
As a result there was considerable uncertainty about the effects of dietary approaches on 
these outcomes including risks of myocardial infarction or stroke. This finding is particularly 
relevant as many people with CKD will die from cardiovascular causes before requiring 
treatment with dialysis or kidney transplantation. 
Dietary effects on health-related quality of life were infrequently reported and were 
documented using different tools, limiting the ability of studies to be combined. In low quality 
evidence, dietary interventions may have clinically-important increases in the SF-36 quality of 
life score. There was evidence that dietary modification impacted risks of ESKD, although 
dietary interventions may increase GFR compared with standard care. Dietary interventions 
lowered systolic and diastolic blood pressure by nearly 10 mm Hg on average and increased 
serum albumin levels. 
Overall, these data suggest that current evidence for dietary interventions in the setting of CKD 
is of very low quality and insufficient to guide clinical practice. Possible beneficial effects of 
dietary modifications on risk factors for disease in this review, the association of healthy eating 
patterns with lower mortality in non-randomised studies (Chen 2016; Gutierrez 2014; Muntner 
2013), and the priority placed on dietary restrictions in research (Tong 2015a) suggest dietary 




Overall completeness and applicability of evidence 
The strengths of this review comprehensive systematic searching for eligible studies, rigid 
inclusion criteria for RCTs, and data extraction and analysis by two independent investigators. 
We aimed to evaluate the effectiveness of dietary modification for range of food groups for 
people with CKD. This review included a small number of studies with heterogeneous 
interventions and implementation strategies. We could not robustly assess the effect of 
dietary pattern on endpoints such as mortality or cardiovascular events in people with CKD as 
there were few studies of sufficient size or duration to examine these outcomes. Despite 
preliminary evidence for improved blood pressure and serum cholesterol with some dietary 
patterns, evidence for the longer-term effects of dietary pattern on patient-level outcomes 
remains to be determined. There was a lack of consistency in estimating health-related quality 
of life among the available studies. Given the patients report dietary requirements and 
restrictions as a sometimes intense burden (Palmer 2015a), this aspect of dietary interventions 
remains important for future exploration. Reporting of health-related quality of life using tools 
validated for CKD would be helpful in future research studies. 
Quality of the evidence 
We assessed the quality of study evidence using standard risks of bias domains within the 
Cochrane tool together with GRADE methodology. Confidence in evidence for all-cause 
mortality, major cardiovascular events and health-related quality of life was very low or could 
not be estimated, meaning future studies might offer different results. No study had low risk 
methods for allocation concealment and none of the participants or study investigators was 
masked to treatment allocation. We downgraded for the possibility of publication bias due to 
the very low numbers of data observations for each outcome, precluding formal testing. 
Data summary was also difficult due to the variable methods of reporting in the individual 
studies. Particularly relevant was the heterogeneous manner of reporting GFR and serum 
creatinine concentrations. Some studies did not report an estimate of variance (SE or SD) and 
some provided data in descriptive or figure format only. 
Potential biases in the review process 
Potential biases in this review relate to the data availability in the individual studies. First, 
there was heterogeneity in treatment interventions and comparisons; due to the small number 
of data observations, robust statistical estimates of heterogeneity could not be estimated. 
Second, we could not assess for potential reporting bias due to the small number of studies in 
the review. Third, while most participants had moderate CKD (stage 3 or 4), there was wide 
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variation in the definition of kidney disease for inclusion in eligible studies. Fourth, studies 
were frequently at high risks of bias, but poorer quality studies could not be excluded from 
sensitivity analyses due to the limited number of data observations. Fifth, the treatment 
endpoints were principally surrogate markers of health (blood pressure, serum cholesterol, 
serum albumin) and the effects of dietary interventions on longer term outcomes remains 
uncertain. Sixth, adverse event reporting in the available studies was infrequent and 
inconsistent. Finally, selective outcome reporting was a limitation across the included studies. 
Agreements and disagreements with other studies or reviews 
A recently published Cochrane review (McMahon 2015) evaluated salt restriction among 
patients with CKD. While the intervention decreased blood pressure, as in this review there 
were insufficient data available to assess the impact of salt restriction on all-cause mortality or 
cardiovascular mortality. Similarly, in a Cochrane review of dietary interventions for mineral 
and bone disorder in CKD, there was low quality evidence that calcium enriched bread might 
influence biochemical parameters, and data were insufficient to identify treatment effects on 
clinical outcomes including cardiovascular mortality and fracture (Liu 2015). In a Cochrane 
review of low protein diets among people with CKD, a delay in progression of CKD was 
observed with a low protein intake (Fouque 2009). A recent meta-analysis of eight non-
randomised of eating patterns among 15,285 people with CKD, healthy eating was associated 
with lower risks of all-cause mortality (RR 0.73, 95% CI 0.63 to 0.83), but no effect on ESKD was 
detected (personal communication). The possible reasons for differences between the findings 
of that review and the present meta-analysis could include the non-randomised nature of the 
data, with the possibility of residual confounding accounting for the results, or a larger sample 
size providing greater statistical power to observe differences between treatment groups. A 
non-randomised study conducted in the general population reported a dietary pattern rich in 
whole grains, fruit, and low-fat dairy foods was associated with lower urinary albumin to 
creatinine ratio (Nettleton 2008). Albumin to creatinine ratio is used as a proxy marker for 
possibility of development of kidney disease in the general population and is also suggestive of 
increased risk of cardiovascular disease in patients with diabetes and hypertension. The finding 
that a study in this review showing a diet pattern with lower red meat and carbohydrates and 
higher olive oil content was associated with lower risks of kidney failure suggests larger studies 






Implications for practice 
Overall, these data suggest that current evidence for dietary interventions in the setting of CKD 
is of very low quality and insufficient to guide clinical practice. Possible beneficial effects of 
dietary interventions include clinically-important increases in health-related quality of life, 
lower blood pressure and serum LDL cholesterol levels and higher kidney function and serum 
albumin levels. These preliminary findings represent potential mechanisms for benefit of 
dietary modifications in larger studies, but the longer term impact of dietary changes need to 
be examined. 
Due to variation in dietary implementation and content, the range of clinical settings in the 
studies, and the lack of evidence for clinical outcomes, specific dietary recommendations or 
counselling cannot be currently recommended in the care of CKD or people treated with 
dialysis or a kidney transplant. As patients report dietary changes to be frequently confronting 
and intrusive and challenging to implement, patient input into future study design could 
strengthen the quality and acceptability of tested interventions. Not all areas of the world 
have health systems where dietitians are able to provide patient-centred care or patients have 
access to food types used in the studies in this review, and food availability and health service 
funding might be important barriers to future clinical studies. 
Implications for research 
Questions remain about the impact of dietary patterns on long-term clinical outcomes in the 
setting of CKD. Dietary restrictions are a priority uncertainty in CKD for patients and clinicians. 
This review highlights potential intermediary mechanisms (lowering blood pressure or serum 
cholesterol) through which dietary counselling or specific dietary patterns might act to benefit 
long-term health outcomes among people with CKD. 
Given existing non-randomised studies suggest benefits of healthy, plant-based dietary 
patterns on lowering mortality in CKD (Chen 2016; Gutierrez 2014), and large RCTs show the 
Mediterranean diet lowers cardiovascular complications among people at risk of 
cardiovascular disease (Estruch 2013), further research is needed to evaluate the impact of 
dietary patterns on hard clinical outcomes including mortality and cardiovascular endpoints in 
CKD. Qualitative data are available about the impact of dietary restrictions on patient well-
being (Palmer 2015a) that might be considered when designing dietary strategies and their 
implementation. Given that existing studies have generally small sample sizes and insufficient 
power to determine effects on mortality and cardiovascular events, consideration of a 
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pragmatic study design to ensure efficient participant recruitment, such as a registry-trial 
design, might assist with study feasibility and cost. 
Future research should pay specific attention to outcomes that have been relatively under-
researched, but are important causes of significant morbidity. Due to the considerably higher 
risk of death and cardiovascular events compared to ESKD, future studies should be powered 
to assess dietary effects on these outcomes. We plan to add these to the review outcomes in 
future review updates if they become available. There were no studies incorporating economic 
analyses; we suggest future studies should include analyses of the relative costs and benefits 
of dietary management. Dietary studies involving participants in resource-constrained settings 
should be considered. 
Given the variation in outcome measures routinely collected and reported in nephrology 
studies including studies in the present review, a core (minimum) data set, such as that being 
generated by the SONG collaboration (Tong 2015b), together with a validated measure of 
health-related quality of life would facilitate development of clinically-relevant studies and 
useful meta-analyses of dietary interventions. 
Future studies in this area would benefit from drawing on a framework for studies of complex 
interventions, which explicitly requires theoretical modelling between processes and 
outcomes in the pre-trial stage, and a process evaluation of the study (Anderson 2008). All 
studies should provide greater description of intervention and standard models of care being 
assessed (Hoffmann 2014) and include process evaluations of how they are being 
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Table 1. Summary of included studies 


























> 18 years; eGFR < 30 mL/min/1.73 
m2; CKD not previously seen by a 
dietitian for stage 4 CKD; absence of 
communication or intellectual 
impairment; absence of malnutrition 
from a cause other than CKD; not 



















eGFR 20 to 60 mL/min for ≥3 
months; presence of urinary protein; 
adult (≥ 19 years); hypertension or 
taking at least 1 antihypertensive 














18 to 85 years; receiving dialysis for 
at least 9 months; mean serum 
albumin level for previous 3 months 
< 3.70 g/dL (bromcresol green 

































Treatment with CAPD for 3 months 















20 years or older; communicate in 
Mandarin or Taiwanese; aware of 







Standard care Transplant Transplant 
46 (6.9) 
45 (19) 










18 to 70 years; receiving long-term 














3 30-60 52.5 (6.2) 99 52.6 (5.9) 30.9 (3.4) 
40 to 65 years with BMI ≥ 27 kg/m2; 
individuals with type 2 diabetes or 
coronary heart disease were eligible 
regardless of age. Post-hoc analysis 
among participants with eGFR 30 to 

























Stable transplant function 















Non-malignant hypertension; eGFR 
15 to 29 mL/min/1.73 m2; plasma 
TCO2< 22 mM; no diabetes or 
cardiovascular disease; two or more 
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primary care physician visits in 
















Non-malignant hypertension, eGFR 
30 to 59 mL/min/1.73 m2; plasma 
TCO2< 25 mM; macroalbuminuria; 
able to tolerate angiotensin-
converting inhibition; non-smoking 
for ≥ 1 year; no diabetes or 
cardiovascular disease; 2 or more 
primary care physician visits in 
previous year; ≥ 18 years 














Type 2 diabetes; referred to 
nephrology clinic for kidney failure 
(15 ± 75 mL/min); otherwise 
unexplained proteinuria (350 ± 
12,000 mg/d); kidney disease 
attributed to diabetes 







Standard care Transplant Transplant 
33 
32 





Table 3. Narrative description of health-related quality of life outcomes 
 




Kidney Disease Quality of Life Short 
Form Version 1.3 (combining the SF-
36 with a kidney-disease specific 
module) 
"There was a clear trend for a mean increase in ratings from the intervention group with a 
clinically significant mean improvement in 13 of the 18 sub-scales from baseline to week 12, 
indicated by an effect size of 0.2 or greater...". There was a statistically significant difference in 
mean change for scores of symptoms of kidney disease (7.1 (0.1-14.1) P = 0.047); cognitive 




-- Not reported 
Flesher 2011 Self-Management Questionnaire 
"Overall, the experimental group showed 'improvement' in exercise frequency, concern over 
health condition, and frequency of visits to health providers or hospitalisation. Overall the 
control group answers indicated an improvement in their communication with health providers 
in asking question and discussing personal issues." 
Leon 2006 
Kidney Disease Quality of Life 
questionnaire (combining the SF-36 
with a kidney-disease specific 
module) 
"There were no differences between intervention and control patients in quality-of-life 
subscales, including general health, physical functioning, emotional well-being, social function, 
pain, and dialysis-related symptoms." 
Orazio 2011 -- Not reported 
Riccio 2014 -- Not reported 
Sutton 2007 -- Not reported 
Teng 2013 52-item HPLP-IIC questionnaire 
Intervention had a significant effect on health responsibility and physical activity, but not stress 




"The mean SF-36 score at 6 months was significantly higher in the intervention group compared 
with the control group (583±13 vs 436±22, P = 0.008), reflecting an improved perception of 
health status. ... The intervention group had improvements compared with the control group in 




Kidney Disease Quality of Life Short 
Form Version 1.3 (combining the SF-
36 with a kidney-disease specific 
module) 
"Prior to intervention, the differences in KDTA and SF-36 scores were not statistically significant 
in both groups (P >0.05 for all). After intervention, both KDTA and SF-36 scores were improved in 
the study group, but decreased in the control group. The difference in KDTA (P = 0.001) and SF-





-- Not reported 
Mekki 2010 -- Not reported 
Stachowska 
2005 
-- Not reported 
Increased fruit and vegetables 
Goraya 2013 -- Not reported 
Goraya 2014 -- Not reported 
Carbohydrate-restricted, low-iron-available, polyphenol-enriched diet 
Facchini 
2003 
-- Not reported 
High-protein, low carbohydrate diet 
Whittier 
1985 
-- Not reported 
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Table 2. Adverse events  
Study Adverse events reported in study 
Campbell 2008 Mortality; need for dialysis. 
Chanwikrai 2012 None reported 
DIRECT 2012 None reported 
Facchini 2003 None reported 
Flesher 2011 None reported 
Goraya 2013 No participants meeting eGFR and plasma potassium criteria developed plasma potassium concentration >5.0 mEq/L. 
Goraya 2014 None reported 
Leon 2006 None reported 
Mekki 2010 None reported 
Orazio 2011 None reported 
Riccio 2014 None reported 
Stachowska 2005 None reported 
Sutton 2007 Mortality; transfer from peritoneal dialysis to haemodialysis. 
Teng 2013 None reported 
Tzvetanov 2014 None reported 
Whittier 1985 Dialysis due to elevated blood urea and potassium concentrations. 




Summary of findings table - Dietary intervention versus control 
Dietary modifications (counselling or dietary change) compared with control for chronic kidney disease  
Patient or population: People with chronic kidney disease 
Intervention: Dietary modifications 
Comparison: Control 
 










Assumed risk Corresponding risk 
Standard care Dietary intervention 




+- - - 
very low1,2,3 
Studies were not designed to 
measure effects of dietary 
interventions on mortality. 
150 per 1000 Not estimable 
Medium risk population 
25 per 1000 Not estimable 
Major cardiovascular 
event 









Studies were not designed to 
measure effects of dietary 
interventions on cardiovascular 
events. 0 studies reported major 
cardiovascular events. 
150 per 1000 Not estimable 
Medium risk population 
45 per 1000 Not estimable 
Progression to end-stage 
kidney disease 
Measured as requiring 
dialysis treatment in 
people with chronic 
kidney disease 





+- - -  
very low1,2,3,4 
29 participants developed end-
stage kidney disease in these 
studies. 0 studies included 
recipients of a kidney transplant. 
Health related quality of 
life 
Health-related quality of 
life measured using the 
Short Form-36 scale from 
0 to 100. 
The mean SF-36 
score ranged 
across control 
groups from 43.6 
to 48.8. 
The mean SF-36 score in 
the intervention groups 
was 11.46 higher (95% CI 





0 studies included recipients of a 
kidney transplant. None of the 
studies were blinded. 
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*The basis for the assumed risk of mortality (e.g. the median control group risk across studies) was obtained from the absolute population risk 
estimated from previously published cohort studies or data registries (Johnson 2011; Weiner 2006). The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: 
Risk Ratio. 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the 
estimate. 
Very low quality: We are very uncertain about the estimate. 
Footnotes 
1 Study limitations were due to high or unclear risks of bias 
2 Confidence interval includes range of plausible values that include substantial benefit or harm 
3 Based on few events and/or participants across all studies 










Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item 















Analysis 1.3 Forest plot of comparison:  Dietary intervention versus control, outcome: 






Analysis 1.4 Forest plot of comparison:  Dietary intervention versus control, outcome: ESKD 
 
 
Analysis 1.5 Forest plot of comparison:  Dietary intervention versus control, outcome: 
Doubling of serum creatinine 
 
 
Analysis 1.6 Forest plot of comparison:  Dietary intervention versus control, outcome: 
Employment 
 









Analysis 1.9 Forest plot of comparison:  Dietary intervention versus control, outcome: eGFR 
 
 






Analysis 1.11 Forest plot of comparison:  Dietary intervention versus control, outcome: 
Systolic blood pressure 
 
 
Analysis 1.12 Forest plot of comparison:  Dietary intervention versus control, outcome: 
Diastolic blood pressure 
 
 










Analysis 1.15 Forest plot of comparison:  Dietary intervention versus control, outcome: BMI 
 
 








Analysis 1.17 Forest plot of comparison:  Dietary intervention versus control, outcome: 
Waist circumference 
 








Analysis 1.20 Forest plot of comparison:  Dietary intervention versus control, outcome: 
















Analysis 3.3 Forest plot of comparison:  Fruits and vegetables versus bicarbonate, Outcome: 
Systolic blood pressure 
 
 







CHAPTER VII: DIETARY AND FLUID RESTRICTIONS IN CKD: A THEMATIC 
SYNTHESIS OF PATIENT VIEWS FROM QUALITATIVE STUDIES 
 
Suetonia C. Palmer, Camilla S. Hanson, Jonathan C. Craig, Giovanni F.M. Strippoli, Marinella 
Ruospo, Katrina Campbell, David W. Johnson, and Allison Tong.  




Background: Managing the complex fluid and diet requirements of chronic kidney disease 
(CKD) is challenging for patients. We aimed to summarize patients’ perspectives of dietary and 
fluid management in CKD to inform clinical practice and research. 
Study design: Systematic review of qualitative studies. 
Setting and population: Adults with CKD who express opinions about dietary and fluid 
management. 
Search strategy and sources: MEDLINE, Embase, PsycINFO, CINAHL, Google Scholar, reference 
lists and PhD dissertations were searched to May 2013. 
Analytical approach: Thematic synthesis 
Results: We included 46 studies involving 816 patients living in middle- to high-income 
countries. Studies involved patients treated with facility-based and home hemodialysis (33 
studies; 462 patients), peritoneal dialysis (10 studies; 112 patients), either hemodialysis or 
peritoneal dialysis (3 studies; 73 patients), kidney transplant recipients (9 studies; 89 patients) 
and patients with CKD stages 1-5 (not treated with dialysis) (5 studies; 80 patients). Five major 
themes were identified: preserving relationships (interference with roles, social limitations, 
and being a burden), navigating change (feeling deprived, disrupting held truths, breaking 
habits and norms, overwhelmed by information, questioning efficacy, and negotiating 
priorities), fighting temptation (resisting impositions, mental invasion, and withstanding 
physiological needs), optimizing health (accepting responsibility, valuing self-management, 
preventing disease progression, preparing for and protecting a transplant), and becoming 
empowered (comprehending paradoxes, finding solutions, and mastering change and 
demands).  
Limitations: Limited data in non-English languages, low-income settings and for adults with 
chronic kidney disease not treated with hemodialysis. 
Conclusions: Dietary and fluid restrictions are disorienting and an intense burden for patients 
with CKD.  Patient prioritized education strategies, harnessing patients’ motivation to stay well 
for a transplant or to avoid dialysis, and viewing adaptation to restrictions as a collaborative 
journey are suggested strategies to help patients adjust to dietary regimens in order to reduce 




CKD causes water, sodium, potassium and phosphorus retention, which contributes to 
cardiovascular events, intra-dialysis symptoms, breathlessness and edema. Obesity is a risk 
factor for end-stage kidney disease,1 while malnutrition is endemic in people with advanced 
CKD and is associated with mortality.2 However, adherence to dietary regimens in CKD is 
challenging due to the burden of constant choices about food and drink, the adaptation to 
complex eating patterns, existing cultural practices, and the competing demands of CKD and 
related illnesses.3-6 
Guidelines recommend that individuals with CKD receive dietary advice to intervene in salt, 
phosphate, potassium and protein intake and emphasize the importance of dietary 
counseling.7 While dietary interventions are considered central to management of CKD, health 
professionals cite insufficient time to implement recommendations8 and inclusion of patient 
experiences and perceptions of dietary treatment in CKD guidelines are limited.7  
We aimed to summarize patients’ perspectives and choices of dietary and fluid management in 




We conducted this review using the Enhancing Transparency of Reporting the Synthesis of 
Qualitative research (ENTREQ) framework.9 
Selection criteria and literature search 
We included qualitative data for adults aged 18 years or older who had CKD and who 
expressed opinions about diet or fluid management. We included CKD stages 1-5, kidney 
transplant recipients (5T), and people treated with dialysis (5D).7  
Data sources and searches 
Electronic databases and reference lists of included studies were searched at May 7, 2013 
(Item S1). Two authors (SP, GS) screened all records and discarded those that were not eligible. 
The full text of the remaining citations was then examined to identify qualitative data. 
Comprehensiveness of reporting 
SP and CH independently assessed the comprehensiveness of reporting using the consolidated 
criteria for reporting qualitative research (COREQ) framework.10 
Synthesis of findings 
We identified descriptive themes in primary data and used thematic synthesis to generate 
analytical themes, which are a higher level of abstraction of concepts, understandings or 
hypotheses.11 We imported text of each primary source into HyperRESEARCH 
(www.researchware.com). One author (SP) performed line-by-line coding, conceptualized the 
data, and inductively identified concepts relating to patient perspectives, experiences and 
values. Similar concepts were grouped into themes and subthemes. Conceptual linkages 
between themes were used to generate a thematic schema. To ensure that coding captured 
the relevant ideas and reflected data from the primary studies, researcher triangulation was 
done where two authors (SP, AT) discussed the primary themes and analytical framework. 





Characteristics of the studies 
Forty-six studies (involving 816 patients) were included (Figure 1 and Table 1). Studies involved 
patients treated with facility-based and home hemodialysis (33 studies; 462 patients), 
peritoneal dialysis (10 studies; 112 patients), either hemodialysis or peritoneal dialysis (3 
studies; 73 patients), kidney transplant recipients (9 studies; 89 patients) and patients with 
CKD stages 1-5 (not treated with dialysis) (5 studies; 80 patients).  
Study appraisal 
The comprehensiveness of study reporting was variable (Table 2).  
Synthesis 
Five major themes conceptualized patients’ experiences: preserving relationships, navigating 
change, fighting temptation, optimizing health, and becoming empowered (Table 3). 
Quotations to illustrate each theme are provided in Table 4.  
Preserving relationships 
Interference with roles (23 studies):  
Patients, principally those on dialysis, experienced challenges to their roles with others. They 
felt infantilized and scolded about their diet.  Family members policed their diet intake12,13 and 
searched for food they thought that patients had hidden.12 Patients on dialysis resented 
unsolicited advice particularly in social situations.13 Some patients felt patronized by medical 
staff for not following food advice12 and others told of eating restricted foods in secret to avoid 
being lectured by clinicians.5,14 
Social limitations (14 studies): 
Food and fluid management stopped many dialysis patients from socializing. It became too 
difficult to explain food restrictions to others for fear of ‘social stigma’, 15 or that refusing food 
or drink would offend their hosts.14-16 Some preferred not to be with others as eating 
restrictively drew attention to their disease15,17 and they became ‘afraid of seeing people.’5 
After declining invitations previously, some were subsequently excluded from social 
occasions.5 Some patients decided to eat and drink normally in social situations and ‘pay for it’ 
later with symptoms due to fluid overload or itch.5,15,18 For first-generation immigrants from 
Bangladesh in the United Kingdom, dietary changes were embarrassing as reducing some 




Being a burden (11 studies): 
Some patients on dialysis depended on family for preparing meals in accordance with their 
dietary restrictions. They felt guilty that family members had to adopt the restrictive renal 
diet.20 Some female Bangladeshi patients were concerned that if they omitted salt from meals 
their families would resent them19 while some patients chose to be vigilant about their dietary 




Feeling deprived (27 studies): 
In addition to experiencing severe illness, diet and fluid restrictions were perceived as a further 
deprivation. Patients viewed diet recommendations as externally imposed and more difficult 
to accept than if they had been a personal choice.5,13,15,21,22 Patients spoke about having life’s 
pleasures removed and how food had become bland and tasteless.12,13,21,23  Some patients on 
dialysis described their restrictions using nihilistic or violent terms such as ‘having no life at 
all’,24 ‘having a meaningless existence’,5 or as like being a prisoner, being condemned to death 
or being tied up.25 Some anticipated they would ‘live again; feel reborn!...and enjoy life again’ 
after a kidney transplant!’26 while those who have received a kidney transplant expressed 
delight at the freedom from their dietary restrictions; ‘I was excited about eating something I 
hadn’t eaten in a while.’27  
Disrupting held truths (12 studies): 
Dietary restrictions were counterintuitive and disorienting. Dietary advice contradicted a 
‘healthy diet’20 and patients felt lethargic, malnourished and starved if they followed the diet 
as instructed.5 Some patients from an ethnic minority felt that recommended diets did not 
consider traditional foods, with one patient from Barbados in the US suggesting ‘something 
could be done to help put some back home foods on the list and let the dieticians learn about 
our foods, …’28   
Breaking habits and norms (21 studies): 
Patients were angry about having to take on a new food and liquid regimen in addition to 
changes to their daily schedules and recreational activities imposed on CKD. Some patients on 
dialysis were ambivalent about the transformation of so many aspects of their lives that were 
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previously worry-free.25 Patients admitted forgetting the dietary recommendations particularly 
when they had a change or a break in their routine.15 
Overwhelmed by information (18 studies): 
When learning about diet management, patients described being ‘bombed’ with information 23 
that was sometimes not relevant to their cultural background or existing food preferences;19 
‘[the clinicians] speak in a Latin tongue…and…just jibber, jibber, jibber’.29 Patients spoke of 
listed permissible foods as being unfamiliar to them.28 Comorbid conditions (diabetes and 
heart disease) led to conflicting advice.20 Patients reported not understanding the advice, 
when they were still in ‘emotional turmoil’ after learning about their CKD diagnosis or just 
having had a dialysis catheter implanted.5 Patients ‘preferred to receive advice from a renal 
dietician who could support the rules with a clear rationale and practical advice to help them 
implement any changes’.20 Kidney transplant recipients expressed a lack of knowledge about 
appropriate ways to follow dietary freedoms in a healthy way.27 
Questioning efficacy (17 studies): 
Patients felt that taking the advice about food and fluid was a personal choice.5 Some patients 
had a sense that restrictions had few immediate or longer term benefits or even caused harm 
18 or alternatively that the dialysis could compensate for any excessive intake.29 For this 
reason, some returned to a regular food or fluid intake28 or lacked faith in doctors who advised 
strict restrictions as patients considered them unnecessary.5 
Negotiating priorities (23 studies): 
Patients struggled with making choices between getting pleasure from food and fluid versus 
staying in control and keeping well. Some spoke about ‘cheating’ on their diet by learning how 
to get away with eating treats in moderation.12,13 ‘It isn’t though I don’t ever cheat on my diet, 
everyone does. I cheat in a way that I know from experience will be safe for me’.12 They tested 
the boundaries of dietary restrictions: ‘I try my best to adhere to dietary restrictions. I only eat 
a little bit in secret when I really can’t refrain. … But I don’t do that often.’5 Others perceived 
there was no choice other than to stick to the diet.5,22 
 
Fighting temptation 
Resisting impositions (15 studies): 
For some patients, the dietary and fluid advice was seen as unreasonable. One described 
having a list of ‘forbidden foods’ that occupied ‘four sheets of A4-sized paper’ and which was 
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impossible to incorporate into daily life.5 Consuming food in restricted amounts was unfeasible 
and impractical. ‘When I eat banana, I’ve to eat just half. Where do I put the remaining half 
then? It’d be better to eat the remaining half as well.’5 Some saw the dieticians’ role as ideally 
not to impose change but to support patients in their adaptation to new diet and fluid habits.30 
Mental invasion (14 studies): 
Some patients on hemodialysis were tormented by unrelenting thoughts of food and drink.31 
Compulsive thoughts about fluid provoked ‘mirages’ that made them look for water even 
when it was not present32 or experience ‘visions…such as a mountain with fresh water gushing 
forth’.25 Patients would consider the need to drink as ‘stronger than me’ describing themselves 
as ‘tortured’,14 ‘fixated’,25 ‘obsessed’14 or ‘addicted’.24,25 Thirst was distressing4 and for some 
could never be satiated.33 
Withstanding physiological needs (15 studies): 
Food and fluid were seen as a physical need which were ‘indispensable elements for life’.25 
Patients couldn’t conceive of how medical advice leading to dehydration could be beneficial.25 
Some recipients of a kidney transplant found it impossible to control their appetite: ‘the larger 
the dose of prednisone, my appetite just got bigger and bigger’ while another mentioned that 
he ‘never got full’.27 Dietary restrictions were both ‘fighting nature’ and ‘fighting against 
themselves’ against thirst or appetite.14  
 
Optimizing health 
Accepting responsibility (22 studies): 
Adherence to diet and fluid restrictions became more manageable once they learned to accept 
responsibility for their treatment and recognized the potential consequences of their behavior 
on their future health. Some learned to cope better over time and by being ‘grown up’ and 
simply what they had to tolerate.31 Some accepted that food and fluid changes were ‘part of 
the deal’14 and having taken charge no longer allowed diet to be a dominating concern in their 
lives.20 
Valuing self-management (31 studies): 
For some patients, diet and fluid advice was part of the suite of specific actions they could do 
to care for themselves12 to feel better.5 Some wanted to tell other patients to persevere on 
diet and fluid advice to improve quality of life based on their own critical experiences such as 
severe fluid overload.25,29 Some patients gained confidence in their own dietary strategies by 
196 
 
regulating their diet according to blood test results:6 ‘I’ve kept my chemistries at a level and I 
know that if it goes up, I know how to bring it down’.34 
Preventing chronic kidney disease progression (5 studies): 
Some patients sought comprehensive guidance about how to prevent the progression of their 
disease18 and wished in hindsight that they had taken more heed of dietary advice if they had 
known it might have slowed down the rate of their CKD progression. 
Preparing for and protecting transplant (8 studies): 
Some patients on dialysis harnessed the prospect of a transplant as motivation to keep 
themselves healthy,5,13,21 while viewing not getting a transplant as equivalent to giving up 
hope.13 Some African American patients on dialysis believed that weight loss was difficult if not 
impossible while on dialysis and were angry they might be excluded from getting a transplant 
without weight loss.35 Kidney transplant recipients refrained from foods they feared might 
cause transplant rejection.36 
 
Becoming empowered 
Comprehending paradoxes (21 studies): 
Through a process of adaptation and negotiation, patients learned how to incorporate 
complicated dietary ideals into their lives.3 By adjusting to the counterintuitive idea that many 
‘healthy’ foods were now off limits and making decisions based on how their symptoms 
responded to their choices, patients learned to navigate through complex clinical instructions 
until it became second nature.13 Once they had ‘grappled’ with the many adjustments needed 
to adapt to dialysis treatment, some felt confident to share their experiences with their 
peers.12 
Finding solutions (23 studies): 
Some dialysis patients used practical responses to cope with dietary restrictions, such as 
buying cookbooks and learning to read nutritional labels to identify sodium-free products.12 
They developed libraries of foods that were high in potassium, phosphorus and sodium19 and 
valued regular contact with renal dieticians and their peers to consolidate their learning and 
build confidence.15 Patients believed that the person who did the shopping and cooking for 
their household should also be invited to attend education sessions. They expressed a 
preference for a repeated problem-solving approach rather than didactic teaching methods 
when learning how to manage their food and fluid intake.20 
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Mastering change and demands (25 studies): 
Gaining and keeping control of diet and fluid was one way of finding meaningful ways to stay 
alive and feel good and that surviving their chronic disease was worth the effort. They saw that 




In this review, we found that dietary and fluid management is a disorienting challenge and 
intense burden for patients when adapting to and coping with different stages of CKD. The 
substantial number and complexity of restrictions on food and fluid exacerbates the impaired 
quality of life caused by CKD and has a profound impact on patients’ relationships with others. 
Patients experience unresolved conflict between their medical team who advocate strongly for 
a narrow window of diet and fluid choices on the basis of ‘improved health’, and their own 
sense of well-being which is undermined by what they perceive as an unrealistic and 
unpalatable diet devoid of taste and interest. Studies reveal that patients avoid social 
situations and are overwhelmed by a confusing array of advice that seems contrary to their 
normal cultural beliefs and which is difficult to implement fully. In sparse data, kidney 
transplant recipients find it difficult to readjust to normal eating patterns and cope with an 
increased appetite despite considerable relief at renewed freedom from restrictions. Thus, 
some fear their lack of knowledge about diet may contribute to transplant rejection. Patients 
indicate that information about appropriate diet management is frequently difficult to 
comprehend due to reliance on didactic one-off education sessions and thus prefer multiple 
problem-solving and collaborative approaches to learning in partnership with their dieticians 
and families. Some patients find feedback from blood tests helpful in their own self-
management. This review finds that over time, individual patients draw on the strength of 
achieving incremental dietary changes, motivations of a future kidney transplant, slowing CKD 
progression or feeling better as ways of sustaining dietary and fluid recommendations in their 
lives. 
This thematic integration from studies across a range of clinical and cultural contexts highlights 
three potential factors that might be relevant to helping patients learn and incorporate dietary 
restrictions. Our review suggests that 1) approaches to education, 2) harnessing patient 
motivation, and 3) identifying adaptation as a journey might be ways of helping patients 
positively adapt to dietary recommendations. 
Patients desire knowledge about diet and fluid but may be counselled at a difficult time, such 
as when they are adapting to dialysis or transplantation or comprehending a diagnosis. In 
diabetes, patients who receive dietary counselling soon after diagnosis with consultation 
offered every three months and monthly nursing support show improved glycemic control, 
lower body weight and less use of diabetes drugs, suggesting that continued support over the 
months after diagnosis is helpful to generate meaningful dietary changes in other settings and 
are possibly applicable to CKD.37 This also aligns with CKD patients’ preference to form an 
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alliance with their clinical team rather than feeling they are being scolded or patronized for not 
adhering to advice.  
Partners and families are important sources of support who can shop for appropriate foods 
and make food palatable as well as ‘take on the stress and concern of planning meals’.20 This 
review suggests care-givers might be routinely involved in dietary education, as involvement of 
caregivers in nutrition counseling improves recall on messages about foods and food 
preparation information.38 Advice about reading nutritional labels and building a personal 
library of foods to minimize or avoid relevant to cultural practices are helpful for patients in 
this review. In addition, the opportunity for patients to learn about and respond to regular 
blood test results aligns with existing data showing patients with diabetes experience 
improved glycemic control in response to immediately available blood results.39 Patient 
experiences in our review are also supported by evidence showing education to avoid foods 
high in phosphorus additive at the time when patients purchase groceries or go to a fast-food 
restaurant lowers serum phosphorus levels.40 Some patients prefer group education sessions 
where they can support each other and discuss their concerns and find solutions. Patients 
favor problem-based learning on multiple occasions to build their confidence and gradually 
adapt to diet changes. This preference is supported by CKD data showing that individualized 
fortnightly dietary counselling with ongoing follow-up is more effective than written 
materials41 and a nonrandomized study showing that regular 6-monthly dietetic review and 
intensive follow-up targeted to specific nutritional parameters is associated with improved 
nutrition, serum potassium and phosphorus levels, and fluid overload.42 
This review indicates that kidney transplant recipients need ways to manage their increased 
appetite and advice to stay well and be reassured about their dietary approaches and the risk 
of transplant rejection. To support this need, a small exploratory study showed that body 
weight was increased by about 6% in the first months after transplantation without 
measurable changes in dietary intake.43 While regular dietary consultations and 
multidisciplinary care-modified dietary patterns might slow weight gain,44 effects of lifestyle 
modification on patient-relevant outcomes in solid-organ transplantation are lacking.45 
Patients with earlier stages of CKD wish to address dietary approaches specifically targeted at 
preventing CKD progression, which aligns with evidence showing patients prioritize diet as an 
intervention to prevent CKD progression when asked.46 
Patients often find changing their diet and fluid habits unacceptable as they view the 
restrictions as externally imposed and additional to other losses associated with CKD. Once 
patients experienced an increased sense of responsibility for food and fluid management as 
200 
 
‘part of the deal’, they became empowered and the dietary changes were much less important 
to their lives. Therefore, the key experiences of patients in this review might be used to inform 
decisional balance activity (patients and health workers exploring the pros and cons of 
changing and not changing health practices)47 to help assist patients to incorporate dietary 
changes by better articulating the perceived benefits of change (feeling better; hope for better 
CKD, dialysis and transplantation outcomes; reducing burden to others) and costs of not 
changing (fluid overload, itch, not gaining self-management) against their reasons to remain 
the same (inadequate information and understanding, ambivalence over efficacy, 
unsustainability of the changes needed, competing priorities in CKD). Some patients who had 
found internal motivation to sustain dietary adjustments were keen to tell their peers about 
what they had learned so that others might shorten the time it took to adopt the restrictions. 
Meeting patient peers to discuss care has been suggested previously in the setting of CKD as 
inspirational and a ‘powerful and persuasive method for patients to gain knowledge about 
their treatment options’ and may be widely applicable for people with CKD who face 
treatment that is complex and demanding and has been shown to have a positive influence on 
diet self-management in other settings.48,49 
While we conducted a thematic synthesis drawing on a broad and comprehensive search of 
the literature, considering a coding and analytical framework agreed between multiple 
researchers and evaluating the comprehensiveness of reporting in primary studies, this review 
has limitations that need to be considered. First, we did not include non-English research and 
while studies were situated within different cultural settings or reflected on the impact of 
culture on patient experiences, we cannot infer the applicability of our findings to all cultural 
and clinical contexts. As studies including patients treated by facility hemodialysis dominated 
the primary literature, the experiences of kidney transplant recipients, home dialysis patients 
and those with CKD may have been underestimated. All studies were conducted in middle- and 
high-income countries and conclusions may not be appropriate for patients in low-income 
regions. 
In conclusion, dietary and fluid restrictions have a powerful negative impact on the 
experiences of patients with CKD that require time for adaptation and patient and family-
centered care. The burden of dietary and fluid management may be alleviated through new 
approaches to patient education, harnessing patient motivations for change, and viewing 
adaptation to dietary and fluid management as a collaborative journey for patients, families, 
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*Age at time of kidney transplant. Abbreviations: USA, United States. Definitions: Constant comparative method, breaks the data into discrete phenomena and coding into 
categories; Content analysis, deductive methodology that involves identification of codes prior to searching for their occurrence in the data; Critical interpretivist 
approach/methodology, analytically disclosing meaning-making practices of people; Ethnography, to discover and describe individual social and cultural groups; Explanatory 
sequential design; collecting qualitative data to explore a phenomenon followed by collection of quantitative data to test an emergent theory or framework; Framework 
method, identifies commonalities and differences in qualitative data, before focusing on relationships between different parts of the data, thereby seeking to draw 
descriptive and/or explanatory conclusions clustered around themes; Grounded theory; discovery of theory through analysis of data; Iterative approach; similar to thematic 
analysis; Naturalistic enquiry, seeking to describe, understand or interpret daily life experiences and structures; Phenomeno logy, to study peoples’ understanding and 
interpretations of their experiences in their own terms and emphasizing these as explanations for their actions; Template analysis; development of a coding template from 
a priori codes expected to be relevant to the analysis, which are modified or dispensed with if they are not relevant to the actual data examined;  Thematic analysis, 
concepts and theories are inductively derived from the data. 
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Table 2. Comprehensiveness of reporting assessment  
Reporting criteria 
References of studies 
reporting each criterion No. (%) 
Characteristics of research team: 








Experience or training in qualitative 
research 
5,12,15,20,23,24,26,55 8 (17%) 
Research team relationship with participants: 
Relationship established prior to study 
commencement 
4,12,20,24,26,35,36,59,63 9 (20%) 
















Setting:   













Data collection:   





































References of studies 
reporting each criterion No. (%) 
(50%) 












Reporting:   




















































































































































































































































































































































































































































































































Preserving relationships  
Interference with 
roles                                                
Social limitations                               •   •     •     •   • • •   •     
Being a burden            •     • •   •             •     •     •                   •         •   •   •     
Navigating change  
Feeling deprived  • •   • • •   • • • • •             • •   •     • • •     •   •   • •   • •     • • • • •   
Disrupting held 
truths        • •   •   • •                       •         •         •     •     •       • •       
Breaking 
habits/norms  •     • • • • • •   • •               •   •     • •       •   •     •   • •       • • •     
Overwhelmed by 
information    •   •       • • • • •                   •       •       • • • •   •   • • •     •         
Questioning 
efficacy  •     •     •   • •         •             •       •       •   •     •     •   • • • • •     
Negotiating 
priorities    •   • •   • • •     •     •       • • • •       • •     • • •     •     •     • • • •     












































































































































































































































































































































































































































































































impositions    •   •           • • • •   •           • •         •               •     •     •   • •     




 •     • •       • •                 •           •   •     •         •   • •     • • •    
  
Optimizing health  
Accepting 
responsibility  • •     •     •                 • •       •   • •   •     • • •     • • • • •   • • • •     
Valuing self-
management  • •     •       •   • •     • • •   •   • • • • • • •   • • • •     • • • • • •   • • •   • 
Preventing CKD 
progression    •                           •           •       •                 •                       
Preparing for and 
protecting 
transplant 
   • •                                   •   •     •             • •                       
  
Becoming empowered  
Comprehending 
paradoxes 
 • •   • •     • • • • •                   •     • • •     •   •     •     •   • • • •       
Finding solutions    •   • •       • • •           •   •     •   • •   •     • • •     • •   •   •   • • •     
Mastering change 
and demands 
 • •   • •     • • • • •         •   •     •   • • • •     • • •     •     •   •   • • •     
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Table 4 Quotations from participants and authors of primary studies to illustrate each theme 
Themes Quotations from participants in primary study 
Preserving relationships 
Interference with roles 
My kids accept it. They watch over me, you’d be surprised how they watch over. Family, you go out to eat with them and you order something, they 
say, 'You can't eat that’.
13
 
When I come in to treatment I will be looking at my tech like ‘What is she going to say about me having all this fluid on?’ I kind of look at her and see 
the look that she gives me like, ‘Boy, you better stop that’.
14
 
You can’t be sneaky. My son knows the routine: what type of medications I take, what I should be eating, and the like. I still like cashews. My husband 




No, it means that, you know, sometimes you go to someplace to eat and there's all this food laying around and you realize that if you don’t eat, you 
know, you’re either gonna not eating anything and/or, you know, offend somebody…Probably stuff I shouldn’t eat, you know, but  I’ll eat it anyway 
just because he cooked it up for me you know.
13
 
People will think we are very poor and can’t afford salt. They will think we are starving and have no money.
19
 
I don’t have any social life now, although I could do but I don’t trust myself to go to dinners or cocktail parties because of drinking and eating. I don’t 




Being a burden 
I want to have better health. I don’t want to eat indiscriminately. If I do so, I’d suffer. It’s okay if I can die, but I’d be a burden to others if I don t die. 
…I’d be a burden for the young [my children] because they’d have to come and visit me often. That would be a trouble.
5
 
With the fluid restriction, I think if I’m going to come here four hours, three times a week, and go home and drink what I want, eat what I want, then 






(dealing with loss) 
It’s not an easy diet by any means…its affects life’s little pleasures.
23
 
Lots of changes...Well, my diet. It took away all my goodies.
13
 
Quitting isn’t the most difficult. It’s not being allowed to eat for the long term that’s difficult. It’s adhering to the dietary restrictions in every meal 
that’s difficult. If you give me a time frame, such as telling me not to eat it for 1 month, that would be easy. If you say I’m not allowed to eat it for my 
whole life, that’d be difficult.
5
 





Themes Quotations from participants in primary study 
Disrupting held truths 
I always tell dieticians that the dietary restrictions would make people starve. There are so many foods that I should eat just a little. …If I do as 
instructed by the dieticians, I’d die from starving.
5
 
I found my diet has been quite difficult… of all the healthy food I’ve been cooking it has had to stop.
20
  
Breaking habits and 
norms 
...it's a new life, an entire different life, new food, new intake of liquid and everything. Everything is different.
13
 






It’s confusing. …The funniest thing is that they asked me what I ate because I didn’t have any potassium. I told them I didn’t eat those foods because 
they asked me not to eat them. They said I didn’t have any potassium at all, and asked me to eat bananas because bananas contain potassium. Later, I 
had another blood test, after which they told me to stop eating bananas and eat like normal.
5
 
It is hard to know what to eat. They say less vegetables and fruits…I try to not eat soya beans no nuts…still high…still itchy…where am I going wrong?
15
 








Well the food they tell you to eat, it have no substance. It make you feel so weaky, weaky. If you could eat some of your back home food, maybe you 
could have a little strength in your body.
28
 




Half an hour I regret it but it happens again and again, and I struggle with that, and it becomes like a struggle between life and death.
24
 
I like to drink lots of water, even before I started dialysis. I try my best, but at the end of the day I’ll be dead anyway.
24
 
I have the choice. I can choose to survive for 2 or 3 more years; I have to restrict my diet. I can also choose to neglect it if I don t want to survive. 
That’s simple. If I want to be able to eat for a longer time, I should adhere to dietary restrictions. If not, I may as well choose to eat whatever I like. I’d 





Just name anything, and you’d find out that I shouldn’t eat it. There’re too many foods that I shouldn’t eat… It’d be impossible to refrain from eating 




My son says, ‘‘Mama, that’s not good.’’ But I say, ‘‘I’m 72, I’m going to eat what I want. It’s not going to get better anyway. I’m so tired.
58
 
I was getting fed up of being told off, but I know she (the dietician) was doing good. Mum told me off about the diet and not sticking to it as well. It 
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Themes Quotations from participants in primary study 




And when I drink, I just don’t like myself. When I have the water in my mouth then I don’t want to swallow. You know when you are making love and 
you want to stop half way, how many people can control that. So when I have that water in my mouth it’s like something is holding my hand, maybe 
god, and then I give up and I say, oh well I’ll have it all.
24
 
I fail to resist, I am always thirsty, and my thoughts remain always fixed upon thirst and water… I can’t resist, I can’t find a way to avoid the drinking 
need; my thoughts are always fixated on the bottle, and I am always close to the fridge.
25
 






I think I will succeed in reducing fluid although I do not yet succeed in understanding: is not drinking beneficial for my body? Dehydration also derives 
from the fact that one doesn’t drink. Do I have a problem with dehydration or not? Do you have this type of problem with your physiology?
25
 





I’ve taken actions such as being educated about dialysis, to take responsibility for my health and diet and I never miss my medications.
12
 




Every time I have follow-up, I ask the nurse to write them [the laboratory results] down for me as a reference, and tell me whether my sodium and 
phosphorus levels are high. If my sodium or potassium level is high, the doctor would warn me, and I’d adhere to dietary restrictions. …That s for my 





If your attitude is right, I’ve got a, I’ve got a problem. I have a renal disease, but there’s ways around it. I can go to dialysis, and if . . . I stick to the diet, 
and I do my treatment, and I take the medication, er, I can make a better quality of life for myself.
62
 
I oftentimes just think about me and what I need to do for me. Who is going to stop you from doing for you? Nobody. Help yourself.
29
 
… I don’t have the prospect of a transplant, so I have to stay as well as possible. If I carry a regular weight I can hope to live another 10 years. This is 





I am very keen on controlling this quite fast, if I can, to avoid dialysis.
20
  
Preparing for and 
protecting a transplant 
I’m on the waiting list for a kidney transplant. Therefore, I must keep myself healthy. This is to ensure that when the hospital calls and tells me that 
there are kidneys for me, be immediately fit to undergo the operation. If my body can’t tolerate the surgery or if I don t feel well when the hospital 
calls, I won’t be allowed to undergo the surgery. I’ll miss the chance then. That would be a pity because we’ve to wait for a  very long time for a 
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Well, I found it hard, what made it difficult for me was just getting myself adjusted to the regulations and so forth. Having to do things that had to be 
done. Of course, Iike, it was hard but then, all of a sudden, it became so customary, I more or Iess got used to it...I have found that you have to, 
because of the dialysis, you have to adjust yourself to the situation. Therefore, it automatically becomes more or Iess customary.
13
 




I used to have a problem with potassium, but I think the dialyzers today are better and have largely solved that problem. I look at the blood work, and 
feel that the more I know the better I can juggle my diet.
12
 
That's when the nurses are really, really good at coming up with suggestions, alternatives and stuff like that. We had one patient that only ate like 
frozen meals. He didn't cook, he only had a microwave. And he would go and buy brands of, like, you know, those frozen TV dinners and that was 
basically his only source of nutrition. So, his primary nurse contacted the company to find out how much fluid they were putting in the gravy, how 
much potassium, how much sodium, how much whatever whatever each of his favorite meals was. And they, the company actually sent packets 
describing all of that so that the patient had a little library, like knowing which foods were high in phosphorous, potassium or sodium and that kind of 
stuff. So, that helped the patient adjust. Those sorts of things would help the patient adjust.
13
 
Mastering change and 
demands 
I don’t know how you get people to stay on diets because it’s all got to come from inside them and they’ve got to really want to do it and really, well, 
they’ve got to look after their health.
30
 





Figure 1: Results of search strategy and identification of publications included in the review  
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Figure 2: Conceptual framework for understanding patient’s experiences of diet and fluid 




Conclusions and future perspectives 
The aim of this body of work was to understand the impact of diet on CKD and ESKD and the 
association between nutrition and clinical adverse events in the setting of hemodialysis. The 
broader aim of the work of the research team in which I operate is to explore novel determinants 
of cardiovascular risk in people with CKD treated with hemodialysis, whose mortality is still very 
high and substantially unchanged during the past decades, despite introduction of multiple 
intervention, primarily but not only pharmaceutical.   
The work done here has explored several factors related to nutrition in CKD and hemodialysis.  Key 
findings have been generated, but also many studies confirmed the strong need for further 
research in the area, particularly in the form of primary studies, and namely intervention studies.   
The first network meta-analysis run in the area of CKD/ESKD shows that there is insufficient  
evidence that any phosphate binding agent improves survival. Despite this, phosphate binding 
agents are broadly used in ESKD patients, their use is strongly promoted and advocated. There is a 
clear need for randomized trials to finally test the assumption that they would provide a survival 
advantage. 
The second network meta-analysis, run in the area of diabetes management with glucose lowering 
agents, found no evidence of differences in the performance of any of the glucose lowering drugs 
(alone or in combination) on cardiovascular mortality, all-cause mortality, serious adverse events, 
myocardial infarction, or stroke, despite recommendations from global guidelines. This specific 
finding is reflective of the fact that even in an area where there is a strong development of new 
trials, these are primarily aimed at showing whether differences existing between drugs on 
surrogate biomarkers, while the data on survival remains scant. And, in general, there is no drug 
yet of proven superiority when it comes to survival, with the possible exception of SGLT2 
inhibitors, proving that also this is a proper ground for further studies. 
What this part of my thesis aimed to show is that even in areas of consolidated knowledge and 
practice, and related to nutrition (diabetes, phosphate control), the evidence remains suboptimal 
and guidelines provide strong statements which are and remain unsubstantiated by the evidence. 
More specifically, the most relevant part of my PhD focused on dietary aspects related to CKD and 
ESKD/hemodialysis. The findings of the meta-analysis of cohort studies which opens this thesis 
showed that dietary patterns rich in vegetables and fruits, legumes, whole grains, and fiber 
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together with lower consumption of red meat, sodium, and refined sugars were consistently 
associated with reduced mortality in people with chronic kidney disease. This was the first 
cumulative assessment of whole dietary patterns and their impact on mortality and clinical 
complications in people with chronic kidney disease.  
These associations, together with the possible beneficial effects of dietary modifications on risk 
factors for disease found in the review of randomized trials, suggested that dietary interventions 
remain an important research and clinical uncertainty in the setting of kidney disease. The data 
suggested that also the current evidence for dietary interventions in the setting of chronic kidney 
disease is of very low quality and insufficient to guide clinical practice.  
When asking patients their perspectives about dietary and fluid management, our qualitative 
review showed that this is a disorienting challenge and intense burden for patients when adapting 
to and coping with different stages of CKD. The substantial number and complexity of restrictions 
on food and fluid exacerbates the impaired quality of life caused by CKD and has a profound 
impact on patients’ relationships with others. This review found that over time, individual patients 
draw on the strength of achieving incremental dietary changes, motivations of a future kidney 
transplant, slowing CKD progression or feeling better as ways of sustaining dietary and fluid 
recommendations in their lives. 
In all systematic reviews performed in this thesis, study quality was suboptimal, mortality was 
often an outcome not correctly evaluated and several methodological shortcomings were present.  
For this reason, we decided that our major contribution to the field of enquiry would be the design 
and conduct of a large primary study, the DIET HD prospective cohort study.  This was designed 
and intended to be the largest multinational prospective cohort study investigating nutritional 
determinants of adverse clinical outcomes in hemodialysis. The study will include a large number 
of “a priori” defined analyses, of which the first I contributed to forms a fundamental part of this 
PhD.  In the first analysis arising from the DIET study, there appeared to be no association between 
the dietary intakes of n-3 PUFA and cardiovascular and all-cause mortality among adults treated 
with hemodialysis, with only an apparent relationship between dietary intake of PUFA and 
mortality across countries. Mortality was inversely related to the national intake of n-3 PUFA. 




All these findings together, and the ones we are further developing (individual investigators in our 
research team) support the design of primary intervention studies based around nutritional 
strategies in this population. The current evidence for dietary interventions is insufficient to guide 
clinical practice, as arised from the comprehensive systematic review of the existing literature, and 
possible beneficial effects of dietary interventions include clinically-important increases in health-
related quality of life, lower blood pressure and serum LDL cholesterol levels and higher kidney 
function and serum albumin levels. These represent potential mechanisms for benefit of dietary 
modifications in larger trials, but the longer term impact of dietary changes needs to be examined. 
Further research is needed to evaluate the impact of dietary patterns on hard clinical outcomes 
including mortality and cardiovascular endpoints in chronic kidney disease, focusing on outcomes 
that have been relatively under-researched, but are important causes of significant morbidity. 
Also, it is important to consider the variation in outcome measures routinely collected and 
reported in nephrology studies, which is intended to change, as the SONG initiative is currently 
exploring.  
Future trials should be powered to assess dietary effects on these outcomes, together with a 
validated measure of health-related quality of life, to develop clinically-relevant studies and useful 
meta-analyses of dietary interventions, already planned as part of my post-doctoral work. 
 
